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An Investigation into Clinically Relevant Determinants of Azole Resistance in
Candida albicans
Abstract
"Candida albicans is a commensal organism commonly colonizing the human gut and skin. As an
opportunistic pathogen, it can cause persistent and serious infections in individuals with compromised
immune systems, including the very young and elderly. Moreover, C. albicans can cause a wide spectrum
of diseases ranging from superficial mucosal infections to life-threatening invasions of the organs and
bloodstream. Candida species are the most common cause of invasive fungal disease, which is
associated with high mortality and imposes a heavy toll on the healthcare system. Over the last 30 years,
the azole antifungals have been a mainstay of antifungal therapy, being effective in a wide variety of
fungal infections and serving as the primary oral treatment option. However, increased use, inappropriate
dosing, and prolonged treatments have given rise to azole-resistant Candida albicans and other Candida
species. Resistance in C. albicans results from a combination of different mechanisms. Increased
expression of the efflux pump encoding genes CDR1, CDR2, and MDR1 as well as increased expression of
ERG11, encoding the azole target (14α-lanosterol demethylase, also known as CYP51) are all primary
mechanisms of azole resistance that arise in azole-resistant clinical isolates. These changes are known
to be mediated through gain-of-function mutations in the genes of a fungal-specific transcription factor
family known as the zinc cluster transcription factors. Furthermore, genetic changes in the ergosterol
biosynthesis genes, ERG11 and ERG3, encoding a C-5 sterol desaturase, also contribute to clinical azole
resistance in C. albicans. The interplay of these mechanisms can result in azole-resistance, treatment
failure, and ultimately, poorer outcomes in patients. Therefore, to improve healthcare outcomes,
understanding resistance development and the mechanisms that drive them in C. albicans is crucial.
Within a collection of predominantly fluconazole-resistant clinical isolates of C. albicans, our lab had
previously characterized most known mechanisms of azole resistance present in each isolate. Increased
CDR1 expression in isolates lacking TAC1 gain-of-function mutations coupled with recent literature
suggesting a role of the Mrr2 zinc cluster transcription factor in azole resistance lead us to sequence and
test mutations in the MRR2 gene in across this collection. By placing mutant MRR2 alleles in azolesusceptible backgrounds, we hoped to measure the contribution of MRR2 mutations to azole resistance
through changes in CDR1 expression and fluconazole minimum inhibitory concentrations (MICs). Counter
to what has been recorded in the literature, we found no evidence that mutations in MRR2 impact either
CDR1 expression or azole susceptibility in C. albicans. This is a novel finding correcting a previous
mistaken paradigm of a clinically relevant mechanism driving resistance in C. albicans. Next we more
closely examined the role of ERG11 mutations found in clinical isolates. Though the contributory effects
of ERG11 mutations to azole resistance had been quantified, the specific biochemical impact of these
mutations on enzyme function and ligand-binding interaction have only recently come to light. Here we
introduced additional CaCYP51 amino acid substitution mutants (D278N and Y132H) in C. albicans" "vi"
"and tested our entire collection of CaCYP51 mutant strains to determine their in vitro azole
susceptibilities in the context of these findings. In general, we observed differences in the fluconazole and
voriconazole MICs between CaCYP51 amino acid substitutions. In contrast, MICs to itraconazole showed
a small, fairly consistent increase in MIC across tested CaCYP51 strains and MICs to posaconazole did
not increase at all over the wild type except for the G448E substitution, suggesting posaconazole
possesses the best in vitro activity against these CaCYP51 mutants. Overall, we also revealed that not all
ERG11 mutations confer azole resistance through decreased binding interactions with the target and the
azole drug, suggesting that CaCYP51 amino acid substitutions may instead interact with other associated
proteins to confer resistance. Furthermore, it was discovered that many ERG11 mutations from clinical
isolates result in low catalytic turnover of the enzyme, which is crucial to normal rates of ergosterol
production in a healthy cell. Though preliminary results of growth in CaCYP51 mutant strains does not
support attenuated fitness in competitive assay, the findings here prove that some clinical ERG11

mutations result in diminished enzyme function." We also sequenced the collection of clinical isolates
and discovered an A351V Erg3 amino acid substitution in our azole-resistant isolates and predominantly
in those with multiple ERG11 mutations. This suggested a possible connection between CaCYP51
mutants and amino acid substitutions in Erg3. As the proteins encoded for by the ERG11 and ERG3 genes
are involved in the same ergosterol biosynthesis pathway, defects in Erg11 enzyme function might be
expected to impact accumulation of substrates of Erg3, specifically, precursors of the toxic sterol
metabolite 14α-methylergosta- 8,24(28)-dien-3β, 6α-diol. By testing ERG11 mutant strains with and
without the ERG3A351V allele in growth competition experiments, we hoped to observe a conferred
fitness benefit by the ERG3 mutation. Interestingly, we were unable to generate one of our selected ERG11
mutants with the poorest catalytic turnover in the absence of the A351V amino acid change in Erg3.
Future investigation by other lab members is needed to determine if ERG3 mutations can indirectly
influence azole susceptibility through permissive mutation." "Lastly, we tested susceptibility of our clinical
collection to the new tetrazole antifungals VT-1161 and VT-1598, which have been reported to exhibit
potent activity against azole-resistant C. albicans and a host of other fungal species. We additionally
investigated determinants of resistance to the two new agents by obtaining susceptibilities to C. albicans
strains containing individual known mechanisms of azole resistance. While susceptibility to VT-1161 was
reduced when CDR1 and MDR1 were overexpressed, VT-1598 seemed unaffected by any tested
resistance mechanism. Importantly, both retained activity against a significant portion of mutant ERG11
strains. VT-1598 MICs were not affected by any single mechanism of resistance. However, screening of
our azole-resistant clinical isolates identified five isolates with greatly elevated MICs to all tested agents.
While one of these isolates possesses an ERG3 nonsense mutation that likely explains its pan-azole
resistant profile, the other four isolates do not uniquely overexpress known resistance genes or possess
known gene mutations that might explain their resistance. This finding suggests that there are
determinants of azole resistance that are as yet undiscovered in C. albicans."
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ABSTRACT
Candida albicans is a commensal organism commonly colonizing the human gut
and skin. As an opportunistic pathogen, it can cause persistent and serious infections in
individuals with compromised immune systems, including the very young and elderly.
Moreover, C. albicans can cause a wide spectrum of diseases ranging from superficial
mucosal infections to life-threatening invasions of the organs and bloodstream. Candida
species are the most common cause of invasive fungal disease, which is associated with
high mortality and imposes a heavy toll on the healthcare system. Over the last 30 years,
the azole antifungals have been a mainstay of antifungal therapy, being effective in a
wide variety of fungal infections and serving as the primary oral treatment option.
However, increased use, inappropriate dosing, and prolonged treatments have given rise
to azole-resistant Candida albicans and other Candida species.
Resistance in C. albicans results from a combination of different mechanisms.
Increased expression of the efflux pump encoding genes CDR1, CDR2, and MDR1 as
well as increased expression of ERG11, encoding the azole target (14α-lanosterol
demethylase, also known as CYP51) are all primary mechanisms of azole resistance that
arise in azole-resistant clinical isolates. These changes are known to be mediated through
gain-of-function mutations in the genes of a fungal-specific transcription factor family
known as the zinc cluster transcription factors. Furthermore, genetic changes in the
ergosterol biosynthesis genes, ERG11 and ERG3, encoding a C-5 sterol desaturase, also
contribute to clinical azole resistance in C. albicans. The interplay of these mechanisms
can result in azole-resistance, treatment failure, and ultimately, poorer outcomes in
patients. Therefore, to improve healthcare outcomes, understanding resistance
development and the mechanisms that drive them in C. albicans is crucial.
Within a collection of predominantly fluconazole-resistant clinical isolates of C.
albicans, our lab had previously characterized most known mechanisms of azole
resistance present in each isolate. Increased CDR1 expression in isolates lacking TAC1
gain-of-function mutations coupled with recent literature suggesting a role of the Mrr2
zinc cluster transcription factor in azole resistance lead us to sequence and test mutations
in the MRR2 gene in across this collection. By placing mutant MRR2 alleles in azolesusceptible backgrounds, we hoped to measure the contribution of MRR2 mutations to
azole resistance through changes in CDR1 expression and fluconazole minimum
inhibitory concentrations (MICs). Counter to what has been recorded in the literature, we
found no evidence that mutations in MRR2 impact either CDR1 expression or azole
susceptibility in C. albicans. This is a novel finding correcting a previous mistaken
paradigm of a clinically relevant mechanism driving resistance in C. albicans.
Next we more closely examined the role of ERG11 mutations found in clinical
isolates. Though the contributory effects of ERG11 mutations to azole resistance had
been quantified, the specific biochemical impact of these mutations on enzyme function
and ligand-binding interaction have only recently come to light. Here we introduced
additional CaCYP51 amino acid substitution mutants (D278N and Y132H) in C. albicans
v

and tested our entire collection of CaCYP51 mutant strains to determine their in vitro
azole susceptibilities in the context of these findings. In general, we observed differences
in the fluconazole and voriconazole MICs between CaCYP51 amino acid substitutions.
In contrast, MICs to itraconazole showed a small, fairly consistent increase in MIC across
tested CaCYP51 strains and MICs to posaconazole did not increase at all over the wild
type except for the G448E substitution, suggesting posaconazole possesses the best in
vitro activity against these CaCYP51 mutants. Overall, we also revealed that not all
ERG11 mutations confer azole resistance through decreased binding interactions with the
target and the azole drug, suggesting that CaCYP51 amino acid substitutions may instead
interact with other associated proteins to confer resistance. Furthermore, it was
discovered that many ERG11 mutations from clinical isolates result in low catalytic
turnover of the enzyme, which is crucial to normal rates of ergosterol production in a
healthy cell. Though preliminary results of growth in CaCYP51 mutant strains does not
support attenuated fitness in competitive assay, the findings here prove that some clinical
ERG11 mutations result in diminished enzyme function.
We also sequenced the collection of clinical isolates and discovered an A351V
Erg3 amino acid substitution in our azole-resistant isolates and predominantly in those
with multiple ERG11 mutations. This suggested a possible connection between
CaCYP51 mutants and amino acid substitutions in Erg3. As the proteins encoded for by
the ERG11 and ERG3 genes are involved in the same ergosterol biosynthesis pathway,
defects in Erg11 enzyme function might be expected to impact accumulation of substrates
of Erg3, specifically, precursors of the toxic sterol metabolite 14α-methylergosta8,24(28)-dien-3β, 6α-diol. By testing ERG11 mutant strains with and without the
ERG3A351V allele in growth competition experiments, we hoped to observe a conferred
fitness benefit by the ERG3 mutation. Interestingly, we were unable to generate one of
our selected ERG11 mutants with the poorest catalytic turnover in the absence of the
A351V amino acid change in Erg3. Future investigation by other lab members is needed
to determine if ERG3 mutations can indirectly influence azole susceptibility through
permissive mutation.
Lastly, we tested susceptibility of our clinical collection to the new tetrazole
antifungals VT-1161 and VT-1598, which have been reported to exhibit potent activity
against azole-resistant C. albicans and a host of other fungal species. We additionally
investigated determinants of resistance to the two new agents by obtaining susceptibilities
to C. albicans strains containing individual known mechanisms of azole resistance.
While susceptibility to VT-1161 was reduced when CDR1 and MDR1 were
overexpressed, VT-1598 seemed unaffected by any tested resistance mechanism.
Importantly, both retained activity against a significant portion of mutant ERG11 strains.
VT-1598 MICs were not affected by any single mechanism of resistance. However,
screening of our azole-resistant clinical isolates identified five isolates with greatly
elevated MICs to all tested agents. While one of these isolates possesses an ERG3
nonsense mutation that likely explains its pan-azole resistant profile, the other four
isolates do not uniquely overexpress known resistance genes or possess known gene
mutations that might explain their resistance. This finding suggests that there are
determinants of azole resistance that are as yet undiscovered in C. albicans.
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CHAPTER 1.

INTRODUCTION

General Background
Manifestations of Candida infections range from superficial mucosal and dermal
infections such as oral thrush and vaginal yeast infections to disseminated bloodstream
infections and are associated with high mortality rates (upwards of >40%) (1-5).
Candida infections require extreme attention in immunocompromised individuals, such
as AIDS patients, transplant recipients, patients undergoing chemotherapy or
immunosuppression therapies, in which they cause life-threatening invasive infections (68). Studies have suggested that healthy individuals with implanted medical devices,
those who experienced major trauma, and patients requiring extended stays in intensive
care units are at equal risk of acquiring Candida infection (9). Global estimates suggest
that invasive candidiasis occur in ~700,000 cases which clearly exceeds ~250,000 cases
of invasive aspergillosis (10).
In the USA, Candida spp. remain the fourth leading cause of nosocomial
bloodstream infections and the number three cause of bloodstream infections in the
intensive care unit (ICU) (11). Candida spp. are also the third leading cause of centralline-associated bloodstream infections and the second leading cause of catheterassociated urinary tract infections in the U.S. (12, 13). Of all the Candida species, C.
albicans dominates almost all patient groups and disease manifestations in terms of
incidence followed by C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei (14). It is
pertinent to mention here that there has been considerable change in species distribution,
dependent upon geographical location and patient population, with a decrease in the
proportion of C. albicans and an increase in C. glabrata, C. parapsilosis, and other nonalbicans Candida species (14). C. glabrata is the second most common species in the
United States and northwestern Europe in the non-outbreak setting (15, 16). However, C.
parapsilosis and/or C. tropicalis are much more frequently encountered than C. glabrata
in Latin America, Southern Europe, India and Pakistan (17-23). Of the five major
Candida spp., C. krusei is the least common, and it is most often found among patients
with underlying haematological malignancies with prior antifungal exposure (24, 25).
Another worrisome multidrug resistant species that is emerging globally is C. auris (26).
C. albicans is a member of native human microflora and as a commensal
organism colonizes the gastrointestinal (GI) tract, reproductive tract, oral cavity, and skin
of most humans (27). Failure to identify a possible environmental reservoir for C.
albicans suggests that this species is exquisitely adapted to healthy mammalian hosts.
However, this benign commensal colonization can become pathogenic due to shifts in pH
and oxygen levels, alterations in host microbiota (e.g. from antibiotic usage), or changes
in the host immune response (e.g. during stress, infection by another microbe, or
immunosuppressant therapy) (28). Rapid increase in number of Candida infections may
be attributed to availability of modern medical treatments including excessive usage of
broad-spectrum antibiotics, anticancer therapy, solid organ transplantation, presence of
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indwelling catheters, lack of awareness among multiple medical specialties, and poor
performance of routine microbiological tests.
Fluconazole is the first line of antifungal drug available for an effective treatment
for invasive candidiasis and is the recommended treatment for most infections (29).
While antifungal resistance in C. albicans is uncommon relative to species like C.
glabrata, gradual use of fluconazole for long term prophylaxis or treatment may lead to
selective pressure resulting in emergence of secondary resistance in otherwise susceptible
strains/species. Overall, fluconazole resistance (MIC ≥8 μg/ml) in C. albicans ranges
between 0% and 3% (30-34). Although overall azole resistance of naïve C. albicans
isolates is rare, a steady increase in reports of azole resistance, resulting in therapeutic
failures, has been a matter of serious clinical concern. In the current review, we aim to
address the magnitude of azole-resistance in C. albicans and the underlying resistance
mechanism implicated in the development of azole resistance and highlight the
therapeutic concerns.
Biology of Candida albicans
Candida albicans possess key virulence traits that not only differentiate it from
other Candida species but also help it in establishing itself as a successful pathogen. It
secretes a number of proteases, phospholipases, esterases and lipases in the context of
invasive infection that helps in promoting degradation of host connective tissue, cleavage
of host immune defence proteins thereby leading to nutrition acquisition, invasion and
evasion of pathogen from host innate immune response (35, 36).
C. albicans can adapt to use alternative carbon sources due to its ability to
successfully thrive in heterogenous carbon microenvironment in the host. The versatility
of metabolic elasticity of this species helps in morphogenic transition between unicellular
yeast cells, pseudohyphae, and hyphae thereby promoting invasion (37-41). This is in
contrast to C. glabrata, which has the intrinsic inability to form hyphae and does not
require this morphogenic change in order to establish invasive disease. C. albicans has
the ability for cell wall remodeling, white opaque switching and can form highly
structured biofilms composed of multiple cell types (i.e. round yeast-form cells; oval
pseudohyphal cells; and elongated, cylindrical hyphal cells) encased in an extracellular
matrix (42-46). Due to their effective adherence and invasion in endothelial and epithelial
cells they can easily disseminate into the bloodstream. C. albicans can invade host
epithelial cells either through forced hyphal-mediated invasion or by induced endocytosis
into endothelial and epithelial cells (47-50). It is pertinent to mention here that all
Candida species exhibit different antifungal susceptibility patterns depending upon their
site of isolation, geographical location, and prior antifungal exposure. C. albicans and C.
parapsilosis are most frequently susceptible to all antifungals available. On the other
hand, C. tropicalis might exhibit fluconazole resistance while maintaining susceptible
profile to amphotericin B and echinocandins. Interestingly, C. glabrata tends to display
high azole MICs while retaining amphotericin B and echinocandin susceptibility. C.
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lusitaniae, on the other hand, is resistant to Amphotericin B while the emerging fungal
threat C. auris is multidrug resistant.
Epidemiology of Azole Resistance in C. albicans
In vitro susceptibility testing of yeasts and moulds helps in not only selecting the
most clinically active antifungal agent but also in detecting resistance rates. The Clinical
and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial
Susceptibility Testing (EUCAST) methods are reference methods to detect in vitro
resistance of yeasts and moulds against various antifungal agents. Resistance can be
classified as microbiologic or clinical. Microbiologic resistance is defined by the
situation when concentration of antifungal agent required to inhibit the growth of the
pathogen is higher than the range seen for wild-type strains due to presence of an
acquired or innate mutational resistance mechanism. Clinical resistance, on the other
hand, is denominated by therapeutic failure in spite of administering high doses of the
antifungal agent.
Emergence of azole resistance in Candida species, especially those originating
from patients on prolonged azole therapy, have become a worldwide problem thereby
stressing the need for antifungal stewardship. Decreased in vitro susceptibility of C.
albicans to azoles such as miconazole, econazole, and clotrimazole has been recognized
since the late 1970s (51, 52). Horsburgh and Kirkpatrick in 1983 reported two of 21
patients with chronic mucocutaneous candidiasis on ketoconazole treatment suffering
clinical relapses associated with C. albicans possessing high ketoconazole MICs (53).
Similarly, high ketoconazole MICs were subsequently reported by Warnock et al. and
Smith et al. in similar cases (54, 55). These relatively ketoconazole-resistant isolates
demonstrated decreased in vitro susceptibility to miconazole, itraconazole, fluconazole,
and tioconazole. There have also been reports of mucosal candidiasis due to C. albicans
with reduced in vitro and in vivo responsiveness to fluconazole, ketoconazole, and
clotrimazole in HIV-infected patients (56, 57). Evans et al. reported three cases of
treatment failure in invasive mycoses due to fluconazole resistant C. albicans (58).
Most of the data related to the epidemiology of antifungal susceptibility profile of
Candida spp. originates mainly from studies carried out in the USA and Europe.
Cleveland et al., in 2012 showed an azole resistance rate of about 2.3% in C. albicans
bloodstream isolates (59). The SENTRY surveillance data from 2008–2009 investigated
1239 bloodstream Candida isolates from 79 medical centers throughout the world and
reported variation in Candida spp. distribution and antifungal resistance rates (32).
Candida albicans (n=620, 50%) was the most common species isolated in all age groups
followed by C. glabrata and C. parapsilosis (n=215, 17.4%), and C. tropicalis (n=122,
9.8%). None of the C. albicans isolates were resistant to any of the antifungal tested in
this study. Interestingly, a recent SENTRY surveillance data analyzing 1514 Candida
spp. collected from Europe (41.0%), the Asia Pacific (24.5%), North America (23.5%),
and Latin America (11.0%) during 2013 revealed the similar pattern of Candida species
isolation (15). However, azole antifungal resistance of about 0.4% and 0.3% in C.
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albicans (n=712) was noted against fluconazole and voriconazole, respectively. Another
large population-based surveillance program, the ARTEMIS DISK Global Antifungal
Surveillance Study was carried out from 1997 to 2007, analyzing 256,882 isolates of
Candida spp. collected and tested at 142 study centers throughout the world (30). Of all
31 different Candida species isolated, C. albicans (65.3%) was the most common
followed by C. glabrata (10.2% to 11.7%), C. tropicalis, (5.4% to 8.0%), and C.
parapsilosis (4.8% to 5.6%). Of 128,625 isolates of C. albicans tested, 1.4% were
resistant to fluconazole. Of 1782 fluconazole-resistant C. albicans strains, 63.6% were
cross resistant to voriconazole (30). A surveillance study was conducted in Denmark to
evaluate the species distribution and in vitro antifungal susceptibility profile against
fluconazole, itraconazole, amphotericin B and caspofungin in 303 episodes of fungaemia
(60). Here again, C. albicans was the predominant species isolated followed by C.
glabrata, C. tropicalis and C. parapsilosis. Of all the C. albicans tested, 3% (n=6) were
resistant to fluconazole. In another Danish study, a 6-year nationwide study of fungemia
from 2004-2009 reported fluconazole (MIC of >4 μg/ml) resistance rate of about 0.6%
(7/1183 isolates) (61).
A recent study from Spain assessed the incidence and prevalence of antifungal
resistance in bloodstream Candida infections (62). Interestingly, in a collection of 766
Candida strains, C. albicans (45.4%) was the predominant species followed by C.
parapsilosis (24.9%), C. glabrata (13.4%), C. tropicalis (7.7%), C. krusei (2%), and
other Candida species (6.5%). Of all C. albicans strains tested for antifungal
susceptibility, 1% was resistant to fluconazole. A multi-center study from Belgium
during 2013-2014 demonstrated eleven different Candida species, with C. albicans being
the most prevalent (50.4 %), followed by C. glabrata (27.3 %), C. parapsilosis sensu lato
(9.8 %), and C. tropicalis (5.6 %) (63). About 3.9% (n=7) of C. albicans (n=179)
isolates were found be fluconazole resistant here. A twenty-two year Norwegian national
surveillance of candidaemia found 98.8% C. albicans isolates to be susceptible to
fluconazole (64). Only 0.25% of C. albicans isolates were fluconazole resistant during
2004-2012.
Chapman et al., from Australia reported two (0.9%) isolates of C. albicans that
were resistant to fluconazole, cross-resistant to voriconazole and had non-wild type MICs
of itraconazole (>16 mg/L) and posaconazole (>8 mg/L) (65). A national South African
surveillance for candidemia from 2009-2010 revealed 98% C. albicans isolates to be
azole susceptible. However, a single fluconazole-resistant C. albicans isolate exhibited
cross resistance to voriconazole (66). In a 2015 study conducted in ICU centers across
India, 5.2% of C. albicans strains sourced from ICU-acquired candidemias were
identified as fluconazole-resistant (67).
Overall, the global data suggests that C. albicans remains the predominant
infective organism identified in Candida-based infections. While reported resistance
rates vary from study to study, collected surveillance data suggests that fluconazoleresistance and azole resistance rates in general for C. albicans remains relatively low.
However, superficial mucosal C. albicans infections pose a considerable threat in
immunocompromised populations, and the high morbidity and mortality associated with
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serious invasive Candida infections continues to burden our healthcare systems (68-70).
As such we must not overlook C. albicans as a serious antimicrobial resistance threat.
Current Antifungal Treatment of C. albicans Infections
Currently, antifungal therapy revolves around three main classes of antifungal
drugs: the azole antifungals, echinocandins, and polyene antifungals such as amphotericin
B. The antimetabolite pyrimidine analog flucytosine is also used in treatment of certain
invasive Candida infections and cryptococcal meningitis, but is limited to combination
therapies with amphotericin B (29). The azole antifungals are a current mainstay of
therapy for treatment and prophylaxis of both superficial and invasive candidiasis.
Through inhibition of the ERG11-encoded protein 14α-lanosterol demethylase, the
production of ergosterol normally required for membrane integrity is halted. In C.
albicans, the inability to demethylate lanosterol via Erg11 shunts sterol biosynthesis
production to other alternate biosynthesis pathways, resulting in the accumulation of 14αmethylergosta-8,24(28)-dien-3beta,6alpha-diol (71). The accumulation of this compound
is toxic to the cell and results in the fungistatic effect seen with the azole antifungals (72).
While there are dozens of azole antifungal drugs sold commercially worldwide,
ranging from research use to topical antifungal use in humans to agriculture, only a select
few triazoles are typically used for treating invasive candidiasis in the United States.
While recent updates to clinical practice guidelines now recommend the echinocandin
class of antifungals in many invasive Candida infections, fluconazole remains a viable
first-line alternative in many cases, such as in non-neutropenic patients with Candida
bloodsteam infection (29). Voriconazole is another triazole considered as alternative or
step-down therapy in many instances where fluconazole is also used, and the triazoles
itraconazole and posaconazole have niche uses in invasive candidiasis, such as
alternatives for oropharyngeal or esophageal candidiasis in fluconazole-refractory
disease. Additionally, as currently no orally available echinocandin exists, fluconazole
and the other triazoles are important for outpatient and step-down therapies for
prophylaxis and treatment. The newly approved triazole prodrug isavuconazonium
sulfate, while effective against Candida, including azole-resistant Candida species, does
not currently have a place in treatment of invasive candidiasis and is instead reserved for
the serious mould infections like aspergillosis and mucormycosis (73, 74).
Notably, a new subclass of azole antifungal compounds are in the drug pipeline.
The tetrazole compounds, VT-1129, VT-1161 and VT-1598, so named because of an
additional nitrogen on the five-membered azole ring that defines the class, are currently
awaiting or undergoing clinical trials to treat a wide variety of fungal infections (75, 76).
VT-1161, more specifically, is currently undergoing clinical trials as a treatment for
recurrent vaginal candidiasis and may be a plausible future therapy against azole-resistant
C. albicans.
There are many barriers to effective treatment with the azole antifungals in
invasive candidiasis. Improper dosing and inadequate drug delivery to the source of
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infection are obvious clinical faux pas to avoid, however, C. albicans and other Candida
species have a variety of methods to survive even proper treatment practices. The next
section details the specifics of the known azole resistance mechanisms in Candida
albicans.
Azole Resistance Mechanisms in C. albicans
Efflux pumps
Cdr1 and Cdr2
Like many infecting organisms, C. albicans utilizes an efflux system to transport
drugs extracellularly, thereby reducing intracellular drug concentrations. As such the
overexpression of azole-targeting efflux pumps is a key mechanism driving azole
resistance in C. albicans. The ATP-binding cassette (ABC) transporters Cdr1 and Cdr2
have both been well-documented as drivers of azole resistance and were first implicated
in clinical azole resistance in isolates in HIV-infected patients with oropharyngeal
candidiasis (77-79). In two separate studies, it was found that isolates of C. albicans
taken from HIV-infected individuals had increased mRNA levels of CDR1, which has
been shown to confer resistance to the azole antifungals (79-81).
Importantly, the zinc-cluster transcription factor Tac1 was discovered to regulate
the expression of both CDR1 and CDR2 and that a codominant mutation in the putative
C-terminal activation domain conferred hyperactivity of the Tac1 transcription factor,
leading to constitutive increased expression of CDR1 and CDR2 (82, 83). In a
comparison of azole-susceptible versus azole-resistant matched isolates, constitutive high
expression of these transporters was suggested to be a result of both increased
transcription and increased mRNA stability, the latter of which is tied to mRNA
hyperadenylation and loss-of-heterozygosity at the poly(A) polymerase 1 locus (84, 85).
Since then, multiple gain-of-function mutations in Tac1 leading to increased expression
of the Cdr1 and Cdr2 efflux transporters have been described (83, 86-88).
Additionally, it was shown that increased CDR1 expression could be induced in
agents such as estradiol or fluphenazine (89). While it was previously shown that CDR1
expression could be induced in response to fluconazole in a Cdr1-GFP fusion protein
construct, a more recent study found that no increase in CDR1 or CDR2 expression as
measured by RT-qPCR could be observed in the presence of fluconazole in a C. albicans
strain with 6His3Flag-tagged Tac1 (90, 91). Both the constitutive and transient
expression of CDR1 and CDR2 genes seems to be regulated via interactions at multiple
cis-acting elements within the CDR1 and CDR2 promoters (92). The presence of drugresponsive elements (DRE) within each gene’s respective promoter regions, for example,
has been shown to contribute to the induced and constitutive expression of CDR1 and
CDR2, while a separate basal expression element (BEE) contributes to CDR1 baseline
expression (82, 89, 93).
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In a genome-wide location analysis of Tac1 binding sites using ChIP-chip, Tac1
was shown to bind to the DRE of both CDR1 and CDR2 under nonactivating conditions,
indicating that post-binding mechanisms such as repressor interaction loss or coactivator
recruitment may occur during Tac1 activation (93). More recently, components of the tail
module of the Mediator complex have been identified as required for Tac1-activated
CDR1 expression. In a study examining the coactivator requirements for hyperactive
Tac1 regulation, Liu and Myers described decreased fluconazole MICs in TAC1 gain-offunction mutant strains lacking either Med3 or Med15, both of which are part of the
Mediator tail module (91). Furthermore, not only was Tac1-driven transcription of CDR1
decreased in gain-of-function Tac1 mutant strains lacking either Med3 or Med15, but
deletion of MED3 also diminished xenobiotic-induced expression levels of CDR1, CDR2,
and RTA3 with fluphenazine and estradiol. ChIP assays revealed that occupancy of the
Mediator tail module at the CDR1 DRE increases during Tac1 hyperactivation, as well as
with TAC1 overexpression, however higher occupancy at the DRE did not result in
increased fluconazole MICs, unless Tac1 was activated. Importantly, the authors also
delineated a C-terminal region of Tac1 (amino acids 865 to 981), so called the
transcription activation domain (TAD), whose interaction with an as yet uncharacterized
inhibitory middle domain, may be crucial to Tac1 hyperactivation, and have posited that
gain-of-function mutations in Tac1 may work to antagonize the normally inhibitory
interaction between these two regions (91).
Mdr1
Mdr1, part of the major facilitator superfamily of transporters, has also been
shown to play a role in fluconazole and voriconazole resistance, though it does not effect
large MIC changes with other azole antifungals such as itraconazole, isavuconazole, and
posaconazole (94-96). The gene encoding the Mdr1 efflux pump in C. albicans was
originally discovered by its ability to confer resistance to several structurally-unrelated
compounds such as the anti-mitotic drug benomyl, methotrexate, cycloheximide,
sulfometuron methyl, 4-nitroquinoline-N-oxide, and bentriazoles in Saccharomyces
cerevisiae expressing the C. albicans MDR1 gene, which at the time was known as BENr
(97, 98). It was not until serial isolates taken from HIV-infected patients with
oropharyngeal candidiasis were analyzed for ERG11 and MDR1 mRNA expression levels
was a link established between the MDR1 gene and fluconazole resistance (99).
A study assessing sequential isolates of C. albicans in patients with recurrent
oropharyngeal candidiasis treated with fluconazole found that increased MDR1 mRNA,
as well as increased CDR1/2 and ERG11 gene expression, correlated with increasing
fluconazole drug resistance, indicating that MDR1 plays a role in the multifaceted
development of resistance in C. albicans (100). When the MDR1 gene was disrupted in
two fluconazole-resistant clinical C. albicans isolates, susceptibility increased to
fluconazole compared to the resistant isolates with intact MDR1, demonstrating a direct
relationship between MDR1 and fluconazole resistance in clinical isolates (101).
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Importantly, matched pairs of fluconazole-susceptible and fluconazole-resistant
isolates were shown to lack major polymorphic differences in the nucleotide sequence of
their respective MDR1 promoter regions, despite high expression of MDR1 mRNA in the
fluconazole-resistance isolate (102). Subsequent expression of GFP from the MDR1
promoter in the fluconazole-resistant isolate but not the fluconazole-susceptible isolate
indicated that MDR1 expression was likely guided by a trans-regulatory factor.
Induction of MDR1 mRNA expression through benomyl and tert-butyl hydrogen
peroxide identified several cis-acting elements in the MDR1 promoter involved in
induction with these agents, though fluconazole itself failed to induce the MDR1
promoter (103).
It was not until more recently in 2007 that the zinc-cluster transcription factor
Mrr1 was discovered to regulate the Mdr1 efflux pump. Transcriptional profiling of three
MDR1-overexpressing clinical isolates via DNA microarray analysis revealed 21 genes
coordinately upregulated with MDR1 and seven genes downregulated in all three isolates
(104). Among these, the then putative zinc cluster transcription factor Zcf36, later known
as the multidrug resistance regulator Mrr1, was hypothesized to control MDR1
expression. Deletion of MRR1 in MDR1-overexpressing isolates F5 and G5 managed to
abolish MDR1 promoter activity in a PMDR1-GFP reporter fusion, implicating Mrr1 in the
constitutive expression of MDR1 in these fluconazole-resistant clinical isolates.
Interestingly, deletion of MRR1 in each MDR1-overexpressing isolate did not yield
identical MICs to strains lacking MDR1 in the same background. Deletion of MDR1
alone in both cases, resulted in a higher MIC in the resistant clinical isolate background
compared to deletion of its transcriptional regulator Mrr1, providing evidence that Mrr1
may regulate other determinants of fluconazole resistance apart from Mdr1.
Similar to the zinc cluster transcription factor encoding gene TAC1 in CDR1- and
CDR2-overexpressing isolates, mutated MRR1 alleles were present in the MDR1overexpressing clinical isolates (104). Moreover, sequencing of the MRR1 alleles in the
MDR1-overexpressing isolates F5 and G5 revealed a loss of heterozygosity and retention
of two copies of a mutant MRR1 allele in both clinical isolates. Replacement of a single
copy of the mutant MRR1 allele encoding either a P683S or G997V amino acid
substitution into SC5314 lacking both native copies of MRR1 resulted in increased
resistance to fluconazole and increased MDR1 promoter activity as measured by a PMDR1GFP reporter construct, demonstrating the presence of gain-of-function mutations in
MRR1 that regulate MDR1 expression in C. albicans.
Indeed, multiple amino acid substitutions in Mrr1 originating from both human
clinical isolates and in vitro generated strains have been shown to be gain-of-function
mutations driving constitutive MDR1 expression (105). Furthermore, through DNA
sequence analysis of a the F1 through F5 matched series clinical isolates, it was revealed
that gain-of function mutations appear to occur in a single MRR1 allele initially, which
provides an intermediate level of resistance compared to the matched isolates collected
chronologically later in the series that were homozygous for the MRR1P683S allele.
Through analysis of marker polymorphisms along chromosome 3 distal to MRR1 and
proximal to the telomere, Dunkel et al. revealed that loss-of-heterozygosity with selection
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of mutated MRR1 alleles was accomplished through mitotic recombination in clinical
isolates, though chromosome loss was also observed as a cause in MDR1 overexpressing
strains developed in vitro.
Upc2 and increased ERG11 expression
Upc2 is another Zn(II)-Cys(6) transcription factor involved in sterol biosynthesis
and azole resistance. Initially identified as a homolog of the S. cerevisiae (ScUPC2)
gene, UPC2 in C. albicans was initially reported to upregulate the ergosterol biosynthesis
genes ERG2 and ERG11 when exposed to fluconazole (106). The overexpression of
ERG11 had been shown to contribute to azole through increased production of the azole
target 14α-lanosterol demethylase (80, 99, 107, 108). However, not only was the
induction of ERG11 abolished when UPC2 was deleted, but the deletion strain was also
hypersusceptible to the azole drugs as well as the squalene epoxidase (Erg1) target drug
terbinafine, the Erg2 and Erg24 target drug fenpropimorph, and the HMG-CoA reductase
inhibitor lovastatin, illustrating UPC2’s important role in sterol biosynthesis regulation
(106, 108).
Importantly, overexpression of Upc2 via expression of the ORF from the MET3
promoter increased resistance to fluconazole and ketoconazole, and it was also
demonstrated for the first time that the DNA-binding domain of Upc2 bound directly to
ergosterol biosynthesis genes, binding to a putative sterol responsive element in ERG2
(108). Furthermore, investigation of the ERG11 promoter through deletion and linker
scan mutations concluded that two 7-bp inverted repeat sequences located -231 and -251
bp upstream of the start codon form an azole-responsive element (ARE) regulated by
Upc2, and that this ARE was sufficient to induce ERG11 expression (109).
Upc2, however, was also shown to have a regulatory role in more than just sterol
biosynthesis genes. Through genome-wide gene expression profiling, several ergosterol
biosynthesis genes, including ERG11, were determined to be coordinately upregulated
with UPC2 in fluconazole resistant isolates, and ChIP-microarray location analysis
identified 202 promoters bound by Upc2, including not only ergosterol biosynthesis
genes (NCP1, ERG11, ERG1, ERG2, ERG24, ERG4, ERG5, ERG6, ERG9, ERG10,
ERG25, ERG251, UPC2) but also other transcription factors and the drug transporter
genes CDR1 and MDR1 (110-112). As with the zinc cluster transcription factors Tac1
and Mrr1, gain-of-function mutations in Upc2 were found to lead to increased gene
expression of ERG11 conferring fluconazole-resistance in clinical isolates (110, 113115). When UPC2 was disrupted, the ∆upc2 mutants had decreased cellular ergosterol
content and were more susceptible to fluconazole not only in the azole-susceptible
SC5314 strain but also in a highly resistant clinical isolate 12-99 which overexpresses
CDR1, MDR1, ERG11 and possesses a mutation in ERG11, suggesting that UPC2 is
required for clinical azole drug resistance (115, 116).

9

Other zinc cluster transcription factors
Apart from the zinc cluster transcription factors Tac1, Mrr1, and Upc2, which are
well-known players in C. albicans azole resistance, there has been significant interest in
the azole-resistance role of the remaining zinc-cluster transcription factors as well. In
2013, Morschhäuser et al. demonstrated that laboratory strains exhibiting hyperactive
transcription factors Aro80, Mrr2, Stb5, Cta4, Zcf25, Zcf35, and Znc1 also displayed
increased azole resistance comparable to hyperactive Tac1, Mrr1, and Upc2,
demonstrating that in theory other ZCFs may play a role in azole resistance in C. albicans
(117). Additionally, in the hyperactive ZCF strains, Znc1 and Mrr2 appeared to activate
the CDR1 promoter, indicating that these ZCFs may contribute to increased efflux pump
expression.
In 2015, Wang et al. described the first clinical isolate containing putative gainof-function mutations in the ZCF Mrr2, identifying amino acid substitutions that
appeared increased CDR1, but not CDR2 expression (118). In contrast to this finding, a
recent report investigating these mutations in MRR2 when inserted into the native locus
as well as when the gene is overexpressed failed to identify any changes in fluconazole
susceptibility or CDR1 expression compared to wild type (119). Given the contradictory
findings, the clinical impact of other ZCFs outside of Tac1, Mrr1, and Upc2 in azole
resistance remains in question.
Mutations in ERG11
Mutations in the ERG11 gene itself is another common azole resistance
mechanism in C. albicans, in stark contrast with the haploid organism C. glabrata, in
which the frequency of mutations in ERG11 appears relatively low (14, 120). Most
ERG11 mutations are thought to alter the ability of the azoles to bind and inhibit the
lanosterol demethylase enzyme, either through steric hindrance in the ligand binding
pocket where the azole antifungals compete with ergosterol precursor or by altering or
reducing important interactions, such as the H-bond interactions with the azole ring and
the heme group of the Erg11 protein.
The earliest point mutation resulting in an amino acid substitution (R467K) in the
ERG11 gene of a clinical isolate was sequenced and discovered in 1997 (121). Soon
after, multiple additional amino acid substitutions in Erg11 were uncovered, and notably,
the effect of these amino acid changes on triazole antifungal MICs were not uniform
(122). This altered susceptibility to the azoles was noted to likely be a result of altered
interaction with azole binding and overall reduced fluconazole binding affinity to the
mutant 14α-lanosterol demethylase target enzyme (123, 124). As the azole antifungals
emerged as a common, first-line option in the treatment of many superficial and invasive
fungal infections, documentation of new ERG11 mutations in azole-resistant clinical
isolates continued to appear, though not all documented mutations were definitively
shown to be tied to azole resistance (125-138).
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The isolated contribution towards azole-resistance of several predominant Erg11
amino acid substitutions found in clinical C. albicans isolates was investigated through
homozygous replacement of the native ERG11 alleles with a mutant ERG11 ORF
encoding either a single or double amino acid substitution in the Erg11 protein (139).
Single substitutions in Erg11 showed variable responses to fluconazole and other
triazoles ranging from no effect to a 16-fold increase in MIC over the fluconazolesusceptible parent, and double substitutions in Erg11 further increased the MIC beyond
the individual contribution to azole resistance of any single amino acid substitution.
Interestingly, while some substitutions, such as Y132F/H, K143R, G307S, and S405F,
are located on the exposed active-site cavity of the Erg11 protein and presumably directly
influence or interfere with azole binding, other substitutions not predicted to directly
interact with azole binding, such as the G450E substitution found on the fungal CYP51specific β5-hairpin, may indirectly affect resistance through interaction with cytochrome
P450 reductase-Erg11 interactions (140).
Recently substitutions in purified, recombinant C. albicans Erg11 expressed from
E. coli revealed that Erg11 variants differ substantially in their baseline catalytic turnover
and affinity for azole binding (141). Despite some substitutions showing relatively loose
azole binding, their observed contribution to azole resistance in in vitro C. albicans
susceptibility testing was significant; making it conceivable that Erg11 amino acid
substitutions may contribute to azole resistance through more nuanced ways than simply
reducing azole binding affinity.
Mutations in ERG3 and alternative sterol biosynthesis
Alterations in sterol biosynthesis pathways in C. albicans remains an important,
albeit rare clinical mechanism of azole antifungal resistance. Defective C5-6 desaturase,
homologous to the Erg3 enzyme C-5 sterol desaturase, identified in azole-resistant
isolates of Saccharomyces cerevisiae initially led to the currently hypothesized mode of
action of the azole antifungals.
14α-methylergosta-8,24(28)-dien-3β, 6α-diol, a metabolic byproduct not normally
produced in significant amounts during normal ergosterol biosynthesis, was found to
accumulate in C. albicans cells following treatment with fluconazole (72). However,
isolates with defective C-5 sterol desaturase, which lacked detectable amounts of
ergosterol presumably because they no longer possessed the Erg3 enzyme function
required for ergosterol production, avoided accumulation of 14α-methylergosta-8,24(28)dien-3β, 6α-diol after treatment with fluconazole. The continued growth of isolates with
defective Erg3 in the presence of fluconazole has led to the current belief that 14αmethylergosta-8,24(28)-dien-3β, 6α-diol is toxic to the C. albicans cell, and its
accumulation results in the inhibition of growth. Moreover, mutations and amino acid
substitutions that confer defects in Erg3 also confer resistance to the azole antifungals,
specifically due to the inability to produce 14α-methylergosta-8,24(28)-dien-3β, 6α-diol,
which requires Erg3.
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While relatively few in number compared to isolates containing other more
common resistance mechanisms, several mutant ERG3 clinical isolates have been
identified, and reportedly possess resistance to the azole antifungals and cross-resistance
to the polyene amphotericin B (72, 130, 142-145). However, some question the clinical
significance of ERG3 mutant isolates during infection as isolates with an ERG3 resistance
phenotype also displayed hyphal growth defects and attenuated virulence (146-148).
Recently, it has been shown that changes within the ERG3 promoter that affect
expression and activity may be sufficient to confer azole resistance in niche-specific
instances without affecting C. albicans pathogenicity, which implicates changes in the
ERG3 locus as potentially more clinically relevant than previously believed (149).
Aneuploidy and loss of heterozygosity
Aneuploidy plays a role in azole resistance as well as genetic diversity in C.
albicans. Gain or loss of chromosomes have been tied to azole resistance and attenuated
virulence (150, 151). Loss of heterozygosity at gene loci of isolates serially passaged in
azole-containing media as well as lab strains passaged through mice models of
hematogenously disseminated disease both suggest that significant genetic
rearrangements take place as a result of host and drug stress (152, 153). Studies using
comparative genome hybridization in various C. albicans laboratory strains observed
aneuploidies mainly on chromosomes 1, 2, and 5 (154), and it was later shown that some
genomic changes such as isochromosome formation confer azole resistance in C.
albicans (155).
Overrepresentation of efflux pumps, ERG11, or zinc cluster transcription factor
genes involved in azole resistance as a result of chromosomal nondisjunctions, trisomy,
or isochromosome formation is very likely to contribute to decreased drug resistance in
these cells. Indeed, it had been shown for both TAC1 and MRR1 that loss of
heterozygosity was responsible in some clinical isolates for homozygous gain-of-function
mutations conferring increased efflux pump expression and azole resistance (83, 105). A
recent analysis of large-scale genomic changes in 43 clinical isolates of C. albicans
showed that while loss of heterozygosity events are persistent and often associated with
resistance, aneuploidies in clinical isolates are often transient and did not correlate with
drug resistance (156). The discovery of tetraploid cells of C. albicans, containing four
homologous sets of chromosomes, and their ability to generate a diverse range of fitness
and heterogeneity through increased rates of heterozygosity loss suggests that aneuploidy
plays an important role in adaptive fitness to selective pressures under these
circumstances (157, 158). The recent investigations into trisomy of chromosome R and
chromosome 4 possibly conferring azole resistance in two different clinical isolates of C.
albicans also underscores the importance of aneuploidy in the microevolution of drugresistant C. albicans (159, 160).
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Azole import
Currently there is limited evidence suggesting that reduced azole uptake has any
clinical relevance to azole resistance in C. albicans or any other Candida species.
However, it should be mentioned that it is plausible that reduced azole import could be a
potential uncharacterized mechanism of drug resistance. In a study examining the in
vitro accumulation of fluconazole into the Candida cell, it was observed that fluconazole
import displayed saturation kinetics in cells de-energized with 2-deoxy-D-glucose and
therefore unable to efflux drug via active transport mechanisms like the ABC transporter
Cdr1 (161). Additionally, maximal accumulation of fluconazole did not progress in a
temperature-dependent manner inconsistent with simple passive diffusion. The kinetics
of fluconazole import, therefore, suggests that fluconazole is uptaken by means of a
carrier protein via facilitated diffusion and that this mechanism is likely conserved across
many fungal species (161, 162).
The carrier protein(s) responsible to importing fluconazole and presumably the
other azoles, however, has/have not yet been identified despite prolific research. In
theory, cells possessing defective carrier protein (via mutation, for example) or protein in
low amounts would not accumulate lethal or significantly inhibitory amounts of drug,
resulting in resistance.
Azole tolerance
Candida albicans is usually classified as either susceptible (and susceptible dosedependent) or resistant when referring to clinical antifungal breakpoints, which are used
in helping to predict response to therapy against fluconazole or other antifungal agents
(29, 33, 163-165). Antifungal “tolerance” is an oft-used and loosely-defined term that
refers generally to the residual growth of cells at or above inhibitory concentrations of
drug.
Unlike resistant cells, which may be able to survive drug treatment due to genedependent mechanisms directly affecting the drug, drug target, or accumulation of the
drug in the cell, cells displaying tolerance have been defined as those able to survive
transient exposure to drug without an accompanying change in MIC (166-168). The
“trailing growth” phenomenon, describing the residual population of cells that grow at
supra-MIC levels observed in broth dilution assays, can be considered related to azole
tolerance and has been well-documented in C. albicans (168-171). Recently, RTA3,
encoding a putative lipid translocase coordinately upregulated with CDR1 in clinical
isolates with Tac1 gain-of-function mutations, has been associated with increased azole
tolerance and trailing growth in C. albicans (172).
The presence and degree of trailing growth has been known to be affected by
different parameters such as temperature and pH and can affect the MIC interpretation
depending on the time of reading (24 hours versus 48 hours) (170, 173, 174). However,
the clinical significance of trailing growth has been dubious at best. Past literature
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suggests that the C. albicans isolates exhibiting trailing growth phenomena responds to
azole treatment similarly to susceptible isolates in murine models and in a small sample
size of HIV-infected patients with recurrent oropharyngeal candidiasis (175-177).
Importantly, a recent study delineated parameters to describe the antifungal
tolerance observed with certain strains. The “fraction of growth,” or FoG, measured on
antifungal disk diffusion assay and the “supra-MIC growth,” or SMG, as measured by
broth microdilution assay are objective measurements assessing growth either inside the
zone of inhibition or above the MIC for a given strain, respectively (178). Neither
parameter correlated with MIC and instead measured a drug response distinct from MIC.
Interestingly, FoG and SMG were independent of inoculum size, cell density or drug
concentration, and in contrast to tolerance in bacteria, tolerant C. albicans cells did not
have reduced growth rates. Additionally, FoG did not correlate with growth rate or
colony size, indicating that high levels of FoG are not due simply to faster cell growth.
Instead, C. albicans isolates with high levels of FoG or SMG suggests a larger
subpopulation that can respond to high levels of antifungal drug stress better than isolates
with low FoG or SMG.
When comparing the drug responses of clinical isolates taken from patients with
persistent candidemia versus patients with candidemia that was cleared after a single
treatment course of fluconazole, significantly higher FoG and SMG levels was observed
in clinical isolates originating in patients with persistent candidemia (178). This was
despite the fact that the tested isolates in both groups all had in vitro MICs considered
fluconazole-susceptible, and identified FoG and SMG as potential parameters to guide
treatment outcome in patients with candidemia. This tied with the identification of
several adjuvant drugs that could reduce FoG but not MIC in clinical isolates suggests
that drug tolerance in C. albicans may be an overlooked issue of significant clinical
relevance.
Future Directions
As we have discussed, C. albicans has an arsenal of defense mechanisms that it
uses, alone and in combination with each other, to overcome inhibition by the azole
antifungals. Despite the numerous resistance pathways already discovered, continued
investigation is required to fully characterize azole resistance in C. albicans. For
example, the azole importer(s) in Candida and other fungal species has still not been
identified, and its discovery would plausibly reshape our approach to overcoming azole
resistance.
Ongoing research is also identifying potential novel mechanisms of azole
resistance, though the clinical significance of these are still unknown. Recently, a Nature
Communications paper published that alteration of sphingolipid synthesis mediated
through FEN1 and FEN12 deletion results in fluconazole resistance, and these
composition changes are similar to what is observed in wildtype cells treated with
fluconazole (179). Furthermore, transposon-based mutagenesis and disruption of the C.
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albicans genome in a haploid strain identified a number of potential genes involved in
drug stress response through Gene Set Enrichment Analysis, providing further insight
into C. albicans acquisition of drug resistance.
As more of the machinery driving azole resistance becomes unveiled, we can
begin to isolate the cogs critical to its function. Targeting these components with novel
drug development and improved use of our existing armamentarium becomes the
immediate goal in addressing the rising problem of azole resistance and antifungal drug
resistance in general.
Hypothesis and Objectives
Although C. albicans is a commensal organism that is part of normal flora in the
majority of the human population (2), it is an opportunistic pathogen that has been the
major infective species of Candida found in invasive candidiasis (17, 180, 181). For
invasive fungal infections like Candida bloodstream infections, mortality rates remain
high (182, 183). Fluconazole and other members of the azole class continue to be
commonly used in the treatment of Candida infections, and overall have good activity
against a majority of C. albicans isolates (15). However, azole-resistant Candida is of
serious concern, especially in those patient with prior exposure to the azole antifungals
(184-186). The ultimate, overarching goal of my research has been to improve the health
outcomes of patients treated with the azoles for C. albicans infections. By investigating
mechanisms of azole resistance in C. albicans, I hope to identify novel determinants in C.
albicans that may prove useful either in the determination and detection of clinical
isolates predisposed to azole non-susceptibility or as a drug target in the development of
new antifungals.
In previous work performed by our research group, the major known resistance
determinants, including the expression of the efflux pump encoding genes CDR1, CDR2,
and MDR1 as well as mutations in and increased expression of ERG11, encoding the
azole target 14α-lanosterol demethylase, were identified and characterized in a large
collection of predominantly fluconazole-resistant clinical isolates (115, 116). Here it was
revealed that some clinical isolates possessed higher fluconazole MICs than what could
be reasonably justified based on the known mechanisms of azole resistance (Figure 1-1).
Hence, I had reason to further investigate these clinical isolates for hidden contributors of
azole resistance.
Previous literature supports the hypothesis that other mechanisms of azole
resistance remain uncharacterized in clinical isolates. The critical role of the zinc cluster
transcription factors Tac1, Mrr1, and Upc2 in regulating gene expression of azole
resistance determinants led to identification of several other zinc cluster transcription
factors in C. albicans that can influence azole susceptibility in laboratory strains (117).
Through sequencing of the ZCF encoding gene MRR2, I identified several novel
mutations in our clinical isolates. A recent publication suggested that this ZCF is
important in the regulation of CDR1 expression in clinical isolates (118). In some of our
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Figure 1-1. Expression levels of CDR1, CDR2, MDR1, and ERG11 in 63
fluconazole-resistant clinical isolates
All gene expression levels were measured in triplicate, and fold expression of genes in
resistant isolates was compared to the average of the expression levels in three
susceptible isolates. Results for 63 isolates with reduced susceptibility to fluconazole are
represented, but only even-numbered isolates' results are labeled. Error bars show
standard errors. Reprinted from final submission with permission from the American
Society for Microbiology. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG,
Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a
frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida
albicans. Eukaryot Cell 11:1289-99. doi: 10.1128/EC.00215-12.
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isolates, CDR1 expression was increased without a corresponding gain-of-function
mutation in TAC1. Therefore, I hypothesized that gain-of-function mutations in MRR2
was responsible for increased CDR1 expression and increased fluconazole MICs in some
of our clinical isolates. My summarized aim was to characterize these mutations with
respect to their effect on fluconazole susceptibility and CDR1 expression by placing the
mutation-containing MRR2 alleles in a fluconazole-susceptible clinical isolate.
Previously, our research group had defined the contributions of individual and
combination amino acid substitutions in Erg11 (CaCYP51) to azole resistance in C.
albicans (139). Amino acid substitutions in CaCYP51 are a well-established resistance
mechanism that C. albicans possesses to reduce the ability of the azoles to inhibit
CaCYP51 activity. The effects of these amino acid substitutions on CaCYP51 function
and cell fitness, however, had not been previously studied. In a collaborative effort, our
research group aimed to determine the differences in biochemical function and
interaction between mutant CaCYP51 proteins, and whether this translates to reduced in
vitro azole susceptibility in C. albicans cells. We hypothesized that mutant CaCYP51
protein have variable binding affinities with the azole antifungals, affecting azole
susceptibility. Furthermore, we believed that amino acid substitutions not only affect
CaCYP51’s interaction with the azoles but also CaCYP51 native activity. My goal was
to create additional mutant CaCYP51 C. albicans strains and evaluate the in vitro
susceptibility data as compared to the biochemical data in this project.
Mutations in ERG3, a gene encoding the C-5 sterol desaturase important for
ergosterol and toxic sterol production, are an oft overlooked mechanism of azole
resistance due to its relative scarcity in clinical isolates. As part of the investigation into
azole resistance within our clinical isolates, I also sequenced the ERG3 gene in our
collection. Interestingly, in addition to a nonsense mutation in ERG3 in one clinical
isolate with altered sterol composition, I frequently sequenced an uncharacterized A351V
Erg3 amino acid substitution. Although I found no consistent correlation between
ergosterol content and ERG3 mutations, I noticed a high coincidence of ERG3 mutations
with ERG11 mutations. I posited that amino acid substitutions in Erg3, such as the
A351V mutations may play an indirect role in azole resistance by conferring either a
fitness advantage to isolates with ERG11 mutations. Preliminary data detailed in our
research group’s collaborative work with Erg11 mutants suggested that in addition to
conferring varying changes in azole susceptibility, Erg11 amino acid substitutions also
conferred changes in the Erg11 enzyme’s functional efficiency and, therefore, also to the
fitness of the cell. My hypothesis was that the A351V amino acid substitution in Erg3
was a permissive substitution that compensated for changes in Erg11 activity resulting
from deleterious amino acid substitutions. My initial aim was to determine whether the
A351V amino acid substitution conferred any advantage to cells also containing ERG11
mutations.
Lastly, the novel investigational drugs VT-1161 and VT-1598 had been
previously shown to have good activity against Candida and a wide variety of other fungi
(187-189). However, C. albicans mechanisms of resistance against these two agents
have not been clearly defined. Given our collection of azole-resistant clinical isolates and
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laboratory strains with defined mechanisms of azole resistance, our research group
endeavored to analyze the susceptibility data of our strains and isolates against both
drugs. The goals here were to identify known mechanisms of azole resistance that may
affect drug susceptibility to either VT-1161 or VT-1598 and to identify clinical isolates
that possess increased MICs to the tetrazoles. Identifying mechanisms affecting tetrazole
susceptibility would be useful in determining the role of either VT-1161 or VT-1598 as
prospective therapeutic agents in invasive Candida infection, especially in resistant or
recurrent infection. Additionally, given that our collection of clinical isolates contained
isolates with unusually high azole MICs that could not be explained, we hoped that the
additional tetrazole susceptibility data might provide insight on their resistance.
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CHAPTER 2. THE CONTRIBUTION OF CLINICALLY-DERIVED
MUTATIONS IN THE GENE ENCODING THE ZINC CLUSTER
TRANSCRIPTION FACTOR MRR2 TO FLUCONAZOLE ANTIFUNGAL
RESISTANCE AND CDR1 EXPRESSION IN CANDIDA ALBICANS1
Introduction
Candida spp. account for one of the most common pathogen groups implicated in
nosocomial bloodstream infections in the US (12, 183). Candida albicans is the most
common Candida spp. in invasive candidiasis and the primary cause of mucosal Candida
infections such as oropharyngeal candidiasis (34, 70, 183, 190, 191). Fluconazole and
other azoles are a mainstay of treatment in invasive candidiasis and oropharyngeal
candidiasis, and despite the emergence of other antifungal drug classes, there has been no
substantial decline in fluconazole resistance rates in C. albicans (29, 30, 34, 192).
Moreover, the high mortality rate for C. albicans in invasive fungal disease provides
compelling reason to further investigate how we can better utilize the available antifungal
drugs in order to overcome treatment failure (190, 193, 194). Therefore, it is imperative
that we achieve a comprehensive understanding of the mechanisms of azole resistance
within this organism.
Current understanding of fluconazole resistance within C. albicans involves sterol
biosynthesis gene mutations as well as zinc-cluster transcription factor-mediated changes
in efflux pump activity and drug target abundance (14). Zinc-binding proteins play a
crucial role in the transcriptional regulation of a vast number of genes in eukaryotes, and
in particular, the zinc cluster transcription factors (ZCFs) within the fungal kingdom
make up one of the largest regulatory protein families in yeast (117, 195). Regarding
azole antifungal resistance in Candida spp., ZCFs play a major role in almost all species
where azole resistance mechanisms have been elucidated, including C. glabrata and C.
parapsilosis (14). Changes in the zinc-cluster transcription factors Tac1, Mrr1, and Upc2
are thought to be responsible for the bulk of fluconazole resistance in C. albicans (14, 78,
79, 83, 104, 113, 115, 116, 196). The presence of gain-of-function mutations in the
transcription factor genes TAC1 and MRR1 results in increased expression of the efflux
pump genes CDR1/CDR2 and MDR1, respectively, while gain-of-function mutations
discovered in UPC2 lead to overexpression of the gene encoding the azole target, Erg11
(14α-sterol demethylase) (83, 104, 113). Other mechanisms of azole resistance include
changes in the azole target 14α-sterol demethylase through mutations in its encoding
gene ERG11 and less commonly through mutations in the sterol-C5(6)-desaturase
encoding gene ERG3 (71, 121, 122, 142).
There is evidence strongly suggesting that other mechanisms of azole resistance
________________________
1

Reprinted from final submission with permission. Nishimoto AT, Zhang Q, Hazlett B, Morschhäuser,
Rogers PD. (2019). The contribution of clinically-derived mutations in the gene encoding the zinc cluster
transcription factor Mrr2 to fluconazole antifungal resistance and CDR1 expression in Candida albicans.
Antimicrob Agents Chemother. doi:10.1128/aac.00078-19:AAC.00078-19.
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in Candida spp. exist. For example, it has been previously demonstrated that other ZCFs
can alter susceptibility to fluconazole when transcriptionally activated (117). In
particular, decreased fluconazole susceptibility was observed in a laboratory strain
expressing artificially-activated Mrr2. The hyperactive ZCF Mrr2 was noted to activate
the CDR1 promoter but not the CDR2 promoter, in contrast to activated Tac1, which is
known to increase both CDR1 and CDR2 expression (82). Additionally, fluconazole
sensitivity was restored after deletion of the CDR1 gene in the hyperactive Mrr2 strain
(117). More recently, potential activating mutations in Mrr2 which increased expression
of CDR1 but not CDR2 have been described in fluconazole-resistant clinical isolates of
C. albicans, indicating that not only can these mechanisms manifest in vitro, but also that
they are clinically relevant (118). Mrr2 is a relatively understudied ZCF whose role in
clinical azole resistance has not yet been completely defined, but the potential
significance of Mrr2 as a contributing azole resistance determinant in C. albicans cannot
be overlooked.
In the present study, we investigated the contributions to fluconazole resistance of
mutations in MRR2 oberved among isolates within a collection of azole-resistant clinical
C. albicans isolates. To accomplish this, we sequenced the MRR2 open reading frame
(ORF) in a collection of 57 clinical isolates with reduced susceptibility to fluconazole
(MIC range: 4 to >64 μg/mL, data not shown). Screening of the strains revealed multiple
polymorphisms in MRR2, several of which had been previously described to impact
fluconazole MICs. Clinically-derived MRR2 alleles were introduced in a fluconazolesusceptible background to generate strains containing multiple single nucleotide
polymorphisms (SNPs) in the MRR2 gene. In contrast to a previous report (118), we
found no changes in fluconazole MIC or CDR1 expression upon introduction of any of
the MRR2 SNPs observed in clinical isolates in our collection or described previously.
Results
SNPs in MRR2 among fluconazole-resistant clinical isolates of C. albicans
To identify clinically-occurring amino acid substitutions in Mrr2, we sequenced
the MRR2 gene of 67 C. albicans clinical isolates (10 fluconazole-susceptible, 57
fluconazole-resistant) that we have previously described (115, 139). This collection of
isolates had been previously characterized for known resistance mechanisms and
collectively possessed every known mechanism of azole resistance (115, 139). Overall,
25 (44%) of 57 fluconazole-resistant isolates possessed SNPs resulting in amino acid
changes in Mrr2 (Appendix A), however, many of these SNPs were also observed in
fluconazole-susceptible isolates and would not be expected to influence fluconazole
MICs. Seven amino acid substitutions resulting from SNPs in MRR2 were present only
among fluconazole-resistant isolates within our collection. Three of these substitutions
(R45Q, A459T, V486M) had not previously been described in the literature. The
remaining four substitutions (S466L, A468G, S469T, T470N) had been previously found
in resistant clinical C. albicans isolates and reported to have an effect on fluconazole
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MIC and CDR1 expression (118). Within our collection, these four substitutions
appeared in four clinical isolates and exclusively co-occurred with each other.
Interestingly, constitutive CDR1 expression levels were less than two-fold greater than
that of a composite of fluconazole-susceptible isolates in five clinical isolates containing
either the A459T substitution or the combination substitutions of S466L, A468G, S469T,
and T470N (Table 2-1).
Fluconazole susceptibility in MRR2 mutant strains
To determine if the newly discovered amino acid changes in Mrr2 affected
fluconazole susceptibility, we introduced two copies of the MRR2 allele from
fluconazole-resistant isolates 23, 20, 28, and 29 containing respectively the R45Q,
A459T, V486M, and combined amino acid substitutions S466L, A468G, S459T, and
T470N into the mrr2∆/∆ strain (SCZCF34M4A) via homologous recombination using the
SAT1 flipper technique. This subsequently yielded homozygous mutant strains MRR2R45Q,
V451A
(SCMRR2R2S2), MRR2S143P, L144V, T145A, S165N, A459T, S480P (SCMRR2R4S4),
MRR2T83A, A459T, S480P, V486M (SCMRR2R5S5), and MRR2S466L, A468G, S469T, T470N, S480P
(SCMRR2R6S6), which we hereafter will refer to as MRR2R45Q, MRR2A459T, MRR2A459T,
V486M
, and MRR2S466L, A468G, S469T, T470N, respectively. An additional mutant, MRR2T83A,
V451A, V582L
(SCMRR2R3S3), hereafter referred to as MRR2V582L, was similarly
constructed from the MRR2 allele of fluconazole-susceptible isolate 22 as it contained a
V582L substitution not previously described in the literature. For comparison, we
created a MRR2WT (SCMRR2R1S1) strain by inserting wildtype MRR2 amplified from
fluconazole-susceptible clinical isolate SC5314 into the mrr2∆/∆ strain and included the
previously described hyperactive Mrr2 strain (SCZCF34GAD1), which highly expresses
artificially-activated Mrr2 (117). Surprisingly, none of the MRR2 mutant strains showed
any change in fluconazole susceptibility as compared to SC5314 or MRRWT as measured
by CLSI standard methods (Table 2). This included MRR2S466L, A468G, S469T, T470N, whose
MRR2 alleles contained four of six mutations previously reported to have an effect on
fluconazole susceptibility. As expected, hyperactive Mrr2 exhibited elevated MICs to
fluconazole. Strain susceptibilities measured on RPMI-agar using E-test strips also did
not show reduced fluconazole susceptibility for any polymorphism-containing MRR2
strain compared to SC5314. However, via E-test, we observed that the mrr2∆/∆ strain
was slightly hypersusceptible to fluconazole compared to SC5314, as has been
established previously (Table 2-2) (117).
MRR2 mutant strains do not overexpress CDR1 when expressed from the MRR2
locus
To investigate whether any of the MRR2 mutant strains could constitutively
increase expression of the efflux pump gene CDR1, we measured the CDR1 mRNA
abundance for each MRR2 strain compared to SC5314 (Figure 1A) in triplicate via RTqPCR. Expression of CDR1 was not significantly increased compared to SC5314 in any
of the created strains containing polymorphic MRR2 alleles. MRR2R45Q, MRR2A459T, and
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Table 2-1.
Mrr2 amino acid substitutions found in azole-resistant clinical isolates
expressing CDR1
Mrr2 amino acid substitution
V486M
V486M
V486M
A459T
A459T
A459T
A459T
A459T
A459T
A459T
R45Q
S466L1,2, A468G1, S469T1, T470N1,2
S466L1,2, A468G1, S469T1, T470N1,2
S466L1,2, A468G1, S469T1, T470N1,2
S466L1,2, A468G1, S469T1, T470N1,2

Isolate ID
15
27
28
18
19
20
33
41
48
54
23
16
26
29
46

1

24H MICFLU
(μg/mL)
16
16
64
32
32
64
32
64
32
32
32
8
16
>64
64

Fold CDR1
Expression
15.9
14.2
18.1
10.4
10.0
7.8
16.2
1.7
13.3
0.9
16.3
1.6
0.9
10
0.8

Amino acid substitutions previously reported to increase fluconazole MICs (118).
Amino acid substitutions previously reported to increase CDR1 expression at least twofold versus susceptible comparator (118).

2
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Table 2-2.

Fluconazole susceptibilities for MRR2 mutant strains

Strains
SC5314
SCZCF34M4A
SCZCF34GAD1A
SCMRR2R1S1
SCMRR2R2S2
SCMRR2R3S3
SCMRR2R4S4
SCMRR2R5S5
SCMRR2R6S6
SCMRR2R8S8
SCMRR2GAD1R1S1
SCΔmrr2PADH1MRR2WT A
SCΔmrr2PADH1MRR2WT B
SCΔmrr2PADH1MRR2C9 A
SCΔmrr2PADH1MRR2C9 B

Strain description1
WT
mrr2Δ/Δ
overexpressed MRR2-GAD
MRR2WT
MRR2L143P,L144V,T145A,S165N,A459T,S480P
MRR2T83A,V451A,V582L
MRR2R45Q,V451A
MRR2T83A,A459T,S480P,V486M
MRR2S466L,A468G,S469T,T470N,S480P
MRR2C9
MRR2-GAD
overexpressed MRR2WT
overexpressed MRR2WT
overexpressed MRR2C9
overexpressed MRR2C9

1

GAD = 3X HA-tagged GAL4 activation domain
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24H FLU MIC
(μg/mL, CLSI)
0.25
0.25
0.5
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.5
0.25
0.25
0.25
0.25

24H FLU MIC
(μg/mL, E-test)
0.125
0.064
0.75
0.094
0.125
0.125
0.125
0.094
0.094
0.125
0.19
0.125
0.125
0.125
0.125

MRR2A459T, V486M, which contained novel Mrr2 substitutions found only in fluconazoleresistant isolates, did not appear to express CDR1 to a greater degree than MRR2WT or
SC5314. MRR2S466L, A468G, S469T, T470N, containing four mutations thought to influence
CDR1 expression also showed no increases over MRRWT or SC5314, in line with our
clinical isolates containing these substitutions in Mrr2 but not overexpressing CDR1.
The strain expressing hyperactive Mrr2 showed an approximately eight-fold increase in
CDR1 over the control, consistent with its reduced susceptibility to fluconazole.
Amino acid substitutions S466L, A468G, S469T, and T470N do not influence
fluconazole MICs or CDR1 expression
The four amino acid substitutions S466L, A468G, S469T, and T470N that were
introduced into MRR2S466L, A468G, S469T, T470N failed to alter fluconazole susceptibility or
change CDR1 expression from SC5314. However, since we created this strain by
inserting the entire MRR2 allele taken from a resistant isolate, these substitutions were
accompanied by other polymorphisms within the MRR2 allele, and thus we could not rule
out an interaction between these polymorphisms and the Mrr2 substitutions S466L,
A468G, S469T, and T470N that could mask the increased fluconazole MICs previously
associated with these substitutions. Therefore, we created the mutant MRRS143P, L144V,
T145A, H358N, E439K, V451A, S466L, A468G, S469T, T470N, S480P
strain (SCMRR2R8S8, hereafter
C9
referred to as MRR2 ) by introducing a mutant MRR2 allele containing 13 nucleotide
changes corresponding to 11 amino acid substitutions in Mrr2 (Table 2-3) in order to
verify the phenotype associated with these changes described in the literature (118).
Surprisingly, MRR2C9 fluconazole MICs (Table 2-2) and CDR1 expression (Figure
2-1A) were not different from SC5314, suggesting that these amino acid changes did not
impact fluconazole resistance or CDR1 expression when MRR2 was expressed from the
native promoter.
Our tested strains utilized homologous recombination to re-introduce polymorphic
MRR2 alleles back into the mrr2∆/∆ strain at the native MRR2 locus. In order to
substantiate our method of strain creation, we used the SAT1/FLP strategy to introduce
two copies of the MRR2 allele in which the C-terminal end of the gene was fused to the
GAL4 activation domain and 3X HA-tagged, creating the mutant strain MRR2-GAL4AD3xHA (SCMRR2GAD1R1S1). Fusion of the HA-tagged Gal4 activation domain to fulllength ZCFs had been previously shown to constitutively activate fungal ZCFs such as
Tac1, Upc2, and Mrr1 when expressed from the ADH1 promoter (117). Here, our
purpose was to create a constitutively active Mrr2 strain in which both copies of MRR2
were natively expressed. CDR1 expression increased ~2.5-fold from SC5314 in this
strain, which resulted in slightly increased MICs to fluconazole over SC5314 as well,
showing that homozygous replacement of the MRR2 allele in the native locus using the
SAT1/FLP method was capable of producing changes in CDR1 expression and
fluconazole MIC without foreign promoter-driven overexpression of MRR2. This change
was smaller than the increase in CDR1 expression and fluconazole MIC seen with the
hyperactivated MRR2 strain, in which MRR2 is expressed from the strong ADH1
promoter.
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Table 2-3.

Strains used in Chapter 2

Strains
SC5314
SCZCF34M4 A/B
SCZCF34GAD1 A/B
SCMRR2R1S1 A/B
SCMRR2R2S2 A/B
SCMRR2R3S3 A/B
SCMRR2R4S4 A/B
SCMRR2R5S5 A/B
SCMRR2R6S6 A/B
SCMRR2R8S8 A/B/C
SCMRR2GADR1S1 A/B
SCΔmrr2PADH1MRR2WT A/B
SCΔmrr2PADH1MRR2C9 A/B

Genotype1,2
Wildtype
Δmrr2::FRT/Δmrr2::FRT
ADH1/adh1::PADH1-MRR2-GAL4AD-3xHA-caSAT1
MRR2WT::FRT/MRR2WT::FRT
MRR2S143P,L144V,T145A,S165N,A459T,S480P::FRT / MRR2S143P,L144V,T145A,S165N,A459T,S480P::FRT
MRR2T83A,V451A,V582L::FRT / MRR2T83A,V451A,V582L::FRT
MRR2R45Q,V451A::FRT / MRR2R45Q,V451A::FRT
MRR2T83A,A459T,S480P,V486M::FRT / MRR2 T83A,A459T,S480P,V486M::FRT
MRR2S466L,A468G,S469T,T470N,S480P::FRT / MRR2S466L,A468G,S469T,T470N,S480P::FRT
MRR2C9::FRT / MRR2C9::FRT
MRR2-GAL4AD::FRT / MRR2-GAL4AD-3xHA::FRT
Δmrr2::FRT/Δmrr2::FRT, ADH1/adh1::PADH1-MRR2WT
Δmrr2::FRT/Δmrr2::FRT, ADH1/adh1::PADH1-MRR2C9

1

Source or reference
ATCC
(117)
(117)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Tentative activating mutations in MRR2 described in (118) are underlined.
Amino acid changes in MRR2 in bold were discovered from this study. MRR2C9 refers to the MRR2 allele of isolate C9 as described
in (118) containing S143P, L144V, T145A, H358N, E439K, V451A, S466L, A468G, S469T, T470N, S480P mutations
2
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Figure 2-1. Fold-change in expression levels of MRR2 mutant strains compared to
SC5314
(A) Fold-change in expression levels compared to SC5314 of CDR1 for the mrr2∆/∆
strain (SCZCF34M4A), the mutant MRR2 strains containing MRR2WT (SCMRR2R1S1),
MRR2A459T (SCMRR2R2S2), MRR2V582L (SCMRR2R3S3), MRR2R45Q (SCMRR2R4S4),
MRR2A459T, V486M (SCMRR2R5S5), MRR2S466L, A468G, S469T, T470N (SCMRR2R6S6),
MRR2C9 (SCMRR2R8S8) and artificially-activated Mrr2 strains expressed from either
the ADH1 promoter (SCZCF34GAD1A) or the native MRR2 promoter
(SCMRR2GAD1R1S1). (B) Fold-change in MRR2 expression levels compared to
SC5314 for the mrr2∆/∆ strain (SCZCF34M4A), the mutant MRR2C9 strain
(SCMRR2R8S8), the artificially-activated Mrr2 strains expressed from either the ADH1
promoter (SCZCF34GAD1A) or the native MRR2 promoter (SCMRR2GAD1R1S1).
Expression was obtained in technical and biological triplicate for each strain tested and
error bars reflect standard error of the mean.
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Activated Mrr2 does not appear to regulate MRR2 expression
To determine if Mrr2 autoregulates its expression level, we measured MRR2
mRNA abundance of our created strains relative to SC5314 (Figure 2-1B). The mutant
strain MRR2C9 and the artificially-activated MRR2 strain MRR2-GAL4AD-3xHA did not
appear to have increased expression of MRR2 compared to SC5314. As expected, strains
with hyperactive MRR2 expressed MRR2 ~14-fold higher compared to SC5314.
Therefore, it appears only the relative overexpression of MRR2 from the ADH1 promoter
and not activation of Mrr2 itself had any effect on increased MRR2 expression.
Overexpression of wildtype or mutant MRR2 in C. albicans strain does not affect
fluconazole susceptibility or CDR1 expression
In order to investigate whether changes in CDR1 expression and fluconazole
susceptibility required strong constitutive expression of MRR2, we constructed strains
which lacked both native copies of MRR2 but possessed a single copy of either the open
reading frame of MRR2WT or MRR2C9 fused to the ADH1 promoter. In both cases, MRR2
mRNA expression was increased >30-fold compared to SC5314 in the independently
created mutant strains mrr2Δ/Δ adh1Δ::PADH1-MRR2WT/ADH1 (SCΔmrr2PADH1MRR2WT
A/B) and mrr2Δ/Δ adh1Δ::PADH1-MRR2C9/ADH1 (SCΔmrr2PADH1MRR2C9 A/B, Figure
2B). However, compared to SC5314, CDR1 expression was not markedly different for
any of the strains, with no increase in constitutive CDR1 mRNA greater than 1.2-fold
(Figure 2-2A). As expected, the strains also did not show any change in fluconazole
susceptibility by either MIC or E-test (Table 2-2). Thus, overexpression of either
MRR2WT or MRR2C9 does not appear to influence CDR1 expression or fluconazole
susceptibility in C. albicans.
Discussion
Gain-of-function mutations in the genes encoding fungus-specific ZCFs Tac1,
Mrr1 and Upc2 have long been known to contribute to azole resistance in C. albicans.
However, only recently was it reported that non-synonymous mutations found in the
MRR2 gene of clinical isolates impacted fluconazole susceptibility through increased
Cdr1 efflux pump expression, indicating that MRR2 may be a clinically relevant
mechanism of azole resistance. Here, we sequenced a collection of predominantly
fluconazole-resistant clinical isolates in order to uncover additional mutations in the
MRR2 gene that would contribute to fluconazole resistance. In total, mutations resulting
in fifteen amino acid substitutions were identified across these clinical isolates. Three
(R45Q, A459T, and V486M) were found uniquely in fluconazole-resistant clinical
isolates and had not been previously reported. The remaining were described in a
previous report or were present in fluconazole-susceptible isolates and therefore not
likely directly involved in azole resistance. Our results indicate that none of the tested
SNPs in MRR2 have an impact on susceptibility to fluconazole. Similarly, CDR1
expression also did not appear to be affected by the presence of any of the tested SNPs.
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Figure 2-2. Fold-change in CDR1 and MRR2 expression compared to SC5314
(A) Fold-change in expression levels compared to SC5314 of CDR1 for strains
possessing either MRR2WT (SCΔmrr2PADH1MRR2WT A and B) or mutant MRR2C9
(SCΔmrr2PADH1MRR2C9 A and B) expressed via the ADH1 promoter. (B) Fold-change
in MRR2 expression levels compared to SC5314 for the same strains shown in (A).
Expression was obtained in technical and biological triplicate for each strain tested and
error bars reflect standard error of the mean.
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In particular, four mutations identified in isolates in our collection (S466L,
A468G, S469T, and T470N) had been previously shown to impact fluconazole
susceptibility. The amino acid substitutions S466L and T470N had also been reported to
increase CDR1 expression by at least two-fold as compared to a control strain. In our
hands the amino acid substitutions S466L, A468G, S469T, and T470N do not appear to
have any effect on susceptibility to fluconazole and CDR1 expression does not increase
in the mutant strains containing these Mrr2 amino acid substitutions compared to
SC5314. This finding is consistent with our clinical isolates that possess these changes in
Mrr2 but do not highly express CDR1.
Since the publication of the original report first describing them, mutations in
MRR2 have been referenced as a clinically relevant mechanism of fluconazole resistance
(160, 197, 198). While our results confirm that artificial activation of the Mrr2 ZCF
indeed results in CDR1 upregulation and a consequent increase in fluconazole resistance
as previously described (117), we were unable to replicate the changes attributed to these
mutations in a previous report (118). We were unsuccessful in obtaining isolate C9 from
this previous report, which contained the MRR2 mutations in question, and as such could
not make a direct assessment of this clinical isolate. One possibility for the disparity seen
between our results and those reported previously could be differences in methodology.
We expressed MRR2 from its native promoter, including replacement of both ORFs in the
MRR2 locus, in order to mimic natural Mrr2 expression. This is in contrast to the
methods used previously whereby MRR2 was placed in the ADE2 locus utilizing a single
copy of the ORF under control of the ADH1 promoter. This could possibly cause altered
metabolic burdens in these strains compared to ours. Furthermore, the ADH1 promoter
has been described to have variability in activity over time under different conditions
(199), and therefore Mrr2 protein levels may be different depending on the time at which
cells were harvested or observed for assays. Lastly, we used 50% inhibition from the
fluconazole-free control well for identifying the MIC of our strains, as directed by the
CLSI reference method for broth microdilution antifungal susceptibility testing of yeast
(200, 201). The MICs presented in the previous report were identified by 80% inhibition
of cell growth in the control well, which could explain increased MICs observed in
MRR2 mutant strains, especially if the trailing growth phenomenon was observed in these
strains.
Given the lower expression of MRR2 that we observed in our strains using the
native MRR2 promoter compared to hyperactive Mrr2, which overexpressed MRR2 via
fusion to the ADH1 promoter, we considered that MRR2 was not being sufficiently
expressed in our strains to allow for detection of changes in CDR1 expression or
fluconazole susceptibility. However, the MRR2-GAL4AD-3xHA strain expressing
artificially-activated Mrr2 via its native promoter demonstrates that native MRR2
expression levels are sufficient to observe changes in fluconazole MIC and CDR1
expression. Moreover, we believe our strains, which tested the effects of the
homozygous SNPs in MRR2 at the native locus, more closely approximates the effects
these nucleotide changes would have in a clinical isolate. Lastly, we constructed our own
PADH1-MRR2 overexpressing strains to test whether there were differences in CDR1
expression or fluconazole susceptibility between strong, constitutive expression of either
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MRR2WT or MRR2C9 and were unable to discern any phenotype differences between the
strains. Overall, in all strains and conditions tested here we were unable to detect any
change in CDR1 expression or fluconazole susceptibility between strains containing
mutant MRR2 versus wildtype.
The ATP-binding cassette transporter Cdr1 has been shown to be regulated not
only by Tac1, but also Ndt80. Furthermore, it has been shown that through artificial
activation and overexpression, the zinc cluster transcription factors Mrr2, Znc1, and Stb5
also can influence Cdr1 expression levels. Thus, we speculate that there remain
additional determinants of efflux pump upregulation that have clinical relevance.
However, our experiments indicate that the nucleotide changes observed here, and
reported previously, in MRR2 do not impact fluconazole susceptibility or CDR1
expression and are not clinically relevant to fluconazole resistance in C. albicans. Given
that azole resistance cannot be fully explained by known mechanisms, further
investigation of other ZCFs in azole resistance is warranted.
Materials and Methods
Strains and growth conditions
Table 2-2 lists the C. albicans strains used in this study. C. albicans isolates were
obtained from a repository of clinical isolates at the University of Iowa and have been
previous reported elsewhere (115). Strains were stored in 40% glycerol frozen stocks at 80° C. Routine growth of cells was performed in YPD liquid media (1% yeast extract,
2% peptone, 2% dextrose) at 30°C. Nourseothricin-containing (200 μg/mL) YPD agar
plates were used for selection of strains containing the SAT1 marker. For plasmid
propagation, DH5α™ competent E. coli cells (Invitrogen) were grown in Luria-Bertani
(LB) broth or on LB agar plates containing either 100 μg/mL ampicillin or 50 μg/mL
kanamycin.
Plasmid construction
Plasmids were derived from plasmid strain pBSS2, which contains the SAT1
flipper disruption cassette from pSFS2 (202) placed in the pBluescript II KS+ vector.
The 3’ flanking region of the MRR2 ORF was amplified from SC5314 genomic DNA
using primers CaMRR2C_(NotI) and CaMRR2D_(SacI) and ligated into pBSS2 at the
NotI and SacI restriction sites to create pMRR2CD. The 5’ upstream region and MRR2
ORF of isolates SC5314, 20, 22, 23, 28, and 29 were amplified using primers
CaMRR2A_(KpnI) and CaMRR2E_(XhoI) and cloned into pMRR2CD to obtain
plasmids pBSS2-MRR2WT, pBSS2-MRR220, pBSS2-MRR222, pBSS2-MRR223, pBSS2MRR228, and pBSS2-MRR229, respectively. For pMRR2_C9.3 which replicated the
MRR2 allele of isolate C9 described by Wang et al. (118), primers CaMRR2_P1_F and
CaMRR2_C9_R were used to amplify a 5’ portion of the MRR2 ORF from genomic
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DNA of isolate 33. The resulting amplicon was fused to a synthesized gBlocks fragment
(Integrated DNA Technologies) containing the 3’ portion of the MRR2 ORF using
CaMRR2_Nested_F_KpnI and MRR2_Nested_DR_XhoI and cloned into pMRR2CD to
give pMRR2_C9.2. Final changes of nucleotides were accomplished using short,
overlapping extension (SOE) PCR on plasmid pMRR2_C9.2 using primer pairs
pBSS2_1F.2 and CaMRR2_C9.2_R6, CaMRR2_C9.2_F6 and CaMRR2_C9.2_R7,
CaMRR2_C9.2_F7 and CaMRR2_C9.2_R8, and CaMRR2_C9.2_F8 and pBSS2_
MAL2_R to generate amplicon fragments of the MRR2 ORF. Fragments were fused
together via SOE PCR using CaMRR2_Nested_F_KpnI and CaMRR2_Nested_
DR_XhoI and were cloned into pMRR2CD to create pMRR2_C9.3. Plasmid
pMRR2GAD1 was generated using genomic DNA from SCZCF34GAD1A and primers
CaMRR2GAD1A_F_KpnI and 3XHA_ACT1_R_XhoI to amplify the MRR2 ORF
including the fused GAL4 activation domain and 3X HA-tagged C-terminal region. The
resulting amplicon was cloned into pMRR2CD to yield plasmid pMRR2GAD1.
Plasmids pPADH1-MRR2WT and pPADH1-MRR2C9 were used to express the open reading
frame of MRR2 from the ADH1 locus, utilizing the ADH1 promoter and termination
sequences. The MRR2 open reading frame of either SC5314 or the C9 isolate was fused
to the 3’ ADH1 terminator via overlap extension PCR utilizing primers CaMRR2_2F_
EcoRI, CaMRR2_R_ADH1t.2, CaADH1t_F, and ADH1t_R_XhoI. The ADH1 promoter
was PCR amplified using primers CaPADH1_AF_KpnI and CaPADH1_2R_EcoI. Both
the ADH1 promoter and fused MRR2-ADH1t amplicons were digested with either KpnI
and EcoRI or EcoRI and XhoI, respectively, and subsequently ligated into the KpnI-XhoI
linearized plasmid pADH1CD, a pBSS2 derivative containing the 342 bp 3’ flanking
homology near the ADH1 locus generated with primers CaADH1_C_SacII and
CaADH1_D_NcoI_SacI. Successful transformants were screened on LB agar plates
containing 50 μg/mL ampicillin and sequenced for the MRR2 open reading frame
corresponding to either SC5314 or isolate C9 for plasmid pPADH1-MRR2WT and pPADH1MRR2C9, respectively.
MRR2 amplification and sequencing
Table 2-4 lists the primers used for MRR2 amplification and sequence
verification. The MRR2 coding sequence of each isolate was PCR amplified from
genomic DNA using primers CaMRR2_F_Amp and CaMRR2_R_Amp. PCR products
were purified using the QIAquick® PCR Purification Kit (Qiagen) and product was
sequenced on an ABI 3130XL genetic analyzer using MRR2 sequencing primers.
Sequencing was accomplished in duplicate in independently grown isolates.
Candida albicans strain construction
The SAT1/FLP-containing MRR2 replacement cassette was excised from plasmids
pBSS2-MRR2WT, pBSS2-MRR220, pBSS2-MRR222, pBSS2-MRR223, pBSS2-MRR228,
and pBSS2-MRR229, pMRR2_C9.3, and pMRR2GAD1 were digested using KpnI-HF
and NcoI-HF restriction enzymes and transformed via electroporation into C. albicans
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Table 2-4.

Primers used in this study

Primer name by purpose
Amplification
CaMRR2_F_Amp
CaMRR2_R_Amp
CaMRR2GAD1A_F_KpnI
3XHA_ACT1_R_XhoI
CaPADH1_AF_KpnI
CaMRR2_2R_EcoRI
CaMRR2_2F_EcoRI
CaADH1t_R_XhoI
CaADH1_C_SacII
CaADH1_D_NcoI_SacI
Sequencing
CaMRR2SeqA
CaMRR2SeqB
CaMRR2SeqC
CaMRR2SeqD
CaMRR2SeqE
CaMRR2SeqF
CaMRR2SeqG
CaMRR2SeqH
Short, overlapping extension
CaMRR2_P1_F
CaMRR2_C9_3R
CaMRR2_Nested_F_KpnI
CaMRR2_Nested_DR_XhoI
pBSS2_1F.2
pBSS2_MAL2_R
CaMRR2_C9.2_F6
CaMRR2_C9.2_R6
CaMRR2_C9.2_F7
CaMRR2_C9.2_R7

Sequence1
5’ – TACGAAATACTTGGAGTTATTCCCTAC – 3’
5’ – CTAGTTTTGTGTCTAGTTCTATTGTTATTG – 3’
5’ – CAGGGTACCAACTTGAAAAATTGCTCAACTCTTATATAGCAAAAATAAACAACCAAT
AGCTTCTTCGCCAATGACCAAACGTGATCGTAC – 3’
5’ – CTACTCGAGGATTTCCAGAATTTCACTCTTA – 3’
5’ – GATGGTACCACTACCACTGCAGCTGCATC – 3’
5’ – CTTTTTGAGTTTTTGGGATTTGTTCGAATTCAATTGTTTTTGTATTTGTTGTTGTTGTTG – 3’
5’ – GATGAATTCATGACCAAACGTGATCGTACAAT – 3’
5’ – CATCTCGAGTTAACCAAAATCAACGACAAATTG – 3’
5’ – GATCCGCGGCATTGATTGTTTGTGTTAGTTTTTCA – 3’
5’ – GATGAGCTCCCATGGAACACCCAGTTTAATTTCCATGA – 3’
5’ – GCAGAAGCGAGGGAACTTGAAA – 3’
5’ – ACTTGGAGAAGCATACATACCGAG – 3’
5’ – TACTCGCTCGCCTTACATCGA – 3’
5’ – AATCTCAACTACATCCACCTTGTC – 3’
5’ – CGAAACTTCTGCCATCCTCAAT – 3’
5’ – GTACATCGGACGACCGTTCC – 3’
5’ – CTATACTTTGCTCCATTGGCGG – 3’
5’ – GAACGATGTTAATGGGTCAGCAAAG – 3’
5’ – CACTGTGATCGGTTATCTTTGTTGCAC – 3’
5’ – GTTGCTTGGGGTTGTTTTCGCCAATG – 3’
5’ – AGCGGTACCTTGGACTTTGACTGTTCAGA – 3’
5’ – CAACTCGAGGGGCGATGATTGTTAGTTGTATATT – 3’
5’ – CGTGGTTTCAGTGGCTACAAC – 3’
5’ – GGGCCCACAGATCGACGGACATTAC – 3’
5’ – GTAATGTCCGTCGATCTGTGGGCCC – 3’
5’ – CATTAACATCGTTCTTTAGTCTCATCCC – 3’
5’ – GGGATGAGACTAAAGAACGATGTTAATG – 3’

32

Table 2-4.

(Continued)
Sequence1

Primer name by purpose
CaMRR2_C9.2_F8
CaMRR2_C9.2_R8
CaMRR2_2F_EcoRI
CaMRR2_R_ADH1t.2
CaADH1t_F
CaADH1t_R_XhoI

5’ – CAGATTTACCAGTTGCCAAAAGAC – 3’
5’ – GTCTTTTGGCAACTGGTAAATCTG – 3’
5’ – GATGAATTCATGACCAAACGTGATCGTACAAT – 3’
5’ – GCTATTTGCTTACGAGATTTTGAGGAAATCCC – 3’
5’ – CAAAATCTCGTAAGCAAATAGCTAAATTATATACG – 3’
5’ – CATCTCGAGTTAACCAAAATCAACGACAAATTG – 3’

Real-time qPCR
CaMRR2_qPCR_F
CaMRR2_qPCR_R
CaCDR1-f_qPCR
CaCDR1-R_qPCR
CaACT1-FWD_qPCR
CaACT1-rvs_qPCR

5’ – TCCAAGTAAGTGTGGGTGTCC – 3’
5’ – ATGTAAGGCGAGCGAGTAGC – 3’
5’ – ATTCTAAGATGTCGTCGCAAGATG – 3’
5’ – AGTTCTGGCTAAATTCTGAATGTTTTC
5’ – ACGGTGAAGAAGTTGCTGCTTTAGTT – 3’
5’ – CGTCGTCACCGGCAAAA – 3’

1

Underlined nucleotide indicates introduction of a restriction site sequence.
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strain SCZCF34M4A to generate strains heterozygous for their respective MRR2 alleles
of interest. Figure 2-3 diagrams the general strain construction method for allelic
replacement of MRR2 at the native locus (Figure 2-3A) and inserted at the ADH1 locus
(Figure 2-3B). The nourseothricin marker in all strains was recycled by FLP
recombinase induction after 48 hours growth in YPD liquid media. Repeat
transformation of the resultant strains generated the homozygous MRR2 allele
replacements MRR2WT (SCMRR2R1S1), MRR2S143P, L144V, T145A, S165N, A459T, S480P
(SCMRR2R2S2), MRR2T83A, V451A, V582L (SCMRR2R3S3), MRR2R45Q, V451A
(SCMRR2R4S4), MRR2T83A, A459T, S480P, V486M (SCMRR2R5S5), MRR2S466L, A468G, S469T,
T470N, S480P
(SCMRR2R6S6), MRR2C9 (SCMRR2R8S8), and MRR2-GAL4AD-3xHA
(SCMRR2GAD1R1S1), respectively. MRR2 allelic replacements were confirmed by
Southern blot and confirmation of polymorphisms or fused domains present in generated
strains were accomplished through Sanger sequencing. For strains
SCΔmrr2PADH1MRR2WT and SCΔmrr2PADH1MRR2C9, plasmids pPADH1-MRR2WT and
pPADH1-MRR2C9 were similarly digested with KpnI-HF and NcoI-HF to excise and purify
the MRR2-containing SAT1/FLP cassette targeting the ADH1 locus. Paired doubled
strand breaks near the 5’ and 3’ ends of the ADH1 were induced utilizing the CRISPRCas9 technology using previously described methods (203). Briefly, 100 pmol Alt-R®
CRISPR-Cas9 tracrRNA (Integrated DNA Technologies, Inc.) was duplexed with an
equal amount of crRNA targeting either the 5’ or 3’ region of the ADH1 locus at 95˚C for
5 minutes. The duplexed guide RNA was then complexed with 2 ug of Alt-R® S.p. HiFi
Cas9 Nuclease V3 (Integrated DNA Technologies, Inc.) to form the resulting
ribonucleoprotein complex. Approximately 1 ug of purified digests from either pP ADH1MRR2WT or pPADH1-MRR2C9 were transformed via electroporation along with Cas9
ribonucleoprotein complex into SCZCF34M4A to create SCΔmrr2PADH1MRR2WT and
SCΔmrr2PADH1MRR2C9 expressing a single copy of the MRR2 open reading frame from
the ADH1 locus.
Azole susceptibility testing
Fluconazole MICs were determined using the broth microdilution methods as
described by the Clinical Laboratory and Standards Institute (200, 201), with slight
modification by addition of 2% glucose to Roswell Park Memorial Institute 1640 (RPMI)
media to reduce trailing growth in wells. Fluconazole concentration for MICs ranged
from 256 to 0.06 μg/mL. Measurements were read visually at 24 and 48 hours after
incubation at 35° C for a 50% reduction in growth from drug-free control wells. For
fluconazole susceptibility testing using E-test strips (bioMérieux), cells were diluted to an
OD600 of 0.100 and swabbed using sterile cotton tips onto RPMI-agar plates. MICs were
visually read at the border of the zone of inhibition after 24 and 48 hours of incubation at
35° C.
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Figure 2-3. Representative schematic of MRR2 mutant strain construction in C.
albicans
The diagram shows the MRR2/CaSAT1/FLP cassette integration at either (A) the native
MRR2 gene locus or (B) replacing the ADH1 open reading frame at the ADH1 locus. The
black line represents the sequence of a single allele of genomic DNA. Open reading
frames are depicted as filled arrows along the genomic sequence with gene names
labeled. Promoter regions, terminators, and the FLP recognition target sequences are
represented by bent arrows, hairpins, and black triangles, respectively. The double
slashes interrupting the genomic DNA sequence in (B) represent the CRISPR-Cas9
cutting sites. The homologous 5’ and 3’ flanking sequences for targeted fragment
integration are represented as forward-striped and backwards-striped rectangles,
respectively.
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Quantitative real-time reverse transcription PCR
First strand cDNAs were synthesized from 1 μg of total RNA using the
SuperScript® VILO™ for qRT-PCR (Invitrogen). Real-time PCR primers for ACT1,
CDR1 and MRR2 were synthesized by Integrated DNA Technologies (Table 2-4).
Relative mRNA abundance of CDR1 and MRR2 was measured in triplicate on the
StepOnePlus Instrument (Applied Biosystems) against the endogenous control gene
ACT1 and the reference strain SC5314. To assess statistical significance, standard error
of the mean of the average expression levels of each isolate measured in triplicate was
calculated.
Nucleotide sequence accession numbers
The coding sequences of the MRR2 alleles described in this study have been
deposited in GenBank under the accession numbers [MK332630] through [MK332702].
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CHAPTER 3. MUTATIONS IN ERG11 HAVE VARYING CONTRIBUTIONS
TO AZOLE RESISTANCE, ERG11 PROTEIN FUNCTION, AND
COMPETITIVE GROWTH FITNESS OF THE CELL2
Introduction
Candida albicans is a polymorphic, opportunistic pathogen responsible for
causing a wide range of infections. In the United States, C. albicans is the most common
cause of invasive candidiasis (59, 190). Morbidity and mortality rates for invasive
candida infections such as candidemia remain high. Such infections have a significant
impact on the health care costs. In 2014, it was estimated that Candida infections in the
US accounted for more than 25,000 hospitalizations totaling $1.4 billion, with invasive
candidiasis contributing to 84% of the incurred costs (68). Even the less serious
superficial Candida infections such as vulvovaginal or oropharyngeal candidiasis were
responsible for over 3.5 million outpatient visits that year at an expense of nearly $2.1
billion.
In cases of both invasive and non-invasive Candida infection, the azole
antifungals have been and continue to be an important agent used in treatment. The
azoles work through inhibition of the ERG11-encoded protein 14α-lanosterol
demethylase, also known as the CYP51 enzyme. While resistance in C. albicans to
azoles like fluconazole has remained relatively constant in recent years, azole-resistant
Candida continues to be a serious threat needing to be addressed (34, 184, 204).
Mechanisms of azole resistance often involve the regulation and overexpression
of genes controlled by the zinc-cluster transcription factors (ZCFs), a fungal-specific
transcription factor family. The ZCFs Tac1 and Mrr1 have been well-studied in their
regulation of the expression of the ATP-binding cassette transporters Cdr1 and Cdr2 and
the major facilitator superfamily transporter Mdr1, respectively (82, 83, 104, 105). The
ZCF Upc2 is responsible for the regulation of most ergosterol biosynthesis genes,
including ERG11, which encodes for the azole drug target (Erg11/14α-lanosterol
demethylase, hereafter referred to as CaCYP51), and can also influence azole
susceptibility through overexpression of ERG11 (108, 110). Mutations in ERG11
resulting in amino acid substitutions that directly alter the drug target 14α-lanosterol
demethylase’s protein sequence are another common azole resistance mechanism (121,
122, 131). It is commonly a combination of these mechanisms that confer azole
resistance in clinical isolates of C. albicans (107).
________________________

2
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To date, over 160 CaCYP51 amino acid substitutions have been reported in
clinical isolates of C. albicans (131, 134, 136, 139). While mutation hot spots have been
noted where amino acid substitutions cluster, the breadth of substitutions in CaCYP51
covers virtually the entire length of the 528 amino acid protein (Figure 3-1) (205).
However, the effects of these substitutions are variable – while some have been shown to
confer resistance to fluconazole and other azoles, others have never been shown to affect
susceptibility to the azoles. A previous report by Flowers et al. showed the individual
contributions of several amino acid substitutions in CaCYP51 and also found that several
double substitutions conferred greater azole resistance than any single substitution,
indicating that the presence of multiple CaCYP51 mutations may be beneficial for the
cell in the presence of azoles (139).
More recently, the crystal structures of CaCYP51 complexed with azole
antifungals have been analyzed and residues of significance in the catalytic domain or in
contact with the drug ligands have been identified (140, 206). For example, while some
residues like Tyr-132 lie exposed on the active site cavity of CaCYP51 and predictably
would interfere with fluconazole binding, other residues such as the Ser-405 do not
appear to contact the azoles, yet amino acid substitutions at this residue still confer azole
resistance. Differences in the relative locations on CaCYP51 present an interesting
question as to how amino acid substitutions might have variable effects on CYP51
enzyme function.
There have been significant recent findings regarding the differences in catalytic
activity between amino acid substitutions in CaCYP51 activity, biochemical tolerance to
the azoles, and azole binding affinity (141). In an effort to characterize functional and
biochemical differences between enzymes containing substitutions in CYP51, purified
recombinant CaCYP51 modified for expression in E. coli and 4x histidine-tagged for
purification was synthesized for biochemical analysis. Twenty-four single amino acid
substitution CaCYP51 mutants and five double amino acid substitution mutants were
synthesized and purified, representing documented mutations found in clinical isolates.
A wild type enzyme lacking any mutations representing the native CaCYP51 enzyme
found in azole-susceptible clinical isolates was also synthesized for comparison. The
catalytic turnover rate of the functioning enzyme was determined by quantification of
sterol product form after addition of the CaCYP51 substrate lanosterol and the human
cytochrome P450 reductase to the CaCYP51 enzyme. Even in the absence of azoles,
CaCYP51 mutants varied widely in their catalytic turnover compared to the wild type.
For example, while the V456I and Q474K substitutions seemingly increased relative
velocity of the enzyme over the wild type by more than 50% at baseline, the Y118A,
G307S, Y132H&K143R, and G307S&G450E substitutions all resulted in catalytic
turnover of less than 10% that of the wild type enzyme’s turnover (Table 3-1).
In the presence of either 4μM fluconazole, voriconazole, itraconazole, and
posaconazole, the wild type CaCYP51 enzyme retained less than 1% of its residual
activity (Table 3-2). Many CaCYP51 mutants behaved in a similar fashion in the
presence of the azoles, suggesting that they presumably would not influence azole
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Figure 3-1. Reported locations of CaCYP51 amino acid substitutions in C.
albicans
Amino acid sequence of the 528 amino acid length of the CaCYP51 protein. Highlighted
amino acids represent documented substitution(s). Yellow, green, blue, and purple
highlights represent one, two, three and four possible different amino acid substitutions
discovered, respectively. Bold lettering represents a difference in the SC5314 CaCYP51
reference sequence from the reported source’s original amino acid residue at that
location.
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Table 3-1.

Yield and relative velocities of CaCYP51 proteins
CaCYP51 substitution
Wild type
Y118A
F126V
Y132F
Y132H
K143R
F145L
P230L
Y257H
D278N
S279F
G307S
S405F
V437I
Y447H
G448E
F449Y
G450E
V456I
G464S
R467K
I471T
Q474K
V488I
Y132F&K143R
Y132H&K143R
Y132F&F145L
D278N&G464S
G307S&G450E

Yield1 (nmol L-1)
119
49
235
53
28
143
35
71
93
177
152
193
66
37
36
35
44
163
157
29
38
32
35
152

Relative velocity2
1.000 ±0.047
0.029 ±0.001
0.298 ±0.008
0.795 ±0.005
0.135 ±0.002
0.599 ±0.010
0.476 ±0.021
0.250 ±0.003
0.554 ±0.029
0.645 ±0.028
0.289 ±0.017
0.031 ±0.001
0.758 ±0.011
0.796 ±0.013
0.965 ±0.019
0.407 ±0.007
0.548 ±0.088
0.517 ±0.019
1.560 ±0.018
0.609 ±0.023
0.471 ±0.023
0.634 ±0.015
1.601 ±0.035
1.167 ±0.032

67
79
93
48
136

0.208 ±0.014
0.068 ±0.001
0.405 ±0.012
0.327 ±0.002
0.077 ±0.008

1

Yield of purified CaCYP51 protein isolates from one liter of E. coli expression culture.
Relative velocity of 1.000 relates to a catalytic turnover number of 0.574 min -1 obtained
with the wild type CaCYP51 protein in the CYP51 reconstitution assay.
2
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Table 3-2.

Residual CYP51 activity in the presence of 4 μM triazole antifungal

CaCYP51
substitution
Wild type
Y118A
F126V
Y132F
Y132H
K143R
F145L
P230L
Y257H
D278N
S279F
G307S
S405F
V437I
Y447H
G448E
F449Y
G450E
V456I
G464S
R467K
I471T
Q474K
V488I

Fluconazole
0.11
±0.09
1.51 ±<0.01
0.09
±0.06
±0.27
7.05
0.86
±0.07
±2.04
28.14
±0.15
6.71
0.05
±0.03
±0.18
3.96
±0.58
7.59
±1.67
17.99
0.95
±0.17
±1.41
11.56
0.22
±0.06
±0.51
4.34
±0.20
10.46
0.76
±0.08
±0.94
18.93
±0.95
3.68
±0.17
3.05
±0.61
3.34
±0.33
4.35
0.71
±0.08
1.06
±0.04

Residual CYP51 activity (%) ±SD1
Voriconazole
Itraconazole
0.11
±0.01
0.03
±0.02
0.28
±0.04
1.30
±0.59
0.19
±0.06
0.22
±0.05
1.09
±0.05
0.19
±0.04
0.33
±0.19
0.07 ±<0.01
±0.27
±0.51
3.12
6.27
0.37
±0.11
1.99
±0.04
0.13
±0.12
0.06
±0.01
0.63
±0.27
1.37
±0.28
1.34
±0.05
±0.19
3.00
±0.66
±0.35
6.15
5.97
0.41
±0.04
0.53
±0.21
1.94
±0.12
2.73
±0.13
0.02 ±<0.01
0.13
±0.02
2.07
±1.04
1.45
±0.06
1.89
±0.61
1.75
±0.26
0.56
±0.12
0.84
±0.57
±0.17
±0.54
3.50
7.66
0.79
±0.07
±0.07
3.21
0.10
±0.01
0.54
±0.11
0.52
±0.18
0.45
±0.17
0.92
±0.05
1.21
±0.01
0.34
±0.04
0.49
±0.04
0.13
±0.08
0.98 ±<0.01

Y132F&K143R
Y132H&K143R
Y132F&F145L
D278N&G464S
G307S&G450E

62.04
68.81
49.10
18.26
56.75

±1.21
±5.68
±1.76
±0.08
±2.30

8.86
39.59
13.58
4.79
0.41

±1.09
±8.63
±0.19
±0.11
±0.10

1

0.23
0.70
0.91
3.19
0.20

±0.13
±0.03
±0.05
±0.46
±0.04

Posaconazole
0.66
±0.02
0.46
±0.35
0.10
±0.01
0.93 ±<0.01
0.18
±0.06
±0.02
13.09
1.37
±1.21
0.21
±0.05
±0.59
6.42
±0.92
14.82
±0.10
20.64
0.71
±0.04
±0.53
9.38
0.59
±0.20
±3.58
8.19
±0.29
7.89
±0.04
5.42
±0.21
15.57
±0.05
6.66
0.54
±0.09
±0.09
3.62
±0.58
7.71
±0.18
3.23
2.11
±0.14
0.86
0.74
2.64
14.97
0.26

±0.11
±0.05
±0.08
±1.16
±0.11

Residual activity is expressed as a percentage of the observed CYP51 activity in the
absence of triazole antifungals. Each assay was performed in duplicate. Residual CYP51
activities greater than 3% are indicated in 'bold'.
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susceptibility. However, substitutions such as K143R, S279F, G450E, and
G307S&G450E had at least 3% residual activity versus all tested azoles. Indeed, since
many of these substitutions have been described in fluconazole-resistant isolates, and
likely arose after exposure to the antifungal, it is unsurprising that certain substitutions
conferred much higher residual activities to fluconazole versus any other tested azole.
The double mutations Y132F&K143R, Y132H&K143R, Y132F&145L, and
G307S&G450E, for example, had residual activities of about 50% or greater with
fluconazole, but significantly less activity when exposed to voriconazole, itraconazole, or
posaconazole.
In a comparison looking at the IC50 values of each variant CaCYP51 for
fluconazole, voriconazole, itraconazole, and posaconazole, multiple single amino acid
substitutions, including K143R, D278N, S279F, S405F, G448E, and G450E conferred
IC50 values ≥2 times the IC50 of the wild type (Table 3-3). Furthermore, the single
substitutions K143R, D278N, S279F, and G450E had similarly high IC50 values relative
to wild type for voriconazole and posaconazole in addition to fluconazole. All double
substitutions in CaCYP51 tested also showed high values against fluconazole and
voriconazole, ranging from 2- to >20-fold increases in IC50. Interestingly, the azole
binding affinity assay did not always reflect the biochemical tolerance observed in the
IC50 assay. While the IC50 values of some substitutions implied some degree of
biochemical tolerance to fluconazole or other azoles, the Kd values of these same
substitutions revealed relatively higher affinity for the azole drug, in contrast to what
might be expected if these substitutions conferred azole resistance through weakening of
the azole-CaCYP51 interaction.
These above findings confirm the suspicion that in addition to varied biochemical
tolerance and susceptibility to the azoles, mutations in ERG11 can also alter functional
efficiency of the enzyme. Altering CaCYP51 function to retain better activity in the
presence of the azoles, however, often comes at the cost of worse basal catalytic turnover
and possibly at the cost of overall growth fitness to the cell. In light of these recent
results, we present our findings of the in vitro susceptibilities of select amino
substitutions in CaCYP51 in C. albicans.
Results
In order to determine the impact of CYP51 amino acid substitutions on in vitro
azole susceptibility in C. albicans, we selected several mutations representative of those
that led to the greatest biochemical effect on the CYP51 enzyme. When mutant alleles
were introduced into the fluconazole-susceptible parent strain SC5314, CaCYP51 amino
acid substitutions displayed variable effects on azole drug concentration (Table 3-4).
Nine single CYP51 amino acid substitutions and three double CYP51 amino acid
substitutions were tested against fluconazole, voriconazole, itraconazole and
posaconazole.
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Table 3-3.

Triazole antifungal IC50 values obtained with CaCYP51 proteins

CaCYP51
substitution
Wild type
Y118A
F126V
Y132F
Y132H
K143R
F145L
P230L
Y257H
D278N
S279F
G307S
S405F
V437I
Y447H
G448E
F449Y
G450E
V456I
G464S
R467K
I471T
Q474K
V488I
Y132F&K143R
Y132H&K143R
Y132F&F145L
D278N&G464S
G307S&G450E

Fluconazole
0.384 ±0.019
0.194 ±0.010
0.278 ±0.027
0.606 ±0.066
0.220 ±0.013
1.100 ±0.313
0.450 ±0.083
0.334 ±0.086
0.512 ±0.047
0.838 ±0.027
1.046 ±0.325
0.526 ±0.211
0.820 ±0.042
0.281 ±0.004
0.483 ±0.018
0.796 ±0.087
0.245 ±0.028
1.078 ±0.247
0.483 ±0.022
0.455 ±0.047
0.476 ±0.080
0.600 ±0.017
0.358 ±0.008
0.520 ±0.057

IC50 (μM)1
Voriconazole Itraconazole
0.197 ±0.009
0.389 ±0.013
0.202 ±0.002
0.170 ±0.016
0.341 ±0.020
0.206 ±0.009
0.429 ±0.012
0.309 ±0.003
0.197 ±0.029
0.150 ±0.028
0.424 ±0.035
0.450 ±0.016
0.231 ±0.031
0.300 ±0.013
0.241 ±0.042
0.265 ±0.038
0.350 ±0.039
0.336 ±0.014
0.555 ±0.004
0.545 ±0.044
0.487 ±0.002
0.569 ±0.121
0.439 ±0.018
0.225 ±0.007
0.362 ±0.086
0.350 ±0.019
0.304 ±0.002
0.293 ±0.022
0.377 ±0.055
0.299 ±0.039
0.339 ±0.011
0.238 ±0.013
0.361 ±0.010
0.222 ±0.011
0.427 ±0.031
0.458 ±0.070
0.469 ±0.023
0.603 ±0.002
0.278 ±0.038
0.282 ±0.006
0.298 ±0.049
0.235 ±0.018
0.318 ±0.015
0.218 ±0.002
0.325 ±0.002
0.246 ±0.006
0.457 ±0.016
0.449 ±0.016

Posaconazole
0.195 ±0.009
0.206 ±0.004
0.304 ±0.070
0.343 ±0.020
0.195 ±0.003
0.789 ±0.003
0.359 ±0.018
0.238 ±0.002
0.611 ±0.017
0.908 ±0.020
0.912 ±0.016
0.288 ±0.042
0.637 ±0.054
0.319 ±0.009
0.439 ±0.135
0.542 ±0.051
0.366 ±0.037
0.908 ±0.132
0.602 ±0.017
0.253 ±0.024
0.380 ±0.011
0.522 ±0.064
0.301 ±0.017
0.481 ±0.052

5.857 ±0.524
8.471 ±1.271
3.889 ±0.077
1.243 ±0.064
4.980 ±0.054

0.580 ±0.099
3.074 ±0.042
1.158 ±0.231
0.552 ±0.045
0.433 ±0.033

0.246 ±0.024
0.196 ±0.007
0.433 ±0.102
0.930 ±0.009
0.312 ±0.015

1

0.190 ±0.002
0.237 ±0.007
0.364 ±0.023
0.403 ±0.011
0.318 ±0.017

IC50 determinations were performed in duplicate. Mean IC50 values together with
standard deviations are shown. Bold values indicate IC50 values that are over 2-fold
greater than those obtained with the wild type protein.
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Table 3-4.
CLSI MICs(μg mL-1) for fluconazole, voriconazole, itraconazole, and
posaconazole against strains containing CaCYP51 amino acid substitutions
CaCYP51
None1
Y132F
Y132H
K143R
F145L
D278N
S405F
G448E
G450E
G464S
Y132F, K143R
Y132F, F145L
D278N, G464S
1

Fluconazole
1
8
2
16
4
1
4
8
16
8
32
32
8

MIC (μg mL-1)
Voriconazole
Itraconazole
≤0.03
0.06
0.5
0.25
0.25
0.25
0.5
0.5
0.5
0.25
≤0.03
0.125
0.25
0.25
0.25
0.25
0.5
0.25
0.25
0.25
1
0.25
1
0.25
0.25
0.25

Fluconazole-susceptible parent strain SC5314.
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Posaconazole
≤0.03
≤0.03
≤0.03
≤0.03
≤0.03
≤0.03
≤0.03
0.06
≤0.03
≤0.03
≤0.03
≤0.03
≤0.03

The G450E and K143R amino acid substitutions showed the greatest relative
increase in the minimum inhibitory concentration (MIC) for fluconazole, each exhibiting
a 16-fold increase in MIC compared to the reference strain SC5314, which lacks any
substitution in CYP51. The strains containing the CYP51 single amino acid substitutions
Y132F, G448E and G464S also demonstrated resistance to fluconazole, displaying an 8fold increase in MIC over that of SC5314. The overall strongest effect on fluconazole
MIC occurred with the double substitutions Y132F&K143R and Y132F&F145L, each
conferring a 32-fold increase in fluconazole MIC. The D278N amino acid substitution
did not appear to alter the fluconazole MIC compared to the wild type, and the Y132H
substitution showed only a 2-fold increase in fluconazole MIC, showing that these
individual substitutions have minor effects, if any, on fluconazole MICs.
Against voriconazole, the single substitutions Y132F, K143R, F145L and G450E
had the greatest effect on MIC, and the strongest in vitro effect was observed in the
Y132F&K143R and Y132F&F145L double substitutions. The amino acid substitution
with the weakest effect on voriconazole MIC was again D278N (≤0.03 ug/mL). When
tested against itraconazole, most of the tested CYP51 substitution strains showed a small
increase in MIC, with the strongest single amino acid substitution K143R displaying an
MIC (0.5 μg ml-1) greater than that of any of the double amino acid substitutions. While
most substitutions causes a small 4-fold increase in MIC to itraconazole, the D278N
amino acid substitution only conferred a 2-fold increase in MIC over SC5314. In
contrast to the other azoles, posaconazole appeared to be very effective against all CYP51
mutant strains as the MIC to the reference strain and all other strains tested were identical
with the exception the strain containing the single G448E substitution, which displayed a
slight two-fold increase in MIC over SC5314.
Discussion
While previous investigations have looked into the contributions of substitutions
in CaCYP51 (122, 139), the isolated contributions of the D278N and Y132H amino acid
substitutions when introduced and tested in C. albicans have not been previously
described. Susceptibility testing of these C. albicans strains expressing these
substitutions as well as testing of previously constructed CaCYP51 mutant strains is
clinically relevant as all these mutations have been associated with fluconazole-resistant
clinical isolates.
Furthermore, the recent biochemical and functional findings described by
Warrilow et al. in conjunction with our in vitro susceptibility testing in C. albicans
provides an important insight that amino acid substitutions in CaCYP51 may confer azole
resistance by multiple means. For example, the D278N&G464S conferred an 8-fold
increase in fluconazole MIC over wild type CaCYP51. While the IC 50 value reported by
Warrilow et al. correlated with the increased fluconazole MIC of these substitutions, the
azole ligand binding study showed a relatively low Kd value (15 ±9 nM) of the
D278N&G464S CaCYP51 enzyme for fluconazole. This suggests that these two

46

substitutions in combination with each other do not have a great effect on fluconazole
binding.
This is in stark contrast to the conventional line of thinking that resistanceassociated ERG11 mutations result in CaCYP51 substitutions that reduce the ability of
the azole antifungals to bind and inhibit the enzyme. While this remains a likely
mechanism of azole resistance for many CaCYP51 substitutions (Y132F&K143R and
Y132H&K143R, for example, both have Kd values for fluconazole over 300-fold larger
than the wild type enzyme), our susceptibility data with these mutants suggests that
azole-resistance conferred by CaCYP51 mutants may be more nuanced than simply
altering fluconazole binding. As previously hypothesized, CaCYP51 substitutions could
alter interactions between cytochrome P450-reductase, for instance, to affect azole
resistance indirectly (140).
The amino acid substitution D278N and Y132H by themselves showed modest
increases in azole MIC compared to the wild type. With Y132H, a 2-, 8-, and 4-fold
increase in MIC was observed with fluconazole, voriconazole, and itraconazole,
respectively. D278N failed to show anything except for a two-fold increase in
itraconazole MIC compared to SC5314. Strangely, while Y132H did not show elevated
IC50 values to any tested azole compared to the wild type enzyme, D278N had increased
IC50 values versus fluconazole, voriconazole, and posaconazole and residual activity
versus fluconazole, itraconazole, and posaconazole.
The Y132H CaCYP51 amino acid substitution had previously been shown to
increase MIC to fluconazole approximately 4-fold when test in S. cerevisiae (122).
Y132H is believed to sit in the ligand binding pocket and alter the interaction with
fluconazole and other azoles (140, 206). However, the isolated contribution of the
D278N amino acid substitution to azole susceptibility has not been reported, and current
structural analyses of CaCYP51 do not comment on any significance of the Asp-278
residue in azole binding.
In contrast to the susceptibilities in our tested strains, previous literature showed
that adding the D278N amino acid substitution to G464S increased the fluconazole MIC
from 4- to 16-fold (139). However, MIC readings were taken at 48 hours, rather than at
24 hours in our study. It is possible the D278N amino acid substitution influences
trailing growth and azole tolerance, which might explain the increase in MICs observed
at 48 hours, but not 24 hours.
Azole resistance-causing gain-of-function mutations in the transcription factors
Tac1, Mrr1, and Upc2 have been shown to also confer conditional fitness defects in C.
albicans (207-209). Having more than one of these mutations compounds the fitness
defect observed, though clinical isolates of C. albicans may have compensatory
mechanisms by which to regain their original fitness. Given the findings that CaCYP51
substitutions may alter enzyme function, it is conceivable that these amino acid
substitutions might also confer a fitness defect on the cell.
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In a competitive growth fitness assay, C. albicans strains containing either the
wild type CYP51 or mutant CYP51 were grown against the control strain SCADH1R1A
containing the CaSAT1 nourseothricin resistance marker (210). At approximately 24
hours post-inoculation, relative ratios between the test and control strain were fairly
constant, regardless of the test strain used, indicative that none of the tested CaCYP51
mutants conferred an observable competitive growth defect after 24 hours (Figure 3-2,
unpublished data, personal communication from Joachim Morschhäuser on November 2,
2018). At 48 hours, only strains containing the K143R CaCYP51 amino acid substitution
showed a slight drop in ratio of growth at day 0 versus day 2, indicating a trend towards
less fit growth compared to the control strain. However, the difference in competitive
growth fitness between either wild type strain and the K143R substitution-containing
strain was non-significant (p = 0.12 and 0.23 between WT A and WT B strains,
respectively).
These competitive growth experiments do not indicate that any of our tested
substitutions have an immediate impact on cell fitness by themselves. The K143R
substitution showed a non-significant decrease in competitive growth compared to the
control strain, making it plausible that in longer growth competition experiments, this
strain may eventually be outcompeted versus azole-susceptible strains. Because we only
tested strains with at most two substitutions in CaCYP51, it remains possible that highly
mutated CaCYP51 containing 3 or more amino acid substitutions may display an
exacerbated fitness defect driven by poor CaCYP51 function. In a similar vein, it is
unknown whether the presence of CaCYP51 mutations in combination with gain-offunction mutations in Tac1, Mrr1, or Upc2 might further decrease fitness in the cell
compared to mutations in the ZCFs alone.
CYP51 mutations will likely continue to be a thorn in the side of clinicians and
hospitalists prescribing azole antifungals, even with the expected arrival of newer azole
antifungal drugs. Therefore, documenting these mutations and characterizing their
effects on azole susceptibility, virulence, and fitness are relevant to overcoming azole
resistance and ultimately providing better treatment outcomes for invasive fungal
infections. As we advance our understanding of the azole antifungal target and effects of
amino acid substitutions on drug-target interactions, further investigation should continue
to identify key amino acid substitutions involved in the resistance to specific azole drugs.
Such work would hopefully serve to provide greater information in the selection of
currently available azole antifungals and potentially be useful in the design of future
antifungals.
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Figure 3-2. Competive growth fitness testing of Erg11 mutants
(A) 24 hour and (B) 48 hour growth fitness testing of Erg11 mutants versus wild type Erg11. Experiments were performed in
triplicate. Data used with permission. Source: Joachim Morschhäuser, personal communication, November 2, 2018.
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Methods
Construction of C. albicans CYP51 mutant strains
Strains used in this study are shown in Table 3-5. Strains expressing seven single
mutations (Y132F, F145L, K143R, S405F, G448E, G450E, G464S) and three double
mutations (Y132F&F145L, Y132F&K143R, D278N&G464S) were selected from
aprevious study (139). Two additional strains expressing the Y132H and D278N CYP51
gene mutations were created utilizing the SAT1/FLP cassette described previously (202).
Briefly, C. albicans isolate SC5314 was transformed via electroporation with inserts of
pSFS2-derived plasmid possessing the SAT1 nourseothricin resistance marker, FLP
recombinase, and mutant CaCYP51 genes of interest. The 5’ end of the DNA fragment
contained either by the Y132H or D278N CYP51 ORF and the 3’ end possessed
homology downstream of the CaCYP51 stop codon to ensure homologous recombination
at the CYP51 gene locus. Successful transformants were screened on yeast-peptonedextrose agar plates containing nourseothricin and confirmed via Southern hybridization.
Genomic DNA from nourseothricin-screened transformants were digested with
HindIII restriction enzyme and the resulting DNA digests were loaded on 1% agarose
gels containing ethidium bromide. Digested samples were visualized briefly under
ultraviolet light after approximately 2 hours of electrophoresis (120V) to confirm
appropriate band separation. Lanes containing digested DNA in the gel was transferred
onto a nitrocellulose membrane via vacuum suction and DNA was crosslinked to the
membrane through UV exposure. PCR amplification of the genomic DNA from parent
isolate SC5314 using primers ERG11_Probe_F (5’ –
AGTTCAATGGTGGTTTTACCTACT – 3’) and ERG11_Probe_R (5’ –
ATTTCTGATTGAGTCATCCTAACA – 3’) generated a 254 bp product used as a probe
for the ERG11 gene locus. Probe was labelled and prepared using the Amersham™
AlkPhos Direct Labelling and Detection System (GE Life Sciences) and hybridized to the
membrane through overnight incubation at 55˚C. Bands containing the hybridized,
alkaline phosphatase-labelled probe corresponding to either wildtype ERG11 alleles
(2678 bp) or successfully replaced alleles with the SAT1/FLP cassette included (4318 bp)
or recycled (3119 bp) were visualized with CDP-Star chemiluminescent detection
reagent.
To confirm sequence of the replaced ERG11 allele, a DNA fragment containing
the ERG11 ORF and approximately 435 bp upstream of the start codon and 229 bp
downstream of the ERG11 stop codon was PCR amplified using primers
CaERG11_A_(ApaI) (5’ – GGGCCCGGGTTATTTGAGAACAGCC – 3’) and
CaERG11_E_(XhoI) (5’ – CTCGAGCCAGTGGACAAAAACCATCA – 3’). The
resulting DNA fragment was purified and Sanger sequenced on an ABI Model 3130XL
Genetic Analyzer with sequencing primers CaERG11SeqA (5’ –
GCCACCACACCCTATGGCTATT – 3’), CaERG11SeqB (5’ –
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Table 3-5.

Strains used in Chapter 3

Strainsa
SC5314

Genotype
ERG11-1/ERG11-2

Source or reference
ATCC

Constructed laboratory strains
20E1II1B1
SCERG11R1S1C1
10B1A3A
2A1A18A
SCERG11R3S3C1
21C1M1B1
20NA11A57A
15A3A108A
19A1A1C1
9A14A21A
27A5A33A
13A5A57A

ERG11Y132F::FRT / ERG11Y132F::FRT
ERG11Y132H::FRT / ERG11Y132H::FRT
ERG11K143R::FRT / ERG11K143R::FRT
ERG11F145L::FRT / ERG11F145L::FRT
ERG11D278N::FRT / ERG11D278N::FRT
ERG11S405F::FRT / ERG11S405F::FRT
ERG11G448E::FRT / ERG11G448E::FRT
ERG11G450E::FRT / ERG11G450E::FRT
ERG11G464S::FRT / ERG11G464S::FRT
ERG11Y132F,K143R::FRT / ERG11Y132F,K143R::FRT
ERG11Y132F,F145L::FRT/ ERG11Y132F,F145L::FRT
ERG11D278N,G464S::FRT / ERG11D278N,G464S::FRT

Flowers et al 2015
This study
Flowers et al 2015
Flowers et al 2015
This study
Flowers et al 2015
Flowers et al 2015
Flowers et al 2015
Flowers et al 2015
Flowers et al 2015
Flowers et al 2015
Flowers et al 2015

a

All laboratory strains have SC5314 as background.
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TATTTTCACTGCTTCAAGATCT – 3’), CaERG11SeqC (5’ –
CCAAAAGGTCATTATGTTTTAG – 3’), CaERG11SeqD (5’ –
CATACAAGTTTCTCTTTTTTCC – 3’), CaERG11SeqE (5’ –
CATTTAGGTGAAAAACCTCATT – 3′), and CaERG11SeqF (5’ –
TACTCCAGTTTTCGGTAAAGGG – 3′).
Susceptibility testing of C. albicans CYP51 mutant strains
Azole minimum inhibitory concentrations (MICs) were determined using the
broth microdilution methods as described by the Clinical Laboratory and Standards
Institute (200, 201). Cells were incubated in 96-well microtiter plates containing Roswell
Park Memorial Institute 1640 (RPMI) media and serially-diluted concentrations of either
fluconazole, itraconazole, voriconazole, or posaconazole. Concentration for MICs ranged
from 0.125 to 64 μg ml-1 for fluconazole and 0.03 to 16 μg ml-1 for itraconazole,
voriconazole, and posaconazole. Measurements were read visually at 24 hours after
incubation at 35°C for a 50% reduction in growth from drug-free control wells. MIC
measurements were performed in duplicate and the MIC was reported as the higher of
two values for all strains tested. In cases where the duplicate MIC values were not
identical, the higher of the two MIC values were reported. Overall the MIC values were
consistent with 92% (184/200) MICs within a single dilution of each other for a given
strain and drug combination. Additionally, no MICs differed by more than two dilutions
for a given strain and drug.
Competitive growth assay
Competitive growth assays performed by Morschhäuser et al. were performed in
triplicate as previously described (208, 210). Briefly, each strain was compared to the
control strain SCADH1R1A containing the nourseothricin resistance marker CaSAT1.
Each test strain and SCADH1R1A were inoculated in liquid YPD media in equal ratios
(OD600 = 0.002) and subsequently grown for 26h at 30°C. Cells from the culture were
plate at 0 hours, 24 hours and 48 hours onto YPD-agar plates and YPD-agar with either
200 μg/mL or 15 μg/mL nourseothricin. Colonies on YPD with 200 μg/mL
nourseothricin represented the nourseothricin-resistant SCADH1R1A, and smaller
colonies on YPD with 15 μg/mL nourseothricin represented the nourseothricin-sensitive
test strain. Colonies were counted to determine the percentage in the co-culture at each
timepoint.
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CHAPTER 4.

THE ROLE OF ERG3 MUTATIONS TO AZOLE RESISTANCE
AND ERG11 MUTABILITY IN C. ALBICANS
Introduction

Candida albicans is a commensal organism and opportunistic pathogen that can
cause a wide array of infections, ranging from superficial mucosal infection to lifethreatening invasive disease. In the United States, Candida remains a common cause of
healthcare-associated infection (12, 183). In particular, mortality associated with
Candida bloodstream infections remains high, and proper treatment of the infection
increases hospitalization costs and length of stay considerably (59, 68, 182).
Additionally, mucosal infections such as vaginal candidiasis and, in
immunocompromised patients, oropharyngeal candidiasis are common infections in
which C. albicans remains one of the most frequent causes of disease (211-213).
The azole antifungal drugs are commonly used in treatment and prophylaxis of
candidiasis. By inhibiting 14α-lanosterol demethylase, an enzyme critical to the
production of the important yeast cellular membrane sterol ergosterol, the azoles inhibit
cell growth. The primarily fungistatic action of the azole antifungals is thought to be
linked the accumulation of the toxic sterol 14α-methylergosta-8,24(28)-dien-3β, 6α-diol
within the cell (71, 72).
C. albicans is able to avoid the inhibitory effects of the azole antifungals through
several mechanisms. Commonly, C. albicans isolates resistant to the azole have
increased expression of genes encoding for efflux pumps that reduce the intracellular
concentrations of azoles inside the cell, such as the ABC transporters Cdr1 and Cdr2 and
the MFS transporter Mdr1 (78, 79, 99). Changes to the azole drug target 14α-lanosterol
demethylase brought about by nucleotide changes in its encoding gene ERG11 can also
reduce the effectiveness of the azole antifungals to bind or otherwise inhibit the activity
of the enzyme (107, 139, 140). Additionally, increases in the amount of azole target
through upregulation of ERG11 expression can also overcome to some degree the
presence of the azole antifungals inside the cell (106, 214, 215).
The above mechanisms are among the most commonly reported determinants of
azole resistance in clinical isolates, however, it has been less commonly reported that
alterations in the C. albicans sterol biosynthesis pathway mediated by mutations in ERG3
can also confer azole resistance. ERG3 encodes for the 386 amino acid length C-5 sterol
desaturase in Candida albicans a component essential to the production of ergosterol (71,
216). It had been shown that defective Erg3 confers azole-resistance in C. albicans by
avoiding accumulation of toxic sterol inside the cell and that Erg3-defective cells had
significantly different sterol profiles (72, 144, 149). This signifies that overall without
the presence of a functional C-5 sterol desaturase, the C. albicans cells utilizes alternate
sterol biosynthesis pathways in order to survive. Since the toxic 14α-methylergosta8,24(28)-dien-3β, 6α-diol required Erg3 for its production, mutant isolates lacking
functional C-5 sterol desaturase would not accumulate the toxic sterol even in the
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presence of the Erg11-inhibiting azoles (Figures 4-1 and 4-2). Therefore, isolates
lacking in or defective for Erg3 activity were rendered completely resistant to the azole
antifungal class (142, 148).
Previously, we had characterized a collection of predominantly azole-resistant
clinical isolates of C. albicans (115). Based on this data, we identified several members
among this collection which could not be explained by common mechanisms of
resistance in C. albicans. While mutations in ERG3 can confer azole resistance to
clinical isolates, their rarely reported frequency and debate over attenuated virulence in
these isolates makes the clinical significance of ERG3 mutations questionable. However,
Erg3 is inexorably tied to Erg11 as both proteins are crucial to the biosynthesis of
ergosterol (147). Moreover, a recent finding by Warrilow et al. demonstrated that
mutations in ERG11 can have variable effects on 14α-lanosterol demethylase activity,
and while amino acid substitutions in Erg11 conferred azole resistance, they often came
at a cost to the catalytic turnover of the enzyme (141).
Since loss of demethylase activity by treatment with the azoles triggers
accumulation of the toxic sterol intermediates in C. albicans, it is plausible that some
ERG11 mutations may result in markedly poorer demethylase activity and therefore may
accumulate higher levels of toxic sterol intermediates. Furthermore, since the toxic sterol
production is dependent on Erg3 activity, we believe that mutations in Erg3 that alter
activity or substrate specificity of the enzyme may alleviate accumulation of toxic sterols.
Therefore, it is possible that mutations in ERG3 allows conditional ERG11 mutations in
C. albicans to exist. In other words, ERG3 mutants may increase the mutability of
ERG11, thereby increasing the opportunistic potential to develop azole-resistance through
ERG11 mutation. In this study we identified the mutations in ERG3 across our collection
of clinical isolates and posit that mutations in ERG3 may be more common than
popularly believed and may play a larger role in azole resistance than previously
believed.
Results
Frequency of Erg11 and Erg3 amino acid substitutions in C. albicans clinical isolates
Sequencing of ERG11 and ERG3 within 57 fluconazole-resistant (MIC ≥8
μg/mL) clinical C. albicans isolates revealed 51 of 57 (89%) isolates with Erg11 amino
acid substitutions (Table 4-1). Overall, 20 of 57 (35%) clinical isolates possessed amino
acid substitutions in Erg3. In particular, a C>T nucleotide change at position 1052 in
ERG3 corresponding to an A351V amino acid substitution appeared either alone or
together with another Erg3 substitution in 18 (90%) of all ERG3 mutant isolates. Among
the 51 isolates with Erg11 amino acid substitutions, concomitant Erg3 amino acid
substitutions occurred in 19 (37%) isolates (Table 4-1). Interestingly, all Erg3 mutants
containing either a homozygous or heterozygous A351V amino acid substitution
possessed at least one substitution in Erg11, and 15 of 18 (83%) of those isolates
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Figure 4-1. Normal ergosterol biosynthesis pathway inhibition by the azole
antifungals in C. albicans
Simplified representation of the later stages of ergosterol biosynthesis converting
lanosterol to ergosterol is interrupted with fluconazole treatment. Fluconazole is
represented by the light red rectangle. The azole target enzyme is shown in green.
Grayed areas represent blocked biosynthesis pathways. T-shaped representation of
pathway inhibition is shown at inhibition sites. A skull and crossbones represents the
accumulation of toxic sterol.
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Figure 4-2. Ergosterol biosynthesis pathway inhibition by the azole antifungals in
C. albicans with defective C-5 sterol desaturase
Simplified representation of the later stages of ergosterol biosynthesis converting
lanosterol to ergosterol is interrupted with fluconazole treatment, but the toxic azole
cannot be produced due to defective Erg3. Fluconazole is represented by the light red
rectangle. The azole target enzyme is shown in green. Grayed areas represent blocked
biosynthesis pathways. T-shaped representation of pathway inhibition is shown at
inhibition sites. Erg3 is represented in yellow.
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Table 4-1.
Fluconazole MIC, ergosterol content, and mutations in ERG11 and
ERG3 in clinical isolates of C. albicans

Isolate
11
12
13
14
15
16
18
19
20
21
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
54

MICFLU
(μg/mL)
8
32
32
16
16
8
32
32
64
32
32
16
16
16
16
64
>64
32
>64
8
32
64
16
64
64
>64
>64
>64
64
64
8
>64
64
64
>64
32
>64
>64
>64
32

% Ergosterol
75.5
73.5
54.1
72.3
64.2
27.7
49.1
47.8
52.3
45.0
53.2
41.2
53.6
47.5
53.9
50.7
58.1
51.1
66.9
71.0
60.5
40.4
75.5
76.0
68.1
74.0
70.0
70.0
55.7
58.8
74.0
60.9
76.0
45.7
73.9
70.5
77.7
72.0
57.5
61.5

ERG11 mutationa
E266D, V488I
K143R
K143R
K143R
E266D, V488I
Q21R (h)
S405F
S405F
S405F
A114V, E266D, H283R
I483V, G450E
G450E
D446E
G307S, G448R
E266D, V488I
E266D, V488I
Y132F, F145L
Y132F, H283Y
G448E
G464S
F145L, E266D
G450E
D446E
None
None
G464S
G464S
F449V
S405F
G464S
D278N, G464S
D446E
E266D, G464S
G307S, L403F, G448R
G450E
Y132F
V437I, Y447S
Y132F, K143R
D278N, G464S
G307S, G450E
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ERG3 amino acid
substitutiona
A351V
None
None
None
A351V (h), A353T (h)
A351V
None
None
None
A351V (h), A353T (h)
A351V (h)
None
None
A351V (h)
A351V (h), A353T (h)
A351V (h), A353T (h)
A351V (h), A353T (h)
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
A351V
A351V (h)
A351V (h)
L195V (h), A351V (h)
H28Y (h)
None
None
A351V (h)

Table 4-1.
Isolate
55
56
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

(Continued)
MICFLU
(μg/mL)
>64
>64
>64
>64
>64
>64
32
32
32
64
64
>64
>64

% Ergosterol
66.0
74.2
80.9
71.7
0.8
46.6
69.8
70.3
52.6
74.5
78.3
82.4
60.2

64
32
>64
16

76.0
71.5
71.0
69.5

ERG11 mutation1
None
None
None
Y132F, T229A, F449I
None
Y132F, K143R
D278N, G464S
G450E
G450E
G448E
G448E
G448E
Y132F, E266D, I471M,
V488I
G448E
M258L, G464S (h)
Y132F, V437I, F449L
A114V, D153E, E266D,
G450E

1

ERG3 amino acid
substitution1
None
None
None
A351V (h)
W131*
None
None
None
None
None
None
None
None
None
A351V
A351V (h)
A351V (h)

(h) indicated a heterozygous amino acid substitution. Pink highlighted rows indicate
ERG3A351V mutant clinical isolates.
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contained more than one amino acid substitution in Erg11. By comparison, among
isolates lacking Erg3 amino acid substitutions, 32 of 38 (84%) had at least one Erg11
substitution and only 8 (21%) isolates possessed multiple Erg11 amino acid substitutions.
The frequency with which the A351V Erg3 amino acid substitution coincided with more
than one Erg11 amino acid substitution in clinical isolates and the relatively lower
frequency of multiple Erg11 amino acid substitutions in isolates lacking the A351V
substitution suggested that this substitution may possibly be associated with
hypermutability of ERG11.
Incidentally, we also discovered four novel Erg3 substitutions in select isolates
(Table 4-1). Isolate 49 contained a heterozygous H28Y amino acid substitution, and the
Erg3 of isolate 60 was truncated due to mutation encoding a premature stop codon after
only 130 amino acids. The L195V and A353T substitutions only appeared
heterozygously and only in combination with the heterozygous A351V substitution in
isolates 48 and isolates 15, 21, 27, 28, and 29, respectively.
Sterol content in clinical isolates
In an effort to determine whether substitutions in Erg3 altered sterol content,
whole cell membrane sterol contents from the clinical isolates (Table 4-2). Ergosterol,
normally the major sterol component of the fungal cell membrane, made up on average
approximately 62% (median: 67.5%, range: 0.8% - 82.4%) of whole cell membrane sterol
content in our fluconazole-resistance clinical isolates. In isolates lacking Erg3
substitutions the average ergosterol content was approximately 64% (median: 68.5%,
range: 40.4% - 82.4%) and in the Erg3 mutants containing the A351V substitution, the
cell membrane ergosterol content was approximately 60.4% (median: 62.9%, range:
27.7% - 76%). Thus, the presence or absence of the A351V substitution in Erg3 did not
seem to affect ergosterol content in the cell under normal growth conditions.
The average ergosterol content when looking at all isolates containing Erg3
substitutions of any sort was considerably skewed lower (58.3%) due to the only 0.8%
ergosterol content in isolate 60, containing a nonsense mutation (W131*) in ERG3. This
premature termination of the Erg3 protein very likely would result in a dysfunctional or
nonfunctional enzyme unable to produce significant amount of ergosterol, possibly
explaining the isolate’s low ergosterol content (Figures 4-3 and 4-4).
Allelic replacement of ERG3
The A351V amino acid substitution in Erg3 does not directly affect in vitro
fluconazole susceptibility
To determine whether the A351V mutation had a direct effect on azole resistance,
we created an erg3Δ/Δ strain as well as an ERG3A351V mutant in the azole-susceptible
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Table 4-2.

Percent total cell membrane sterol content composition in C. albicans clinical isolates

Strain
(C. albicans)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Lanosterol
1.3
4.2
3.4
0.7
6.3
8.3
2.1
2.0
7.2
11.1
4.2
6.1
11.8
5.0
3.6
18.0
3.1
14.5
17.2
22.1
8.1
25.6

Eburicol
0.5
0.1
0.7
10.4
0.1
0.5
3.6
0.3
3.2
9.6
2.4
0.8
5.2
0.2
19.0
19.6
6.7
2.8

Fecosterol
0.5
2.5
1.1
1.6
5.0
1.1
1.8
3.5
4.9
1.8
1.1
0.8
2.5
2.3
2.7
5.1
1.7
0.7
0.6
1.7
2.0
0.4

Episterol
1.0
6.2
2.1
2.3
6.5
0.5
5.4
8.6
9.0
2.5
1.7
3.1
4.5
6.3
12.8
3.0
1.2
0.7
2.5
1.9
4.1
1.8

Ergosterol1
91.4
65.8
76.7
69.1
55.0
58.9
74.1
55.7
46.4
62.5
75.5
73.5
54.1
72.3
64.2
27.7
75.2
49.1
47.8
52.3
45.0
60.5
53.2

60

Ergosta7,22-dienol

14-methyl
fecosterol

14α-methyl
ergosta-8,24(28)dien-3β,6α-diol

1.1

0.2

0.4

6.3
1.6
0.4

0.0
0.4
0.4

0.7
2.8
3.1
1.1
1.0
3.6

1.9
2.0
0.5
4.3

Table 4-2.

(Continued)

Strain
(C. albicans)

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Lanosterol
29.5
3.0
20.8
13.7
10.2
12.5
22.4
9.0
5.7
13.2
15.7
1.1
1.0
1.4
2.4
3.1
5.8
6.8
7.6
5.2
4.3
2.9
24.9
5.6

Eburicol
19.2
14.4
1.6
1.0
2.2
2.9
12.1
0.2
1.1
8.0

4.6
0.3
1.9
0.3
0.7
0.5
11.0
3.7

Fecosterol
0.2
3.2
3.9
4.3
4.7
1.3
0.4
1.9
1.5
1.5
2.0
1.2
3.4
1.6
1.9
0.3
2.2
1.2
0.5
2.9
0.6
1.0
0.4

Episterol
1.5
6.0
0.7
7.5
10.3
5.0
2.6
1.4
3.8
4.2
4.6
4.7
3.0
5.0
3.2
4.4
1.4
4.2
4.6
1.2
7.9
2.2
1.0
0.9

Ergosterol
41.2
53.6
47.5
53.9
50.7
58.1
51.1
66.9
71.0
60.5
40.4
75.5
76.0
68.1
74.0
70.0
70.0
55.7
58.8
74.0
60.9
76.0
45.7
73.9
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Ergosta7,22-dienol
1.3

0.4

14-methyl
fecosterol
1.2

14α-methyl
ergosta-8,24(28)dien-3β,6α-diol

3.4

6.4

1.2

1.3

1.5

0.7
0.7
0.9

Table 4-2.
Strain
(C. albicans)

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69

(Continued)

Lanosterol
7.4
6.0
13.0
13.1
3.5
2.6
7.6
1.7
1.3
1.4
1.2
2.0
0.9
15.9
8.5
5.5
11.6
4.0
5.2
3.0
10.0
3.9

Eburicol
3.2
1.6
3.3
1.3
0.4
0.6
20.3
0.1
0.2
3.7
1.0
0.4
11.0
2.1
3.8
11.7
1.4
3.3
1.0
6.2
1.6

Fecosterol
1.2
0.8
0.6
0.8
2.4
1.0
0.5
3.7
3.6
1.7
1.3
1.9
2.0
0.7
0.5

Episterol
2.6
1.4
0.2
2.1
5.1
2.1

1.0
1.2

2.6
2.9
1.4
1.3
3.2
2.0

1.3
0.8

4.1
5.1
3.2
2.4
3.9
4.8
1.5
1.5

Ergosterol
70.5
77.7
72.0
57.5
67.5
73.9
61.5
66.0
74.2
68.8
80.9
71.7
0.8
46.6
69.8
70.3
52.6
74.5
78.3
82.4
60.2
76.0

62

Ergosta7,22-dienol

14-methyl
fecosterol

1.3
0.9

62.1

14α-methyl
ergosta-8,24(28)dien-3β,6α-diol

Table 4-2.
Strain
(C. albicans)

70
71
72

(Continued)

Lanosterol
3.2
6.8
9.2

Eburicol
0.6
4.7
5.7

Fecosterol
1.0

Episterol
2.3
0.9
0.8

Ergosterol
71.5
71.0
69.5

1

Ergosta7,22-dienol

14-methyl
fecosterol

14α-methyl
ergosta-8,24(28)dien-3β,6α-diol

Percent ergosterol content is reflected in the center of the table and colored to indicate increased (greener) or decreased (redder) total
ergosterol content. Isolate 60, whose sterol content closely resembles a typical erg3Δ sterol profile that lacks ergosterol, is highlighted
in yellow. Blank entries under each sterol heading indicates there was none of that particular sterol detected for each isolate.
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Figure 4-3. Normal ergosterol biosynthesis pathway in C. albicans
Simplified representation of the later stages of ergosterol biosynthesis converting
lanosterol to ergosterol. The azole target enzyme Erg11 is shown in green. Red arrows
represent alternate biosynthesis pathways. T-shaped representation of pathway inhibition
is shown at inhibition sites.
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Figure 4-4. Alternative sterol biosynthesis pathway in C. albicans cells with
defective C-5 sterol desaturase
Simplified representation of the later stages of ergosterol biosynthesis converting
lanosterol to ergosterol shows that ergosterol biosynthesis cannot be completed without
Erg3 activity. The azole target enzyme Erg11 is shown in green. Erg3 is shown in
yellow. Red arrows represent alternate biosynthesis pathways. T-shaped representation
of pathway inhibition is shown at inhibition sites. Grayed areas represent blocked
biosynthesis pathways.
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isolate SC5314. Deletion of the ERG3 gene from both native loci resulted in complete
resistance to fluconazole (Table 4-3), consistent with the traditional ERG3 resistance
phenotype. However, when the ERG3 allele containing the nucleotide mutation
corresponding to the A351V amino acid substitution was replaced again in both native
loci, the strains appeared to have no direct effect on fluconazole MICs compared to the
parent isolate. Thus, in our hands, the A351V amino acid substitution does not appear to
directly affect fluconazole resistance as measure by CLSI broth microdilution assay.
However, given the prevalence of ERG3 mutations in resistant clinical isolates and their
co-occurrence with ERG11 mutations, the possibility remained that mutations in ERG3
were conferring a compensatory fitness benefit to the cell in the presence of ERG11
mutations that impair native enzyme function.
A homozygous ERG11Y132H,K143T mutant is conditionally constructed in
combination with ERG3A351V
To this end, we aimed to create double mutant strains containing two copies of
either the ERG3WT allele or the ERG3A351V allele in combination with mutant ERG11
alleles. These mutant ERG11 alleles encoded for select amino acid substitutions
previously shown to affect basal catalytic turnover rate of the Erg11 enzyme. The
original intent in creating these mutants was to determine whether the strains containing
the mutant ERG3A351V allele conferred any additional benefit to fitness over ERG3WT
when either is combined with activity-altering ERG11 mutations. In the case of the
double amino acid substitution Y132H&K143R in Erg11, we were able to successfully
insert both copies of ERG11 in an ERG3A351V background, but not in an ERG3WT
background. Repeated attempts to insert two copies of the ERG11Y132H&K143R allele in
SC5314 yielded a single copy of the mutant allele, and interestingly, the Y132H
unaccompanied by K143R on the second replaced allele, as revealed by Sanger
sequencing. Susceptibility testing of the two independently created strains
SCERG11R2S2L1 and SCERG11R2S2L2 (ERG11Y132H,K143R::FRT / ERG11Y132H::FRT)
had a fluconazole MIC of 1 μg/mL, a 4-fold increase in MIC compared to SC5314 (0.25
μg/mL). Comparatively, the strains SCERG3R1S1ERG11R2S2A and
SCERG3R1S1ERG11R2S2B, which contained two copies of both ERG3A351V and
ERG11Y132H,K143R, displayed an 8-fold increase (MICFLU: 2 μg/mL) over SC5314, likely
because of the additional K143R substitution present in the second allele.
A homozygous ERG11G307S mutant cannot be constructed
Surprisingly, we were unable to retain both copies of the ERG11G307S allele in our
strains. The single amino acid substitution G307S was unable to be produced in either
ERG3 background strain. Repeated attempts were made to construct the above strains,
and Southern blotting in conjunction with screening using a nourseothricin drug selection
marker seemed to confirm successful integration of allelic replacement cassettes. Despite
this, subsequent nucleotide sequencing of tentatively successful strains repeatedly
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Table 4-3.

24-hour fluconazole MICs for C. albicans strains in Chapter 4

Strain
SC5314
SCERG3R1S1A
SCERG3R1S1E
SCERG11R2S2L1
SCERG11R2S2L2
SCERG3R1S1ER11GR2S2A

MICFLU
(μg mL-1)
0.25
0.25
0.25
1
1
2

SCERG3R1S1ERG11R2S2B

2

SCERG3M4A
SCERG3M4B

>64
>64

ERG3 genotype
WT
ERG3A351V::FRT / ERG3A351V::FRT
ERG3A351V::FRT / ERG3A351V::FRT
ERG11Y132H,K143R::FRT / ERG11Y132H::FRT
ERG11Y132H,K143R::FRT / ERG11Y132H::FRT
ERG3A351V::FRT / ERG3A351V::FRT
ERG11Y132H,K143R::FRT / ERG11Y132H,K143R::FRT
ERG3A351V::FRT / ERG3A351V::FRT
ERG11Y132H,K143R::FRT / ERG11Y132H,K143R::FRT
erg3Δ::FRT / erg3Δ::FRTΔ
erg3Δ::FRT / erg3Δ::FRTΔ
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revealed retention of only a single copy of either the ERG11G307S mutant allele. The
inability to retain both copies of the mutant ERG11 alleles suggests that there may be a
selective disadvantage for C. albicans to have the G307S amino acid substitution in
Erg11 in the absence of drug or other cell stressors.
Discussion
We have known for some time that mutations in the ERG11 gene can have
variable effects on azole resistance. However, the differences observed in Erg11 enzyme
function has only recently been discovered. Warrilow et al. measured the relative
velocities of purified recombinant C. albicans Erg11 protein expressed from E. coli and
found that compared to the wild type enzyme, enzymes containing even a single amino
acid substitution altered the protein’s catalytic turnover significantly (141). From these
findings, it was revealed that changes in the amino acid sequence could lower the relative
velocity of the Erg11 enzyme to as low as 3% of the wild type enzyme, and double amino
acid substitutions generally resulted in even poorer relative velocities compared to single
amino acid substitutions. Importantly, many of these amino acid changes also resulted in
higher residual activity in the presence of fluconazole compared to the wild type Erg11.
While the benefit of having such substitutions during azole stress is clear, it raises
questions about the potential deleterious effects of Erg11 amino acid changes and fitness
costs to the cell in the absence of drug. Amino acid changes, such as the Y132H&K143R
double substitution and the G307S substitution, both of which retain less than 7% of the
catalytic turnover of the wild type Erg11, would not be predicted to be advantageous to a
cell in the absence of azole drug stress (141). The low enzyme rate even raises questions
whether such an isolate, without compensatory changes elsewhere in the genome, would
be viable. Poor Erg11 function as measured by the low catalytic turnover in these cases
could have a so-called azole-mimetic effect on the cell, whereby the bottleneck of the
ergosterol biosynthesis pathway is exacerbated by innately poor Erg11 function (Figure
4-5). Ergosterol precursors in this case could possibly be shunted to alternative metabolic
pathways, producing unwanted byproducts and accumulation of the 14α-methylergosta8,24(28)-dien-3β, 6α-diol toxic sterol.
As production of the toxic sterol is dependent on C-5 sterol desaturase activity, it
is plausible that changes affecting either the activity of Erg3 or substrate specificity of
Erg3 may ameliorate toxic sterol accumulation. Moreover, changes within the genome
that might normally incur higher 14α-methylergosta-8,24(28)-dien-3β, 6α-diol levels may
be more permissible when there are accompanying changes in either facet of Erg3
activity. Thus, such Erg3 changes may be the gateway for increased genetic diversity in
the ergosterol biosynthetic genes that might otherwise not be possible.
Here, we attempted to determine whether amino acid changes in Erg3, namely the
A351V amino acid substitution, acted as permissive substitutions that allowed for Erg11
variants with slow enzymatic function to persist in C. albicans isolates. Substitutions in
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Figure 4-5. Proposed sterol biosynthesis pathway in C. albicans cells with ERG11
mutations resulting in slow Erg11 enzyme function
Simplified representation of proposed consequences to the sterol biosynthesis pathway
when Erg11 activity is slowed or lowered as a result of ERG11 mutations. The azole
target enzyme Erg11 is shown in green and the mutant Erg11 protein with poor function
is labeled with an asterisk. Erg3 is shown in yellow. Red arrows represent alternate
biosynthesis pathways. Dashed arrows represent the biosynthetic pathway affected by
low Erg11 catalytic turnover.
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Erg3 that might reduce toxic sterol production through alterations of enzymatic activity
would be expected to also reduce susceptibility to the azole antifungals directly.
However, no detectable changes in susceptibility were observed in ERG3A351V strains. It
is possible that changes in susceptibility were too subtle to be detected through broth
microdilution assay or that perhaps lower concentration ranges for fluconazole should be
used going forward.
By obtaining whole cell membrane sterol profiles, we hoped to readily identify
differences in sterol content between ERG11 mutants with and without ERG3 mutations.
Isolates with multiple Erg11 mutations or mutations known to affect enzyme activity
might be expected to possess lower percentages of ergosterol and potentially higher
levels of 14α-methylergosta-8,24(28)-dien-3β, 6α-diol. However, we were unable to
identify significant differences between the ergosterol content of mutant and non-mutant
ERG3 isolates. One possible explanation for this may be that alterations to total sterol
content may be relatively minor. It is also possible that the alterations in sterol content
and accumulation of toxic sterols may occur more slowly in these isolates than expected,
and that sterol profiles changes would be more apparent after longer periods of growth
than what was performed here.
Lastly, we were unable to generate the ERG11Y132H,K143R and ERG11G307S mutants
in a background with ERG3WT. Previous data suggests that both Erg11 variants retain
extremely poor function relative to the wild type enzyme (141). By comparing these
variant Erg11 proteins with and without the Erg3 A351V amino acid substitution, we
hoped to observe differences in fitness based on our selection of Erg11 variants with
particularly slow turnover. To our knowledge, the Y132H&K143R substitutions and the
G307S substitution in Erg11 have not been reported in clinical isolates solely by
themselves (i.e. without additional, potentially compensatory Erg11 substitutions) and
without an accompanying substitution in Erg3. It is possible that mutations resulting in
these substitutions are a “double-edged sword” for the cell, trading normal Erg11 enzyme
function for azole resistance. Such mutations would only persist in the presence of azole
stress and possibly also only with accompanying compensatory mutations.
Our ability to generate the ERG11Y132H&K143R mutant in the ERG3A351V strain but
not the ERG3WT strain raises interesting questions regarding the role of ERG3 mutations
in azole resistance. C-5 sterol desaturase-mediated azole resistance has so far only been
described to occur as a result of amino acid substitutions in Erg3 that cripple or abolish
desaturase activity. Abolition of Erg3 function results in an inability to metabolize the
toxic sterol precursor, 14α-methylfecosterol to 14α-methylergosta-8,24(28)-dien-3β, 6αdiol in the presence of azoles, conferring azole resistance. This is most likely the same
mechanism of azole resistance occurring in isolate 60, which had a nonsense mutation in
ERG3, preventing transcription and subsequent translation of the full length C-5 sterol
desaturase.
However, our findings leave open the possibility that substitutions in Erg3 may
also play a peripheral role in azole resistance, enabling C. albicans to increase mutability
of ERG11 and possibly other ergosterol biosynthesis genes with mutations that would
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otherwise be unfavorable. If true, mutations in ERG3 could prove to be a valuable
predictor of patient response to azole treatment, as ERG3 mutations may indicate the cells
proclivity to develop additional mutations in the azole-resistance gene ERG11. While
this remains a possibility, further investigation must be conducted to determine the role of
the ERG3 mutations observed in clinical isolates of C. albicans.
Materials and Methods
Strains and growth conditions
The C. albicans strains used in this study are listed in Table 4-3. Cells were
streaked on the YPD agar plates from frozen 40% glycerol stocks and grown overnight at
30ᵒ C. Colonies from YPD agar plates were grown overnight in YPD liquid media (1%
yeast extract, 2% peptone, 2% dextrose) at 30ᵒ C for all routine genomic DNA extraction.
Luria-Bertani (LB) liquid media and agar plates, both containing 100 μg/mL ampicillin
or 50 μg/mL kanamycin, were used to grow E. coli cells used in plasmid construction and
propagation.
Plasmid construction
Table 4-4 shows the primers used in this study. To construct plasmids containing
our transformation cassettes for gene ERG3 and ERG11 gene knockout or replacement,
we utilized the pSFS2-derived plasmid pBSS2 containing the SAT1 nourseothricin
resistance marker and FLP recombinase, described previously (202). To generate the
ERG3 deletion cassette, flanking sequences of the 5’ and 3’ ends of the ERG3 openreading frame (ORF) was amplified from SC5314 genomic DNA using primers
CaERG3_AF_ApaI and CaERG3_BR_XhoI or CaERG3_CF_SacII and
CaERG3_DR_SacI, respectively. Fragments were digested and ligated to plasmid pBSS2
to create plasmid pBSS2-ERG3ABCD. The replacement cassette used in putting two
copies of the ERG3A351V allele back into C. albicans was constructed by amplifying the
ERG3 ORF using primers CaERG3_AF_ApaI and CaERG3_ER_XhoI. The resulting
fragment and plasmid pBSS2-ERG3ABCD were digested with restriction enzymes ApaI
and XhoI and ligated together to form pBSS2-ERG3AECD.
To construct the mutant ERG11Y132H,K143R allele, primer sets CaERG11-1F &
CaERG11SOE-3R Y132H and CaERG11SOE-2F Y132H & CaERG11-4R were used to
amplify fragments of the ERG11 gene from isolate 13 containing the ERG11K143R allele
previously characterized (139). For the ERG11G307S allele, primer sets CaERG11-1F &
CaERG11SOE-6R and CaERG11SOE-5F & CaERG11-4R amplified ERG11 gene
fragments from isolate 26 genomic DNA. Each respective set fragments was combined
and amplified using short-overlapping extension PCR utilizing primers CaERG11-AF
(ApaI) and CaERG11-BR (XhoI) to make a full length ERG11 allele containing either the
Y132H&K143R or G307S amino acid substitutions. Fused PCR products were digested
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Table 4-4.

Primers used in Chapter 4
Oligonucleotide sequencea

Primer
Amplification
CaERG3_F_HindIII
CaERG3_R_BAMHI
CaERG11-AF (ApaI)
CaERG11-BR (XhoI)

5′ – TTGTTAAGCTTTTTTTTCTTCCACCTATTTTG – 3’
5’ – CACACGGATCCATATAACCCTTGATTCC – 3’
5’ – GGGCCCGGGTTATTTGAGAACAGCC – 3’
5’ – CTCGAGCCAGTGGACAAAAACCATCA – 3’

Short, overlapping extension
CaERG11-1F
CaERG11SOE-3R Y132H
CaERG11SOE-2F Y132H
CaERG11SOE-6R
CaERG11SOE-5F
CaERG11-4R

5’ – CAATCTATACGACGACATTTAACTTTTT – 3’
5’ – GACAATCATGAATAACCCCTTTACCGAAAA – 3’
5’ – GGGGTTATTCATGATTGTCCAAATTCCAGA – 3’
5’ – ACCTTTTTCTTTCAATAATTCAACAACT – 3’
5’ – ATTATTGAAAGAAAAAGGTGGTGATTTG – 3’
5’ – GCTGTTGTTGTTGTTGAAAGAAA – 3’

Sequencing
CaERG3SeqA
CaERG3SeqB
CaERG3SeqC
CaERG3SeqD
CaERG3SeqE
CaERG3SeqF
CaERG11SeqA
CaERG11SeqB
CaERG11SeqC
CaERG11SeqD
CaERG11SeqE
CaERG11SeqF

5’ – GACCTAAGATTCCTACAATC – 3’
5’ – CAGCTACTGATTTCATTAATAC – 3’
5’ – GGTTCTTCCAATCTTTACC – 3’
5’ – GGAAAAATAGTCAATGGTCC – 3’
5’ – GTAAACAGATGGCCAGTG – 3’
5’ – TCTGAAAATGTTTGATCTGGC – 3’
5’ – GCCACCACACCCTATGGCTATT – 3’
5’ – TATTTTCACTGCTTCAAGATCT – 3’
5’ – CCAAAAGGTCATTATGTTTTAG – 3’
5’ – CATACAAGTTTCTCTTTTTTCC – 3’
5’ – CATTTAGGTGAAAAACCTCATT – 3′
5’ – TACTCCAGTTTTCGGTAAAGGG – 3′

Deletion and Replacement
CaERG3_AF_ApaI
CaERG3_BR_XhoI
CaERG3_CF_SacII
CaERG3_DR_SacI
CaERG3_ER_XhoI

5’ – ATCTGATTTATATATGGGCCCCAAGTGTTTG – 3’
5’ – AAAAGATAATAGTCTCGAGTTTCTAGTACG – 3’
5’ – ATAGCCGCGGTAACTCTTACAGAAGACC – 3’
5’ – TGTGATGTGAGCTCGTTAGTATTATTTTCA – 3’
5’ – TGTGATGTACTCGAGTTAGTATTATTTTCA – 3’

a

Underlined bases indicate a restriction enzyme cutting sequence, red bases indicate a
base change from reference sequence for base specific mutagenesis
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with restriction enzymes ApaI and XhoI and ligated into pBSS2, a derivative of pSFS2
containing the CaSAT1/FLP cassette in a pBluescript backbone (217). The resulting
ligation yielded plasmid pERG11R2 and pERG11R4, containing the ERG11Y132H,K143R
and ERG11G307S allele, respectively.
ERG3 and ERG11 amplification and sequencing
For sequencing of ERG3 in our C. albicans clinical isolate collection, the ORF for
ERG3 and ERG11 was amplified using primers CaERG3_F_HindIII &
CaERG3_R_BAMHI and CaERG11-AF (ApaI) & CaERG11-BR (XhoI), respectively.
The QIAquick® PCR Purification Kit (Qiagen) was used to purify PCR products.
Approximately 100 – 150 ng of purified PCR product containing the ERG3 ORF was
used in sample preparation with the ERG3 sequencing primers CaERG3SeqA,
CaERG3SeqB, CaERG3SeqC, CaERG3SeqD, CaERG3SeqE, and CaERG3SeqF for
Sanger sequencing by capillary electrophoresis. For ERG11, the sequencing primers
used were CaERG11SeqA, CaERG11SeqB, CaERG11SeqC, CaERG11SeqD,
CaERG11SeqE, and CaERG11SeqF. An ACI 3130XL genetic analyzer was used in
processing sequence reads and sequencing was accomplished in duplicate in
independently grown isolates.
C. albicans strain construction
A DNA fragment containing the SAT1/FLP cassette flanked by sequences at the
5’ and 3’ end of the ERG3 gene was excised by ApaI and XhoI restriction enzymes. The
resulting fragment was transformed via electroporation into C. albicans isolate SC5314,
disrupting a single copy of ERG3 in successfully transformed cells. Cells were screened
on YPD-agar plates containing (200 μg/mL) nourseothricin and successful cells were
grown in YPD for 24 hours to recycle the SAT1/FLP marker. A repeat transformation
and screening was performed to generate the erg3Δ/Δ strain SCERG3M4A. For strains
containing the ERG3A351V mutant allele, the replacement cassette was excised out of
plasmid pBSS2-ERG3AECD with ApaI and XhoI and transformed via electroporation
into SCERG3M4A. As above, recycling of the nourseothricin marker, repeat
transformation and screening on YPD-agar with nourseothricin ensured both alleles
contained the replacement cassette, generating strains SCERG3R1S1A1,
SCERG3R1S1A2, SCERG3R1S1E1, and SCERG3R1S1E2. To generate strains
possessing both mutant ERG11 and ERG3 alleles, we transformed the ERG11
replacement cassettes from pERG11R2 and pERG11R4 into SCERG3R1S1A or SC5314.
Two sequential integrations of the replacement cassette of pERG11R2 generated
homozygous replacement of the native ERG11 alleles with two copies of
ERG11Y132H&K143R. Southern blotting visually confirmed homozygous allelic deletion
and/or replacement of all strains using methods previously described (141).
Confirmation of allelic sequences were confirmed by Sanger sequencing of either the
ERG3 or ERG11 ORF.
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Azole susceptibility testing
MICs for fluconazole were determined by broth microdilution assay in
accordance with the Clinical Laboratory and Standards Institute (200, 201). To reduced
trailing growth observed in isolates, a slight modification through addition of 2% glucose
to RPMI media was made. Assay was prepared in 96-well round bottomed plates and
incubated for 24 hours at 35ᵒ C. Measurements were visually read after 24 hours. MIC
was defined as the concentration at which approximately 50% growth inhibition was seen
compared to isolate or strain growth in drug-free control wells.
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CHAPTER 5. IN VITRO ACTIVITIES OF THE NOVEL INVESTIGATIONAL
TETRAZOLE VT-1161 AND VT-1598 COMPARED TO THE TRIAZOLE
ANTIFUNGALS AGAINST AZOLE-RESISTANCE STRAINS AND CLINICAL
ISOLATES OF CANDIDA ALBICANS3
Introduction
Candida albicans is a dimorphic yeast and opportunistic pathogen that is known to
cause a wide range of infections in healthy and immunocompromised patients. In the
United States, C. albicans is the leading Candida species identified in oropharyngeal and
vulvovaginal infections, where recurrent infections remain problematic (16, 69, 185, 211,
218). In more serious systemic disease such as bloodstream infections (BSI), Candida
species collectively are the fourth-leading cause of nosocomial BSI in the United States
(12). Moreover, resistance to currently available antifungal agents continues to be a
problem, particularly given the relatively limited armamentarium against fungal
infections (32, 219-222). In particular, azole antifungal resistance in Candida spp.
threatens to diminish the efficacy of arguably the most widely used antifungal drug class
(223). Appropriate clinical use of available drugs on the market and eventual expansion
of the antifungal arsenal is therefore paramount to safeguarding its effectiveness.
Azole antifungal resistance in C. albicans can be attributed to multiple
mechanisms. First, efflux pump overexpression, such as the ATP-binding cassette (ABC)
transporters Cdr1 and Cdr2 as well as the major facilitator transporter Mdr1, prevents
drug accumulation within the yeast cell (83, 84, 104, 196). Second, increased production
of the azole target 14α-lanosterol demethylase (CYP51) can attenuate the inhibitory
effects of the azoles drug class (106, 108, 115). Increases in efflux pump and drug target
production is often the result of gain-of-function mutations in zinc cluster transcription
factors (ZCFs) (Tac1 for CDR1 and CDR2, Mrr1 for MDR1, Upc2 for ERG11) that
regulate their gene expression, though polyploidy of chromosomes in the yeast genome
can also result in increased expression of the genes encoding these azole-resistance
determinants. Third, mutations in ERG11 can confer azole resistance through alteration
of the drug target (122-124, 139). Lastly, alternative sterol biosynthesis as a result of
changes within the ergosterol biosynthetic pathway allows some C. albicans isolates to
circumvent the effects of azole inhibition altogether (72, 142, 145, 224).
VT-1161 and VT-1598 are novel tetrazole antifungal agents with high specificity
for fungal CYP51 compared to human CYP enzymes (188, 189, 225), and thus may have
improved adverse effect and drug-drug interaction profiles due to lesser off-target
inhibition. In this study, we compare the in vitro activity of the novel tetrazoles
_______________________

3

Reprinted from final submission with permission. Nishimoto AT, Wiederhod NP, Flowers SA, Zhang Q,
Kelly SL, Morschhäuser J, Yates CM, Hoekstra WJ, Schotzinger RJ, Garvey EP, Rogers PD. (2019) In
vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole
antifungals against azole-resistant strains and clinical isolates of Candida albicans. AntiMicrob Agents
Chemother. doi:10.1128/aac.00341-19:AAC.00341-19.
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VT-1161 and VT-1598 to the current triazole antifungals fluconazole, voriconazole,
itraconazole, and posaconazole against a collection of clinical isolates and laboratory
strains with known resistance mechanisms.
Results
In vitro activity of VT-1161 and VT-1598 against fluconazole-susceptible and
fluconazole-resistant clinical isolates
VT-1161 and VT-1598 showed potent in vitro activity against 68 previously
described clinical isolates of C. albicans, the majority (57 of 68) of which were
fluconazole-resistant (MIC ≥8 μg/mL) and possessed multiple known azole resistance
mechanisms (Appendix B, Table A-1 to B-3) (115). Both VT-1161 and VT-1598 had
lower MIC50 values (0.06 and 0.125 μg/mL, respectively), and VT-1598 had a lower
MIC90 value (0.25 μg/mL) when compared to the other tested azole antifungals (Table
5-1). VT-1161 and VT-1598 MICs were ≤0.015 μg/mL against the 11 fluconazolesusceptible isolates within the collection, and the VT-1598 MICs were 0.03 μg/mL
against 33% (19 of 57) of the fluconazole-resistant clinical isolates. This suggests that
some fluconazole-resistance mechanisms do not affect the in vitro potency of VT-1598.
Posaconazole also demonstrated activity against many, but not all, of the same
fluconazole-resistant isolates, as posaconazole MICs were within a two-fold increase (1dilution difference) to those of the fluconazole-susceptible isolates for 15 of the
fluconazole-resistant isolates. Using this same metric, VT-1161 maintained in vitro
potency against 8 fluconazole-resistant clinical isolates, which was comparable to that of
voriconazole (6 isolates) and greater than that of itraconazole (2 isolates). Overall, VT1598 and VT-1161 thus appear to have additional activity against several fluconazoleresistant isolates, and in this respect are at least comparable to commercially available
triazoles.
VT-1598 MICs were elevated at least four-fold (≥0.06 μg/mL, range 0.06 to >8
μg/mL) against 38 fluconazole-resistant isolates compared to its activity against the
fluconazole-susceptible isolates. VT-1161 MICs were elevated at least four-fold (≥0.06
μg/mL, range 0.06 to >8 μg/mL) against 49 fluconazole-resistant isolates. Five clinical
isolates displayed highly elevated VT-1598 and VT-1161 MICs (range 4 to >8 μg/mL)
and also high fluconazole, voriconazole, itraconazole, and posaconazole MICs.
Sequencing and/or relative quantitation of mRNA expression of known resistance genes
revealed that four of these isolates overexpressed CDR1 relative to the CDR1 mRNA
levels of fluconazole-susceptible clinical isolates (115). The fifth isolate contained a
premature stop codon in ERG3, resulting in truncation of the protein after Gly130, which
likely explains its significantly elevated resistance not only to VT-1161 and VT-1598, but
also to all other tested azole antifungals.
To gain additional insight on the determinants that could confer decreased
susceptibility to VT-1161 and VT-1598 in the clinical isolates, a point-biserial correlation
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Table 5-1.
Geometric mean MICs, MIC50, MIC90, and ranges (μg/mL) for tested
compounds against 68 clinical isolates of C. albicans
Drug
VT-1161
VT-1598
Fluconazole
Voriconazole
Itraconazole1
Posaconazole1
1

GM MIC
0.15
0.05
20.2
0.32
0.31
0.2

MIC50
0.125
0.06
32
0.5
0.25
0.5

MIC90
1
0.25
>64
2
1
2

n = 66 clinical isolates for itraconazole and posaconazole
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Range
≤0.015 - >8
≤0.015 - >8
≤0.125 - >64
≤0.03 - >16
≤0.03 - >16
≤0.03 - >16

between the log2-fold increase in VT-1598 and VT-1161 MICs and the mRNA
expression levels of CDR1, MDR1, and ERG11 in the clinical isolates was performed.
The log2-fold increase in MICs was compared to the baseline MIC measurement for VT1598 and VT-1161 against fluconazole-susceptible isolates (MIC ≤ 0.015) and expression
levels of either CDR1, MDR1, and ERG11 were measured via RT-qPCR in a previous
study (115). The majority of fluconazole-resistant clinical isolates exhibited increased
CDR1 expression, however there was no significant correlation between CDR1
expression and VT-1598 resistance (p = 0.287). In contrast, higher levels of CDR1
expression did positively correlate with increasing VT-1161 MICs (p < 0.01). Similarly,
while there was no relationship between MDR1 expression and VT-1598 MIC (p =
0.105), there was a slight positive correlation between MDR1 expression and increased
VT-1161 MIC (p < 0.05). No significant correlation was established with either drug and
ERG11 expression (p = 0.512 and p = 0.355 for VT-1598 and VT-1161, respectively).
VT-1598 and VT-1161 MICs against the clinical isolates were plotted directly
against those of fluconazole, voriconazole, itraconazole, and posaconazole to visualize
relative susceptibility differences (Figure 5-1). As previously noted, both VT-1161 and
VT-1598 retained potency against several fluconazole-resistant isolates, and all isolates
with reduced VT-1598 or VT-1161 potency were resistant to fluconazole. By
comparison, VT-1161 MICs were disproportionately higher against some clinical isolates
compared to those of the other tested azoles. One voriconazole-susceptible isolate (0.125
μg/mL) that contained a K143R ERG11 mutation and exhibited increased CDR1
expression had an 8-fold increase in the MIC of VT-1161 compared to that observed
against fluconazole-susceptible isolates (≤0.015 μg/mL). In addition, a single
itraconazole-susceptible isolate (0.125 μg/mL) demonstrated a 32-fold increase in the
VT-1161 MIC (0.5 μg/mL). This isolate contained three Erg11 amino acid substitutions
(F126L, Y132F, H283R), but lacked other obvious azole resistance mechanisms. Against
isolates with low posaconazole MICs (range ≤0.03 to 0.25 μg/mL), seven displayed ≥16fold increases in VT-1161 MIC over fluconazole-susceptible isolates. Among these
seven isolates, all contained various ERG11 mutations, four overexpressed CDR1 by at
least two-fold, one overexpressed both ERG11 and CDR1, and one overexpressed MDR1.
In contrast, there were no strong outliers for VT-1598 MICs when compared against
those of the triazoles.
In vitro activity of VT-1161 and VT-1598 against strains with known azole
resistance mechanisms
To identify determinants of VT-1161 and VT-1598 resistance, we evaluated the
influence of specific azole-resistance mechanisms on VT-1161 and VT-1598 MICs when
placed in the fluconazole-susceptible isolate SC5314 (Figure 5-2). Increased CDR1 and
CDR2 expression through artificial activation of the TAC1 gene increased the VT-1161
MICs more than eight-fold compared to the susceptible parent strain. This increase in
VT-1161 MIC was diminished, but not completely abolished, when the CDR1 gene was
deleted, suggesting that overexpression of CDR1 as well as other Tac1 target genes (most
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Figure 5-1. Comparison of the MICs of VT-1161 and VT-1598 against the MICs
of triazoles
VT-1161 and VT-1598 MICs versus the of MICs of (A) fluconazole, (B) voriconazole,
(C) itraconazole, and (D) posaconazole in a collection of C. albicans clinical isolates.
Plotted points represent the MICs of clinical isolates, with darker points representative of
multiple, superimposed points. Concentration of points to the lower right of each plot
represent favorable activity (low MICs relative to susceptible isolates) for VT-1161 or
VT-1598 versus the comparator azole. Conversely, points concentrated to the top left of
each plot represent isolates with high MICs of VT-1161 and VT-1598 relative to the
comparator azole.
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Figure 5-2. MICs of tested azole compounds against strains with individual
known azole resistance mechanisms
Tested strains include those containing the artificially-activated transcription factors Tac1
and Mrr1 in strains SCTAC1GAD1A and –B and SCMRR1GAD1A and -B, respectively,
as well as ∆cdr1 derivatives of SCTAC1GAD1A (SC∆cdr1TAC1GAD1A and -B),
∆mdr1 derivatives of SCMRR1GAD1A and -B (SC∆mdr1MRR1GAD1A and -B), and
SCUPC2R14A and –B containing the G648D gain-of-function mutation in UPC2. The
MICs for the strains with artificially activated Tac1, Mrr1, and for the UPC2G648D gainof-function mutation are displayed as the highest MIC value of both independently
created A- and B- strains for each respective transcription factor. The relative foldchange in expression compared to the parent strain SC5314 of (A) CDR1 for
SCTAC1GAD1A and B and (B) MDR1 for SCMRR1GAD1A and -B is shown on the left
of the figure. The antifungal MICs of the UPC2G648D homozygous strains SCUPC2R14A
and -B is shown in (C).
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likely CDR2) was responsible for the decreased susceptibility to VT-1161. On the other
hand, Tac1 activation did not result in reduced susceptibility to VT-1598, as opposed to
its effect on VT-1161, fluconazole and voriconazole resistance, which increased between
four- and 16-fold compared to that of the parental strain SC5314. Posaconazole and
itraconazole MICs were only slightly elevated (two-fold) by the hyperactive Tac1. Thus,
it appears that while drug efflux via Cdr1 plays a role in VT-1161 resistance, Tac1
activation and the approximately 10-fold increase in CDR1 expression are not sufficient
to alter MICs of VT-1598.
While a hyperactive Mrr1 did not result in increased resistance to VT-1598, it
caused a four-fold increase in the MIC of VT-1161. This increase was abolished upon
MDR1 deletion, suggesting that the Mdr1 transporter is involved in VT-1161 resistance.
Fluconazole and voriconazole were the only tested azole drugs against the MDR1overexpressing strain that showed a greater than two-fold increase in MIC (32-fold and
four-fold, respectively) over SC5314. By comparison, itraconazole showed a minimal
two-fold increase (1-dilution difference) in MIC, and posaconazole MICs were not
affected by MDR1 overexpression. Strangely, there was a 4-fold increase in
posaconazole MIC when MDR1 was deleted in the hyperactive Mrr1 strain. However,
this is consistent with variability observed for posaconazole MICs in other published
strains and fluconazole-susceptible clinical isolates (94).
Upregulated expression of ERG11 via artificial activation of the Upc2
transcription factor also did not affect VT-1161 or VT-1598 MICs. However, despite an
approximate 4- to 8-fold increase in ERG11 expression (data not shown), the activated
Upc2 strain failed to demonstrate a relevant change in voriconazole, posaconazole, and
itraconazole MICs. Surprisingly, this strain also exhibited no change in fluconazole MIC
as has previously been reported. We therefore decided to also test azole susceptibilities in
a strain homozygous for the G648D amino acid substitution, previously shown to be the
strongest clinically-derived gain-of-function mutation in Upc2 (113, 115). Strains
SCUPC2R14A and –B overexpressed ERG11 relative to the parent strain SC5314 by 6.4fold (previously published) and 4.5-fold (unpublished data), respectively (data not
shown) (115). A modest 2-fold increase in fluconazole MIC in these two strains was
observed compared to SC5314, whereas no changes were observed for the MICs of any
of the other antifungal agents.
To compare the effects of different alterations in the azole target enzyme on the
susceptibility of C. albicans to VT-1161 and VT-1598, twelve single Erg11 amino acid
substitutions and four double substitutions in Erg11 were tested (Table B-2, Figure 5-3).
The Y132F single substitution caused a substantial (16-fold) increase inVT-1161 MIC.
Surprisingly, the double amino acid substitutions Y132F&K143R and Y132F&F145L
had a lesser impact on VT-1161 MIC (eight-fold and four-fold increase, respectively)
than the single Y132F substitution alone. Other amino acid substitutions did not have an
appreciable effect on VT-1161 MICs, and none of the tested ERG11 mutants showed
greater than a two-fold increase in the MIC of VT-1598. The F145L and S405F single
mutants and the double substitution mutants D278N&G464S and
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Figure 5-3. Relative fold-change compared to SC5314 in MIC of various azole
antifungal agents against strains containing single and double ERG11 mutations
Open blue circles represent VT-1598 MICs, while open black circles represent VT-1161.
Open grey diamonds represent fluconazole. Solid green triangles represent voriconazole.
Solid orange diamonds represents itraconazole, and solid inverted purple triangles
represent posaconazole.
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Y132F&F145L showed a slight two-fold increase in the VT-1598 MIC compared to that
against SC5314.
Discussion
VT-1598 has previously demonstrated a broad spectrum of activity in vitro
against yeasts such as Candida and Cryptococcus spp., moulds including Aspergillus spp.
and endemic fungi (226), and has shown improved survival and reduced fungal burden in
murine models of CNS coccidioidomycosis (227) and cryptococcosis (228). Pertinent to
the present study, VT-1598 has also recently shown potent in vitro and in vivo antifungal
activity against fluconazole-sensitive and -resistant Candida spp. isolated from chronic
mucocutaneous candidiasis patients (187). Structurally, while the tetrazole moiety has
lower affinity for interaction with the heme iron of CYP51, other structural modifications
have made the drug more fungal-specific. For example, a critical H-bond between VT1598 and the CYP51 enzyme of many fungi likely confers its broad activity (229). This
greater selectivity may decrease the potential for undesirable adverse effects and drug
interactions that occur with the triazoles through inhibition of human cytochrome P-450
enzymes.
Our study supports the previous finding that VT-1598 has potent activity against
C. albicans isolates. Overall, VT-1598 displayed the lowest MIC50 and MIC90 values
compared to fluconazole, voriconazole, posaconazole, itraconazole, and VT-1161 against
the clinical isolates tested. More importantly, VT-1598 MICs often remained unchanged
from its baseline measurement against SC5314 and other fluconazole-susceptible clinical
isolates even against isolates containing known resistance mechanisms, indicating that
this tetrazole may retain activity against isolates that are normally less susceptible to
other azole antifungals. This included multiple fluconazole-resistant isolates with various
combinations of CDR1, MDR1 and ERG11 expression increases and mutations in the
ERG11 gene.
Interestingly, when tested against laboratory strains containing individual azole
resistance mechanisms, VT-1598 MICs changed relatively little. Traditional azole
resistance mechanisms such as efflux pump overexpression (Cdr1 and Mdr1) and
overexpression of the azole target (Erg11) did not alter VT-1598 MICs within the
concentration ranges tested here. While it is possible that testing lower concentrations
might reveal differences in MIC, the clinical relevance at such low concentrations is
questionable. Our current finding suggests that these mechanisms individually are not
sufficient to confer resistance to VT-1598. Previously, the Tyr132 and Lys143
substitutions in Erg11 were reported to have the strongest individual effects on
fluconazole and voriconazole MICs (139). The combination substitutions
Y132F&K143R and Y132F&F145L, which have been shown to have some of the
strongest increases in fluconazole and voriconazole MIC, respectively, did not
appreciably change the MIC of VT-1598. Against VT-1161, both these double
substitutions showed less of an effect than the single amino acid substitution Y132F. The
K143R substitution is thought to alter the H-bond strength of the heme ring propionates
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of the C. albicans Erg11 protein, which may possibly interfere with the coordination of
the azole ring nitrogen and the iron of the CYP51 heme group, and the F145L amino acid
substitution is located on the Erg11 proximal surface, allowing possible interactions with
NADPH-cytochrome P450 reductase (139, 140). Based on the crystal structure of the C.
albicans CYP51 enzyme complexed with VT-1161, the Y132F substitution is thought to
altogether abolish one of six H-bonds between VT-1161 and the protoporphyrin IX
propionates on Erg11 (140). It is possible that the Y132F substitution is more important
to VT-1161 resistance than either K143R or F145L and that combination mutations might
interfere with the primary Y132F substitution, thus leading to the differences in the
observed VT-1161 MICs.
Against a collection of predominantly fluconazole-resistant clinical isolates, VT1161 showed good activity, though its individual MIC50 and MIC90 were higher
compared to VT-1598. In contrast to VT-1598, the potency of VT-1161 appeared to be
more affected by the presence of CDR1 and MDR1 overexpression and ERG11
mutations. This was supported by the significant positive correlation established between
CDR1/MDR1 expression and VT-1161 MIC in C. albicans clinical isolates.
Additionally, susceptibility testing in strains containing individual mechanisms of azole
resistance, wherein the CDR1-overexpressing strains SCTAC1GAD1A and –B and the
MDR1-overexpressing strains SCMRR1GAD1A and -B demonstrated increased VT1161 MICs, further supports Mrr1 and Tac1 as mediators of resistance to VT-1161, at
least in part through increased production of the transporters Mdr1 and Cdr1,
respectively. The recent work by Monk et al. also demonstrated that both the Cdr1 and
Mdr1 efflux pumps reduced the effectiveness of VT-1161, and activity against Cdr1- and
Mdr1-overexpressing isolates could be restored via the Cdr1- and Mdr1-specific
inhibitors RC21v3 and MCC1189, respectively (230). The Erg11 amino acid
substitutions Y132F, Y132F&K143R, and Y132F&F145L also resulted in shifts in VT1161 MIC and may contribute to VT-1161 resistance. However, VT-1161 retained
activity against a number of isolates with known azole resistance mechanisms. The
tested ERG11 mutant strains containing the Y132H, K143R, F145L, E266D, D278N,
S405F, G448E, F449V, G450E, G464S, and D466E single substitutions and the
D278N&G464S, and G450E&I483V double substitutions showed little change in VT1161 MICs compared to the susceptible parent strain SC5314. Thus, VT-1161 has
potential to be a future treatment option of azole-resistant C. albicans infections or
recurrent infections previously treated with older members of the azole class.
Within the five clinical isolates that displayed greatly reduced susceptibility to
VT-1161, VT-1598, and the other commercially available triazoles tested, one isolate
contained an early stop codon at Trp131 within the ERG3 gene, which encodes for sterol
Δ5,6-desaturase and is critical for ergosterol biosynthesis in C. albicans. It has been
previously reported that mutations in ERG3 can result in azole resistance and alternative
sterol biosynthesis by avoidance of accumulation of toxic sterol intermediates through
defective desaturase enzyme (142, 145, 147). The inhibition of the azole target 14αlanosterol demethylase causes accumulation of the toxic sterol intermediate, 14αmethylergosta-8,24(28)-dien-3β,6α-diol, which is thought to be the source of the
fungistatic effect seen with azole antifungal class (71, 72, 224). However, dysfunctional
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Erg3 results in alternative sterol usage and an inability to produce this toxic intermediate.
Therefore, mechanisms that result in a non-functional Erg3 might render an isolate
resistant to the azole antifungal drug class, as is seen in the case of the isolate containing
the premature stop codon in ERG3.
In summary, the in vitro activity of VT-1161 and VT-1598 against azole-resistant
C. albicans clinical isolates and strains with known azole resistance mechanisms suggests
that they may prove useful against resistant C. albicans infections. Furthermore, given
their low and relatively unchanged MICs against many azole-resistant strains, it is
possible that VT-1161 and VT-1598 may fill some of the gaps in coverage against azoleresistant isolates. This, in combination with the potential for favorable safety and drug
interaction profiles, makes VT-1161 and VT-1598 attractive options as alternative
therapies for azole-resistant C. albicans infections. However, the presence of strongly
resistant isolates, such as the five clinical isolates with greatly increased MICs to all
azoles tested here, suggests the existence of azole-resistance determinants that can
provide obstacles to the successful utilization of all azoles, including these new
tetrazoles. Further investigation should be undertaken to identify the mechanism(s)
responsible for resistance to these agents.
Materials and Methods
Isolate and strain growth conditions
Sixty-eight clinical C. albicans isolates were obtained from the University of
Iowa. C. albicans isolates and strains were cultured from -80˚C freezer stock (40%
glycerol in YPD media) onto YPD-agar plates overnight at 30˚C. Colonies from YPDagar plates were then either streaked onto Sabouraud Dextrose agar for azole
susceptibility testing or grown in liquid YPD media and incubated overnight at 30˚C for
preparation of genomic DNA.
Construction of C. albicans strains
Table 5-2 lists the constructed strains used in this study. Ten single ERG11
mutations and four double mutations were selected from previous studies (139). Two
additional strains expressing the Y132H and D278N ERG11 gene mutations were
created in a previous study utilizing the SAT flipper cassette (141, 202). Briefly, to
create the mutant strain SCERG11R1S1C1, ERG11 gene fragments were generated by
primers pairs CaERG11_1F with CaERG11SOE-3R_Y132H and CaERG11SOE2F_Y132H with CaERG11_4R using SC5314 template genomic DNA (Table B-3).
Short-overlapping extension PCR was used to fuse the resulting ERG11 gene fragments
using nested primers CaERG11-AF_(ApaI) and CaERG11-BR_(XhoI). For mutant
strain SCERG11R3S3C1, ERG11 gene fragments were generated by primers pairs
CaERG11_1F with CaERG11SOE-6R using template genomic DNA from clinical
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Table 5-2.

Constructed strains used in Chapter 5

Strains1
SC5314

ERG11-1/ERG11-2

Source or reference
ATCC

Constructed laboratory strainsa
20E1II1B1
SCERG11R1S1C1
10B1A3A
2B1A51A
29NA29A23A
SCERG11R3S3C1
21C1M1B1
20NA11A57A
7A5A5A
15A3A108A
19A1A1C1
22B12A58A
9A14A21A
27A5A33A
13A5A57A
8A4A1A
SCTAC1GAD1A and -B
SCΔcdr1TAC1GAD1A and -B
SCMRR1GAD1B and -B
SCΔmdr1MRR1GAD1A and -B
SCUPC2GAD1A and -B
SCUPC2R14A and -B

ERG11Y132F::FRT / ERG11Y132F::FRT
ERG11Y132H::FRT / ERG11Y132H::FRT
ERG11K143R::FRT / ERG11K143R::FRT
ERG11F145L::FRT / ERG11F145L::FRT
ERG1E266D::FRT / ERG11E266D::FRT
ERG11D278N::FRT / ERG11D278N::FRT
ERG11S405F::FRT / ERG11S405F::FRT
ERG11G448E::FRT / ERG11G448E::FRT
ERG11F449V::FRT / ERG11F449V::FRT
ERG11G450E::FRT / ERG11G450E::FRT
ERG11G464S::FRT / ERG11G464S::FRT
ERG11D466E::FRT / ERG11D466E::FRT
ERG11Y132F,K143R::FRT / ERG11Y132F,K143R::FRT
ERG11Y132F,F145L::FRT/ ERG11Y132F,F145L::FRT
ERG11D278N,G464S::FRT / ERG11D278N,G464S::FRT
ERG11G450E,I483V::FRT / ERG11G450E I483V::FRT
ADH1/adh1::PADH1-TAC1-GAL4AD-3xHA-caSAT1
ADH1/adh1::PADH1-TAC1-GAL4AD-3xHA-caSAT1
cdr1Δ::FRT/cdr1Δ::FRT; ADH1/adh1::PADH1-MRR1-GAL4AD-3xHA-caSAT1
mdr1Δ::FRT/mdr1Δ::FRT; ADH1/adh1::PADH1-MRR1-GAL4AD-3xHA-caSAT1
ADH1/adh1::PADH1-UPC2-GAL4AD-3xHA-caSAT1
UPC2G648D::FRT / UPC2G648D::FRT

Flowers et al., 2015
Warrilow et al., 2019
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Warrilow et al., 2019
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Flowers et al., 2015
Schillig et al., 2013
Schillig et al., 2013
Schillig et al., 2013
This study
Schillig et al., 2013
Heilmann et al., 2010

Genotype

1

All laboratory strains have SC5314 as background.
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isolate 43 and CaERG11SOE-5F with CaERG11_4R using SC5314 genomic DNA.
The resulting fragments were again fused into a single fragment containing either the
D278N-containing mutant ERG11 open reading frame (ORF) using nested primers
CaERG11-AF_(ApaI) and CaERG11-BR_(XhoI). In constructing the plasmids used in
the transformation of both strains, the ERG11 3’ flanking sequence was amplified from
SC5314 genomic DNA and primers CaERG11_C-F' and CaERG11_D-R’. The inserts
3’ of the ERG11 ORF were digested with restriction enzymes NotI and SacII, and
cloned into the pSFS2-derived plasmid pBSS2 previously described by Vasicek et al.
containing the SAT1 flipper cassette from Reuβ et al. (202, 217) to create plasmid
pERG11CD. The ERG11 ORF-containing fragments with either the Y132H or D278N
mutations were digested using restriction enzymes ApaI and XhoI, gel excised, and
cloned into the plasmid pERG11CD to generate plasmids pERG11A1 and pERG11A3.
Plasmids were digested with restriction enzymes ApaI and SacII and used to transform
strain SC5314 by electroporation to generate heterozygous ERG11 mutants. Recycling
of the nourseothricin selection marker through 24 hours of growth in YPD and repeat
transformation of the resultant strains generated the homozygous ERG11 allele
replacements SCERG11R1S1C1 and SCERG11R3S3C1, confirmed via Southern
hybridization and Sanger sequencing. The artificially-activated Tac1, Mrr1, and Upc2
mutants used in this study as well as SC∆cdr1TAC1GAD1A and -B, containing the
artificially activated TAC1 allele in a cdr1Δbackground, were described in a previous
study (117). Strains SC∆mdr1MRR1GAD1A and -B were constructed by introducing
the artificially activated MRR1 allele from plasmid pMRR1-GAD1 (32) into the mdr1Δ
mutants SCMDR1M4A and -B (112), respectively.
ERG11 amplification and sequencing
Table B-3 lists the primers used for ERG11 amplification and sequence
verification. The ERG11 ORF of each isolate was PCR amplified from genomic DNA
using primers CaERG11_F_Amp and CaERG11_R_Amp. PCR products were purified
using the QIAquick® PCR Purification Kit (Qiagen) and product was sequenced on an
ABI 3130XL genetic analyzer using sequencing primers. Sequencing was accomplished
in duplicate in independently grown isolates.
Relative gene expression by real-time PCR
Expression levels of the genes CDR1, MDR1, and ERG11 in clinical C. albicans
isolates were measured in a previous study, and CDR1, MDR1, and ERG11 expression of
laboratory strains were measured similarly using previously described methods (115).
Briefly, first-strand cDNA was generated from 1 μg of extracted RNA for each strain
using the SuperScript® VILO™ Master Mix (Invitrogen) reaction kit. Quantitative
PCRs were performed on the StepOnePlus™ Real-Time PCR System (Applied
Biosystems) in technical and biological triplicate for each sample. SYBR green PCR
master mix (Applied Biosystems) was used for amplification detection of candidate genes
against the CaACT1 normalizing gene. Calculation of the relative quantitation values of
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CDR1, ERG11, and MDR1 gene expression was accomplished using the StepOne
Software v2.3 (Applied Biosystems). Primers used in the amplification of genes
measured via qPCR are listed in Table B-3.
Susceptibility testing
Minimum inhibitory concentrations (MIC) of VT-1161, VT-1598, fluconazole,
voriconazole, posaconazole, and itraconazole were measured using broth microdilution
methods in accordance with the Clinical Laboratory and Standards Institute (200, 201).
96-well microtiter plates containing RPMI-1640 media (0.165M MOPS, with Lglutamine, without sodium bicarbonate, pH 7.0) were used to incubate strains across
serially-diluted concentrations of the each azole. Concentrations ranged from 0.015 to 8
μg/mL for VT-1161 and VT-1598, 0.125 to 64 μg/mL for fluconazole, and 0.03 to 16
μg/mL for voriconazole, posaconazole, and itraconazole. MICs were visually read at 24
hours post-incubation at 35˚ C as the minimum concentration required to reduce growth
of cells by approximately 50% or greater compared to drug-free control wells. MICs
were performed in duplicate for clinical isolates, ERG11 mutant strains and laboratory
strains SCTAC1GAD1A and -B, SCΔcdr1TAC1GAD1A and -B, SCMRR1GAD1A and B, SCΔmdr1MRR1GAD1A and -B and SCUPC2GAD1A and -B. When reporting MICs
for strains and isolates, the higher of the MICs was used in this analysis (Table B-1 and
B-2), though 98% (592/606) of MIC duplicate readings were identical or within a single
dilution of each other. The geometric mean MIC (GM MIC), MIC50, and MIC90 was
reported for clinical C. albicans isolates for each triazole and tetrazole agent used in this
study. The MIC50 and MIC90 values reported for VT-1161, VT-1598, fluconazole,
voriconazole, itraconazole, and posaconazole were defined as the minimum drug
concentrations required to inhibit 50% and 90% of the clinical C. albicans isolates tested,
respectively.
Statistical analysis
A point-biserial correlation or phi coefficient was used for all continuous and
dichotomous variables, respectively, to identify possible predictors of azole resistance.
For all statistical tests, a p-value less than 0.05 was considered significant. Statistical
calculations were performed using IBM ® SPSS© analytical software, version 23.
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CHAPTER 6.

CONCLUSIONS

Introduction
Candida albicans is the leading etiologic cause of Candida-related infection.
While azole-resistance rates in C. albicans remains relatively low, treatment failures still
occur resulting from the emergence of highly azole-resistant C. albicans isolates. For the
foreseeable future, fluconazole and other azole antifungals will continue to be among the
most commonly used and prescribed antifungal medications. However, the increased use
of this drug class in combination with imperfect clinical practice with antifungal drug
dosing will increase risk of azole-resistance development. As has been discussed, C.
albicans has several known mechanisms enabling it to survive in the presence of azoles,
and commonly it is the combination of these resistance mechanisms that arise in clinical
isolates that permit them to thrive, even with appropriate treatment. The main objective
of my dissertation has been to investigate additional possible mechanisms of azole
resistance and resistance-adaptation in C. albicans from mutations derived from a
collection of predominantly azole-resistant clinical isolates. Amino acids substitutions in
the zinc cluster transcription factor Mrr2, and the sterol biosynthetic proteins Erg11 and
Erg3 were the primary focus of this investigation. Furthermore, the novel tetrazole
compounds VT-1161 and VT-1598 proved to be valuable agents to screen for unknown
azole resistance mechanisms present within this collection. Here, I discuss and interpret
the results of each aim of my investigation.
Summary and Conclusions of Chapter 2
In Chapter 2, I sequenced the MRR2 gene in 57 C. albicans clinical isolates with
elevated fluconazole MICs, and identified 15 amino acid substitutions in resistant
isolates. Four of these substitutions (S466L, A468G, S469T, T470N) had been
previously reported to reduce fluconazole susceptibility through increased expression of
the efflux pump encoding gene CDR1 (118). Interestingly, these four amino acid
substitutions were present in clinical isolates that did not possess significantly increased
expression of CDR1 relative to a composite of susceptible isolates. This initially brought
into question the validity of the claim that these amino acid substitutions impacted CDR1
expression and required further investigation.
I tested the effects of these combined substitutions in Mrr2 as well as the novel
substitutions R45Q, A459T, V486M, and V582L by placing the alleles of clinical isolates
containing the MRR2 mutations into the native MRR2 locus of the fluconazolesusceptible parent SC5314. Broth microdilution assay and qPCR did not reveal any
increases in either fluconazole resistance or CDR1 expression among any of my created
strains. Previous work looking at either artificially hyperactive Mrr2 and clinicallyderived mutant Mrr2 increased CDR1 expression and fluconazole resistance (117, 118).
However, in both cases, the created strains artificially overexpressed the MRR2 gene to
observe these effects. I therefore constructed C. albicans strains overexpressing either
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wild type MRR2 or a replica of the MRR2 gene containing mutations previously reported
to show the strongest increase in fluconazole MIC. Even with strong expression of
MRR2, no change in CDR1 expression or fluconazole MIC compared to SC5314 was
observed.
Lastly, by creating an artificially activated MRR2 strain with native promoter
expression. I showed two things. Firstly, artificial activation of MRR2 does not result in
auto-upregulation of the MRR2 gene. The ZCF genes UPC2 and TAC1 both have been
shown to be target genes of their respective proteins, and their expression is upregulated
through gain-of-function activity (93, 231). Our data suggests that activated Mrr2 does
not do this, though further investigation would be required. Secondly, native expression
levels of artificially activated MRR2 is sufficient to confer increased CDR1 expression
and fluconazole MIC. This suggests that any activating effects from MRR2 mutations
should be observable in our created strains expressing mutant MRR2 from the native
promoter. The lack of any change in MIC in these strains coupled with the unchanged
expression of CDR1 suggests that these mutations are not tentative gain-of-function
mutations in MRR2, and more importantly, that they are not clinically relevant for
fluconazole resistance.
Though this is ultimately a negative finding, I strongly emphasize the importance
of these results. A far-reaching goal of my research is to impact and improve patient
outcomes in those with fungal infections treated with the azoles. To this end, discovery
and improvement in the established knowledge of fungal pathogens and resistance within
these organisms is critical. Publishing contrasting findings to previously established
results is important in shaping and correcting the constantly evolving body of scientific
knowledge, from which new discoveries and advancements in treatments and therapy is
derived. Currently, there are published reported referencing mutations in MRR2 as a
relevant mechanism of azole resistance (160, 197, 198). My findings run strongly to the
contrary of these published findings and are therefore important to disseminate in the
interest of my research goals.
Summary and Conclusions of Chapter 3
My own research in Chapter 3 was limited to the creation of the additional Erg11
mutant strains containing the D278N and Y132H amino acid substitutions, and the
analysis of the susceptibility testing data of these new additions to our collection of Erg11
mutant strains. Since ERG11mutations play a large role in azole resistance, the continued
investigation characterizing additional mutations and their effects and interactions in the
C. albicans cell remains critically important. My work was contributory to a
collaborative research aim to investigate these effects.
The results of the investigation showed that Erg11 mutants vary considerably in
their baseline activities as well as their activity in the presence of the azoles (141).
Furthermore, the increased ability to retain activity around the azoles did not, however,
always correlate with decreased binding to the azole. Interestingly, these biochemical
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effects did not always translate into what was seen in C. albicans in vitro susceptibility
testing of the ERG11 mutations. This suggests that some ERG11 mutations may work to
alter interaction with other components, such as NADPH-cytochrome P450 reductase,
that work with CaCYP51 in sterol biosynthesis. Overall, my work in combination with
the biochemical data on these Erg11 mutants shed additional light on the mode of action
by which Erg11 amino acid substitutions interfere with growth inhibition by the azoles.
It also identifies the possibility that these substitutions may impact normal cell sterol
biosynthesis production due to the altered catalytic rates exhibited by the Erg11 mutant
proteins. This notion was important in the justification of my investigation of another
sterol biosynthesis gene, ERG3, which is detailed next.
Summary and Conclusions of Chapter 4
In chapter 4, I sequenced the ERG3 gene of our research group’s collection of
clinical C. albicans isolates in an initial effort to define additional azole resistance
mechanisms present in the collection. We had previously reported the majority of the
major resistance mechanisms present among these isolates (115). However, sterol
profiles on this collection identified isolates with lower ergosterol content. ERG3
mutants resulting in defective C-5 sterol desaturase have been reported as having little to
no ergosterol content and increased amounts of ergosta-7,22-dienol instead (224). One
such clinical isolates matched this “textbook” ERG3 mutant phenotype, and subsequent
sequencing of the open-reading frame confirmed a premature stop codon at the normal
Trp-131 residue. Interestingly, my sequence work identified multiple ERG3 mutations
present in these clinical isolates. Investigating whether these mutations may have any
role in azole resistance, I noticed the high co-occurrence of the A351V ERG3 mutation
with ERG11 mutations.
Given our suspicion that ERG11 mutations may come at a fitness cost and may
require possible compensatory mutations in order to adapt, I proceeded to make ERG3
and ERG11 combination mutants to test whether ERG3 had an indirect role in azole
resistance. Unfortunately, growth competition and fitness testing between ERG11
mutants with and without mutant ERG3 could not be completed since I was unsuccessful
in creating the G307S and Y132H, K143R Erg11 mutants. Based on data from our
collaborators, these two sets of amino acid substitutions conferred the poorest catalytic
turnover rates for the Erg11 enzyme, and would be expected to show the greatest fitness
defects. I was only successful in creating the ERG11Y132H, K143R mutant in the presence of
the ERG3A351V mutation. While not conclusive, it is preliminary evidence that perhaps
the ERG3A351V mutation may confer a compensatory fitness benefit on C. albicans
isolates that accrue multiple ERG11 mutations.
While further work needs to be done to investigate any possible beneficial effects
for the cell, the possibility of mutations in ERG3 conferring a compensatory fitness
benefit raises interesting questions about azole resistance in clinical isolates. If certain
ERG3 mutations are acquired early on by the cell, then the mutagenic potential of the
ERG11 gene, and therefore of azole resistance development, could increase as well. The
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identification of such an evolution of azole resistance could make ERG3 mutations an
intriguing diagnostic marker in the prediction of azole treatment failures through acquired
resistance.
Summary and Conclusions of Chapter 5
Lastly, my work in Chapter 5 involved the analysis of the susceptibilities of our
C. albicans clinical isolates and resistant laboratory strains to the established azole
antifungals used in invasive fungal infection alongside the new tetrazole antifungal
agents VT-1161 and VT-1598. Both newer agents showed potent activity against
predominantly azole-resistant strains and isolates. In particular, VT-1598 displayed
activity against the vast majority of clinical isolates as well as strains overexpressing
CDR1, MDR1, or ERG11 through gain-of-function ZCF mutations. In comparison, the
currently available antifungal agent posaconazole displayed similar activity to VT-1598,
while voriconazole and itraconazole were more comparable VT-1161’s activity against
clinical isolates. Both tetrazoles also appeared to be unaffected by several, but not all,
ERG11 mutations, similar to the triazole posaconazole. Overall, the tetrazole compounds
appear to be promising agents that could be utilized in the future as alternative therapies
in invasive candidiasis.
An important finding in the analysis of this susceptibility data is the identification
of isolates 55, 56, 58, 60, and 65 that all showed greatly increased MICs to the tetrazoles
and all other azoles. Apart from isolate 60, which possesses an early stop codon in
ERG3, the other isolates do not possess any unique traits with respect to known azole
resistance mechanisms that sets them apart from other clinical isolates. This indicates
that these isolates possess as yet undiscovered mechanisms of azole resistance and
provides and interesting future project to investigate these isolates further.
A Final Word
The findings of my research projects leave several questions that remain to be
answered in C. albicans. Whether mutations in additional ZCFs may play a role in azole
resistance is currently an ongoing investigation. The role of compensatory mutations in
ERG3 and other sterol biosynthesis genes is a plausible but as yet unproven mechanism
that could influence azole resistance development. Do mutations in ERG11 also alter
CaCYP51 interaction with peripheral components outside of the azole antifungals that
may influence susceptibility? And what are the means by which some clinical isolates
possess such strongly reduced susceptibility to the azole antifungals, if not by any of the
currently known mechanisms? One can speculate that some of these questions may
ultimately prove to be important in changing the clinical approach to dealing with azoleresistant Candida. For the immediate future, though, we must remember to put one foot
in front of the other – assessing the need for further investigation into these ever-shifting
questions based on the research we gather: one gel, one blot, one cell at a time.
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APPENDIX A. AMINO ACID SUBSTITUTIONS IN MRR2 CLINICAL C.
ALBICANS ISOLATES
Table A-1.

Amino acid substitutions in Mrr2 clinical C. albicans isolates

Isolate
FLU-susceptible
1
2
3
5
7
9
10
17
22
53
FLU-resistant
11
12
13
14
15
16
18
19
20
21
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Amino Acid Substitutionsa,b
V451A (h)
S143P, L144V, T145A, S165N, V451A, S480P
V451A
V451A
T83A, V451A, V582L
-

V451A, S480P
V451A
T83A, A459T, S480P, V485M
S466L, A468G, S469T, T470N, S480P
S143P, L144V, T145A, S165N, A459T, S480P
S143P, L144V, T145A, S165N, A459T, S480P
S143P, L144V, T145A, S165N, A459T, S480P
V451A
R45Q, V451A
S143P (h), L144V (h), T145A (h), V451A (h), S466L, A468G, S469T,
T470N, S480P
T83A, A459T, S480P, V486M
T83A, A459T, S480P, V486M
S466L, A468G, S469T, T470N, S480P
S143P, L144V, T145A, S165N, A459T, S480P
-
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Table A-1.
Isolate
FLU-resistant
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
54
55
56
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

(Continued)
Amino Acid Substitutionsa,b
V451A
S143P, L144V, T145A, S165N, A459T, S480P
T83A, T145A, V451A, S480P
S143P (h), L144 (h), T145A (h), V451A (h), S466L, A468G, S469T, T470N,
S480P
T83A, V451A, S480P
S143P, L144V, T145A, S165N, A459T, S480P
S143P, L144V, T145A, S165N, A459T, S480P
T83A, L143P, L144V, T145A, S165N, V451A
S143P (h), L144V (h), T145A (h), S165N (h), S480P (h)
T83A (h), S143P (h), L144V (h), T145A (h), S165N (h), V451A, S480P (h)
T83A, V451A, S480P
-

a

(h) indicates a heterozygous amino acid substitution
“-“ Denotes no changes in the amino acid sequence of the clinical isolate from the
MRR2 allele of SC5314.
b
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APPENDIX B. SUPPLEMENTARY DATA TABLES TO CHAPTER 5
Table B-1.
Minimum inhibitory concentration values for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole,
posaconazole, and known azole resistance mechanisms in clinical C. albicans isolates
Isolate
ID

VT-1161

VT-1598

Fluconazole

Voriconazole

Itraconazole

Posaconazole

ERG11
mutationsa

Other
Resistance
Mechanismsb

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

1

< 0.015

< 0.015

< 0.015

< 0.015

0.25

0.5

< 0.03

< 0.03

0.06

< 0.03

< 0.03

0.06

2

< 0.015

< 0.015

< 0.015

< 0.015

< 0.125

0.25

< 0.03

< 0.03

< 0.03

0.06

< 0.03

0.06

3

< 0.015

< 0.015

< 0.015

< 0.015

0.25

0.25

< 0.03

< 0.03

< 0.03

0.06

< 0.03

0.06

G129A, D116E

---

5

< 0.015

< 0.015

< 0.015

< 0.015

0.5

1

< 0.03

< 0.03

NA

NA

NA

NA

NA

NA

6

< 0.015

< 0.015

< 0.015

< 0.015

1

1

< 0.03

< 0.03

NA

NA

NA

NA

NA

K128T(h),
D116E(h)
F198fs(h),
K128T. D116E

-----

NA
(h)

K128T ,
D116E(h)
S457F(h),
V437I(h)

7

< 0.015

< 0.015

< 0.015

< 0.015

< 0.125

0.25

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

0.06

9

< 0.015

< 0.015

< 0.015

< 0.015

< 0.125

< 0.125

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

10

< 0.015

< 0.015

< 0.015

< 0.015

< 0.125

< 0.125

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

V437I(h)

11

0.125

0.125

0.03

< 0.015

8

4

0.25

0.25

0.5

0.5

0.25

0.5

E266D, V488I

12

0.125

0.125

< 0.015

< 0.015

32

32

0.06

0.125

0.25

0.125

0.125

0.25

K143R

13

0.06

0.06

0.03

0.06

32

32

0.125

0.25

0.25

0.5

0.25

0.5

K143R

↑ CDR1

14

0.06

0.03

< 0.015

< 0.015

16

16

0.06

0.06

0.25

0.25

0.125

0.25

K143R

↑ CDR1

15

0.125

0.06

0.06

0.03

16

16

0.25

0.25

0.5

0.5

0.25

0.5

E266D, V488I

↑ ERG11,
CDR1

120

------↑ ERG11,
CDR1
↑ ERG11,
CDR1

Table B-1.
Isolate
ID

(Continued)
VT-1161

VT-1598

Fluconazole

Voriconazole

Itraconazole

Posaconazole

ERG11
mutationsa

Other
Resistance
Mechanismsb

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

16

< 0.015

0.03

< 0.015

0.03

4

8

< 0.03

0.06

0.25

0.25

0.06

0.06

Q21R(h)

↑ MDR1

17

< 0.015

< 0.015

< 0.015

< 0.015

2

2

0.06

0.5

0.125

0.25

< 0.03

0.06

A114S, Y257H

↑ CDR1

18

0.5

0.5

0.06

0.03

16

32

0.5

0.5

0.25

0.5

0.125

0.25

S405F

19

0.5

0.5

< 0.015

< 0.015

32

32

0.5

0.5

0.5

0.5

0.125

0.25

S405F

20

1

0.5

0.06

0.06

64

32

0.5

0.5

0.5

0.25

0.25

0.5

S405F

21

1

0.5

0.125

0.06

32

32

0.5

0.5

0.5

0.5

0.25

0.5

A114V,
E266D,
H283R

↑ ERG11,
CDR1

22

< 0.015

< 0.015

< 0.015

< 0.015

0.5

1

< 0.03

< 0.03

< 0.03

0.06

< 0.03

0.06

F145L

---

23

0.125

0.125

0.03

< 0.015

32

32

0.5

0.25

0.125

0.25

0.06

0.125

I483V, G450E

↑ CDR1

24

0.03

0.03

0.03

0.03

16

16

0.25

0.125

0.125

0.25

0.06

0.125

G450E

25

< 0.015

< 0.015

< 0.015

< 0.015

16

16

0.06

0.125

0.25

0.125

< 0.03

0.125

D446E

26

< 0.015

< 0.015

< 0.015

< 0.015

16

16

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

G307S , G448R

27

0.06

0.06

< 0.015

0.03

8

16

0.25

0.125

0.25

0.5

0.125

0.25

E266D, V488I

28

0.5

0.5

< 0.015

0.06

64

64

0.5

1

0.5

0.5

0.25

1

E266D, V488I

29

0.25

0.5

0.06

0.06

>64

>64

2

2

0.5

0.5

0.25

1

Y132F, F145L

↑ CDR1

30

0.25

0.5

0.06

0.06

16

32

0.5

1

0.06

0.125

< 0.03

< 0.03

F126L, Y132F,
H283R

↑ ERG11
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↑ ERG11,
CDR1
↑ ERG11,
CDR1
↑ ERG11,
CDR1

↑ CDR1,
MDR1
↑ ERG11,
MDR1
--↑ ERG11,
CDR1
↑ ERG11,
CDR1

Table B-1.
Isolate
ID

(Continued)
VT-1161

VT-1598

Fluconazole

Voriconazole

Itraconazole

Posaconazole

ERG11
mutationsa

Other
Resistance
Mechanismsb

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

31

0.5

0.5

0.125

0.125

>64

64

0.5

0.5

0.5

1

0.25

0.25

G448E

↑ CDR1

32

< 0.015

0.03

< 0.015

< 0.015

8

8

0.06

0.06

0.125

0.25

0.06

0.125

G464S

↑ CDR1,
MDR1

33

0.125

0.125

< 0.015

< 0.015

32

32

0.5

0.5

0.25

0.5

0.25

0.25

F145L E266D

↑ CDR1

34

0.125

0.125

0.06

0.06

64

16

0.5

0.25

0.5

0.5

0.25

0.5

G450E

↑ CDR1

35

0.015

0.03

0.03

0.03

16

16

0.06

0.125

0.25

0.25

0.125

0.25

D446E

36

0.5

0.25

0.06

0.06

64

64

0.5

1

0.25

0.25

0.125

0.25

None

37

0.125

0.125

0.06

0.06

32

64

0.5

0.5

0.25

0.25

0.125

0.25

None

38

1

0.5

0.125

0.06

>64

>64

2

1

0.25

0.5

0.25

0.5

G464S

39

1

1

0.125

0.125

>64

>64

2

2

1

1

0.5

1

G464S

40

0.5

0.25

0.125

0.125

>64

>64

1

1

0.5

0.5

0.25

0.5

F449V

41

0.06

0.06

0.06

0.03

64

64

0.25

0.25

0.25

0.25

0.125

0.25

S405F

42

0.25

0.125

0.06

0.06

64

32

1

0.5

0.25

0.25

0.125

0.25

G464S

↑ CDR1

43

0.03

0.06

< 0.015

0.06

8

8

0.25

0.5

0.25

0.25

0.06

0.125

D278N G464S

↑ CDR1

44

0.5

0.25

0.03

0.03

>64

64

1

1

0.25

0.5

0.25

0.5

D446E

↑ CDR1

45

0.5

0.25

0.06

0.06

64

32

1

1

0.25

0.5

0.125

0.25

E266D G464S

↑ CDR1

122

↑ ERG11,
MDR1
↑ ERG11,
CDR1
↑ ERG11,
CDR1
↑ ERG11,
CDR1
↑ ERG11,
CDR1
↑ ERG11,
CDR1
↑ ERG11,
MDR1

Table B-1.
Isolate
ID

(Continued)
VT-1161

VT-1598

Fluconazole

Voriconazole

Itraconazole

Posaconazole

ERG11
mutationsa

Other
Resistance
Mechanismsb

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

46

< 0.015

< 0.015

< 0.015

< 0.015

32

64

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

< 0.03

G307S, L403F,
G448R

---

47

0.125

0.125

0.03

< 0.015

>64

64

0.5

0.5

0.25

0.25

0.125

0.25

G450E

↑ ERG11,
CDR1

48

2

2

0.06

0.03

32

32

0.5

0.5

0.25

0.25

0.06

0.125

Y132F

↑ CDR1

49

0.125

0.125

0.06

0.125

>64

>64

0.5

0.5

0.5

0.5

0.25

0.5

V437I, Y447S

↑ ERG11,
CDR1

50

1

0.5

0.06

0.06

>64

>64

2

1

0.25

0.5

0.06

0.25

Y132F K143R

↑ CDR1

51

0.5

0.5

0.06

0.06

>64

64

2

1

0.125

0.25

0.125

0.25

D278N G464S

↑ CDR1

53

< 0.015

< 0.015

< 0.015

< 0.015

1

1

< 0.03

< 0.03

0.125

0.25

0.25

0.25

None

↑ ERG11

54

< 0.015

< 0.015

< 0.015

< 0.015

32

32

< 0.03

0.06

0.06

0.125

< 0.03

0.06

G307S G450E

↑ ERG11,
MDR1

55

4

8

>8

>8

>64

>64

>16

>16

>16

>16

>16

>16

None

---

56

4

8

>8

>8

>64

64

>16

>16

>16

>16

>16

>16

None

↑ CDR1

58

4

4

>8

>8

>64

>64

>16

0.5

>16

>16

>16

>16

None

59

0.5

0.5

0.125

0.06

>64

>64

2

2

0.25

0.25

0.06

0.125

Y132F, T229A,
F449I

60

4

>8

>8

>8

>64

>64

>16

>16

>16

>16

>16

>16

None

61

0.5

0.5

0.03

0.06

>64

>64

1

1

0.25

0.5

0.125

0.25

Y132F K143R

↑ CDR1

62

0.125

0.25

< 0.015

< 0.015

32

32

0.5

0.5

0.25

0.5

0.125

0.25

D278N G464S

↑ CDR1

123

↑ ERG11,
CDR1
↑ ERG11,
CDR1
ERG3W131*,
↑ ERG11

Table B-1.
Isolate
ID

(Continued)
VT-1161

VT-1598

Fluconazole

Voriconazole

Itraconazole

Posaconazole

ERG11
mutationsa

Other
Resistance
Mechanismsb

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

MIC
#1

MIC
#2

63

0.06

0.125

0.125

0.06

32

32

0.25

0.25

0.5

0.5

0.25

0.25

G450E

64

0.25

0.125

0.125

0.06

32

32

0.5

0.25

0.5

0.5

0.25

0.25

G450E

65

4

2

>8

0.5

64

64

1

0.5

1

2

0.5

0.5

G448E

66

0.5

0.5

0.25

0.125

64

64

0.5

0.5

0.5

0.5

0.25

0.5

G448E

67

0.5

0.5

>8

0.25

>64

64

1

1

1

1

0.5

0.5

G448E

68

0.5

0.5

< 0.015

< 0.015

>64

>64

0.5

0.5

0.25

0.5

< 0.03

0.06

Y132F, E266D,
I471M, V488I

69

0.5

1

0.25

0.25

64

64

1

1

1

1

0.5

0.5

G448E

70

0.06

0.03

< 0.015

< 0.015

32

32

0.5

0.5

0.25

0.5

0.125

0.125

M258L, G464S

---

71

0.25

0.125

0.06

0.06

>64

64

0.5

0.5

0.5

0.5

0.125

0.125

↑ ERG11,
CDR1

72

0.25

0.125

0.06

0.125

16

16

0.25

0.25

0.5

0.5

0.25

0.25

Y132F, V437I,
F449L
A114V,
D153E,
E266D, G450E

a

↑ CDR1,
MDR1
↑ ERG11,
MDR1
↑ ERG11,
CDR1
↑ CDR1
↑ ERG11,
CDR1
↑ ERG11,
MDR1
↑ ERG11,
CDR1

↑ CDR1

(h) indicates heterozygous mutation
↑ denotes increased expression of the gene in question
Notes: Low antifungal MICs (within a two-fold increase of that of the fluconazole-susceptible isolates) against fluconazole-resistant
isolates are highlighted in yellow.
b
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Table B-2.
strains
Erg11
substitution
Wildtypea
Y132F
Y132H
K143R
F145L
E266D
D278N
S405F
G448E
F449V
G450E
G464S
D466E
Y132F, K143R
Y132F, F145L
D278N, G464S
G450E, I483V
a

MICs for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole, and posaconazole against ERG11 mutant
VT-1598
MIC
MIC
#1
#2
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
0.03
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
0.03
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
0.03
0.03
0.03
< 0.015
< 0.015
< 0.015

VT-1161
MIC
MIC
#1
#2
< 0.015
< 0.015
0.25
0.125
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
< 0.015
0.06
0.125
< 0.015
0.06
< 0.015
< 0.015
< 0.015
< 0.015

Fluconazole
MIC
MIC
#1
#2
0.5
0.5
4
8
2
1
2
4
4
4
1
1
2
1
4
4
1
2
2
4
2
2
2
2
1
1
32
64
16
32
4
8
2
2

From azole-susceptible parent strain SC5314
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Itraconazole
MIC
MIC
#1
#2
0.125
0.125
0.125
0.125
0.125
0.125
0.06
0.125
0.25
0.25
0.125
0.125
0.125
0.125
0.25
0.25
0.125
0.25
0.125
0.125
0.125
0.25
0.125
0.125
0.125
0.25
0.125
0.125
0.25
0.25
0.25
0.25
0.125
0.125

Posaconazole
MIC
MIC
#1
#2
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03
< 0.03

Voriconazole
MIC
MIC
#1
#2
< 0.03
< 0.03
0.25
0.125
0.125
0.06
< 0.03
< 0.03
0.125
0.125
0.06
0.06
0.125
0.06
0.125
0.125
< 0.03
0.06
0.06
< 0.03
0.06
0.06
0.06
0.06
0.125
0.06
0.25
0.25
0.5
1
0.25
0.25
0.125
0.125

Table B-3.

Primers used in Chapter 5
Sequencea

Primer name by purpose
Amplification
CaERG11_AF_(ApaI)
CaERG11_BR_(XhoI)
CaERG11_C-F’
CaERG11_D-R’

5’ – GGGCCCGGGTTATTTGAGAACAGCC – 3’
5’ – CTCGAGCCAGTGGACAAAAACCATCA – 3’
5’ – AATGCGGCCGCATTTTAACTACTTTTGTTTA – 3’
5’ – CTTCCGCGGTAATCAATTCACCATTTTTAAC – 3’

Sequencing
CaERG11SeqA
CaERG11SeqB
CaERG11SeqC
CaERG11SeqD
CaERG11SeqE
CaERG11SeqF

5’ – GCCACCACACCCTATGGCTATT – 3’
5’ – TATTTTCACTGCTTCAAGATCT – 3’
5’ – CCAAAAGGTCATTATGTTTTAG – 3’
5’ – CATACAAGTTTCTCTTTTTTCC – 3’
5’ – CATTTAGGTGAAAAACCTCATT – 3’
5’ – TACTCCAGTTTTCGGTAAAGGG – 3’

Short, overlapping extension
CaERG11_1F
CaERG11SOE3R_Y132H
CaERG11SOE2F_Y132H
CaERG11_4R
CaERG11SOE-5F
CaERG11SOE-6R
Real-time qPCR
CaCDR1-F_qPCR
CaCDR1-R_qPCR
CaERG11-F_qPCR
CaERG11-R_qPCR
CaBMR1-F_qPCR
CaBMR1-R_qPCR
CaACT1-FWD_qPCR
CaACT1-rvs_qPCR
a

5’ – CAATCTATACGACGACATTTAACTTTTT – 3’
5’ – GACAATCATGAATAACCCCTTTACCGAAAA – 3’
5’ – GGGGTTATTCATGATTGTCCAAATTCCAGA – 3’
5’ – GCTGTTGTTGTTGTTGAAAGAAA – 3’
5’ – ATTATTGAAAGAAAAAGGTGGTGATTTG – 3’
5’ – ACCTTTTTCTTTCAATAATTCAACAACT – 3’
5’ – ATTCTAAGATGTCGTCGCAAGATG – 3’
5’ – AGTTCTGGCTAAATTCTGAATGTTTTC – 3’
5’ – CCCCTATTAATTTTGTTTTCCCTAATTTAC – 3’
5’ – CACGTTCTCTTCTCAGTTTAATTTCTTTC – 3’
5’ – ACATAAATACTTTGCCCATCCAGAA – 3’
5’ – AAGAGTTGGTTTGTAATCGGCTAAA – 3’
5’ – ACGGTGAAGAAGTTGCTGCTTTAGTT – 3’
5’ – CGTCGTCACCGGCAAAA – 3’

Underlined nucleotide indicates introduction of a restriction site sequence
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